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ABSTRACT 
 
Quantitative Studies of Amyloidogenic Protein Residue Interaction Networks and 
Abnormal Ammonia Metabolism in Neurotoxicity and Disease 
 
by 
Jeddidiah Wayne Duke Griffin 
 
Investigating similarities among neurological diseases can provide insight into disease 
processes. Two prominent commonalities of neurological diseases are the formation of 
amyloid deposits and altered ammonia and glutamate metabolism. Computational 
techniques were used to explore these processes in several neurological diseases. Residue 
interaction networks (RINs) abstract protein structure into a series of nodes (representing 
residues) and edges (representing connections between residues likely to interact). 
Analyzing the RINs of non-amyloid forms of amyloidogenic proteins for common network 
features revealed similarities not previously known. First, amyloidogenic variants of 
lysozyme were used to demonstrate the usefulness of RINs to the study of amyloidogenic 
proteins. Next, I compared RINs of amyloidogenic proteins with randomized control 
networks and a group of real protein controls and found similarities in network structures 
unique to amyloidogenic proteins. The use of 3D structure data and network structure data 
of amyloid-beta (1-42) (Abeta42) in a hydrophobic, membrane-mimicking solvent led to 
the identification of an interaction between Val24 and Ile31 as potentially involved in 
preventing Abeta aggregation. Since Abeta causes oxidative damage, since the ammonia 
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metabolism enzyme glutamine synthetase is particularly susceptible to oxidative damage, 
and since glutamate plays a central role in neuronal function, I expanded my research to 
include the study of ammonia and glutamate metabolism in neurological diseases. A 
computational model of the effects of the interactions between the amount of dietary 
protein and the activities of ammonia metabolism enzymes on blood and brain ammonia 
levels supports potentially important roles for these enzymes in the protection of neural 
function. Next, I reviewed the role of amino acid catabolism in Alzheimer’s disease (AD). 
Common tissue pathology and the ability of memantine, an NMDA receptor antagonist, to 
relieve symptoms in patients and animal models of AD, major depressive disorder (MDD), 
and type 2 diabetes (T2D) further support a role for ammonia and glutamate metabolism 
in disease. Lastly, I found that single nucleotide polymorphisms (SNPs) in select ammonia 
metabolism genes are associated with these three diseases. The results presented in this 
dissertation demonstrate that investigating neurological diseases using computational 
approaches can provide great insight into the common underlying pathologies. 
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CHAPTER 1 
INTRODUCTION 
 
Many Neurological Diseases Have Common Etiologies and Phenotypes 
Neurological diseases are a diverse group of disorders, so researchers often study 
them using a reductionist approach. This view has successfully led to a large body of 
knowledge and successful treatments for some diseases. However, a broader approach that 
attempts to find similarities among some of the proposed causes of neurological disease 
could lead to novel and more broad-spectrum treatments. Improper protein folding and 
metabolic abnormalities are two of the proposed shared causes of neurological diseases 
and their symptoms. Improper protein folding results in the formation of insoluble protein 
deposits called amyloid plaques (Rambaran and Serpell 2008). Metabolic abnormalities are 
understandably diverse in neurological diseases due to the central role of metabolism in 
cellular function, but amino acid and ammonia metabolism stand out as having influential 
roles in many diseases. The overall goal of this dissertation is to use computational 
analyses to provide insight into potential molecular contributors to select neurological 
diseases by investigating abnormal ammonia metabolism and the residue interaction 
network structures of amyloidogenic proteins, two likely contributors to neurological 
diseases. I propose two guiding hypotheses for this series of studies. 
(A) Amyloidogenic proteins have similarities in their residue interaction network  
structures that will provide insight into the formation of amyloid plaques. 
(B) Altered ammonia metabolism and changes in the amount of dietary protein 
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under certain conditions affect neurological function and play causative roles 
in several neurological diseases.  
These studies investigated possible contributing factors to neurological diseases 
and report commonalities in improper protein folding and abnormal metabolism. Studies 
of broad scope that attempt to find commonalities in the causes of neurological diseases 
could provide novel insight into possible treatments or preventions. This series of studies 
is organized into specific aims which address hypotheses (A) and (B). 
 
Specific Aim 1 
To determine if amyloidogenic proteins have commonalities in their residue 
interaction networks and to determine how these network structures may affect amyloid-
beta plaque formation when combined with 3D structural data. This aim addresses 
hypothesis (A). 
 
Amyloidogenic Proteins Are Involved in Many Neurological Diseases 
Amyloidogenic proteins are polypeptides that can form amyloid plaques (Knowles 
et al. 2014). Amyloid plaques are associated with a variety of diseases ranging from 
neurological disorders (Glenner and Wong 1984; Hardy and Higgins 1992) to 
gastrointestinal disease (Granel et al. 2002). The symptoms of the diseases depend on the 
tissue in which the amyloids are deposited. There are dozens of different amyloid diseases 
caused by dozens of different proteins (Knowles et al. 2014). The structure of amyloid 
plaques of a variety of proteins consists of insoluble stacks of cross-beta sheets (Sunde et 
al. 1997). There is little known similarity in native structure, sequence, or function of 
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amyloidogenic proteins in monomeric form (Knowles et al. 2014). Several amyloid diseases 
(amyloidoses) are characterized by deposition of plaques in the central nervous system 
(CNS), leading to a variety of different but related symptoms. Amyloidoses of the CNS 
include amyloid-beta (Abeta) in Alzheimer’s disease (Glenner and Wong 1984), alpha-
synuclein (α-syn) in Parkinson’s disease (Spillantini et al. 1997), and human prion protein 
(hPrP) in transmissible spongiform encephalopathies (TSEs) (Kretzschmar et al. 1986; 
Nizhnikov et al. 2016).  
 
Amyloid-Beta and Alzheimer’s Disease. The amyloid hypothesis for Alzheimer’s 
disease was first proposed in 1992 by Hardy and Higgins (Hardy and Higgins 1992), but it 
has its roots in the first studies of purified Abeta (Glenner and Wong 1984). The hypothesis 
states that aggregates of the Abeta peptide are responsible for the cognitive decline and 
cellular damage observed in Alzheimer’s disease. Since then, the amyloid hypothesis has 
been thoroughly investigated with data both supporting and refuting it (Herrup 2015). 
Abeta comes in two main forms that differ in length by only two amino acids: amyloid-beta 
(1-40) (Abeta40) and amyloid-beta (1-42) (Abeta42).  However, a recent study suggests 
many other Abeta fragments are also prevalent in AD brain (Wildburger et al. 2017). 
Studies suggest Abeta42 is more toxic than Abeta40 (Kuperstein et al. 2010). This may be 
because it more readily forms amyloid fibrils (Ogawa et al. 2011). Fibrils are the most 
prevalent form of Abeta found in those with AD, but oligomers appear to be the most toxic 
form (Sakono and Zako 2010). Abeta42 has been shown to stimulate inflammation (White 
et al. 2005) as well as form channels in cellular membranes that disrupt ion homeostasis in 
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neurons (Furukawa et al. 1994; Weiss et al. 1994). The amyloid plaques are typically 
extracellular and are thought to disrupt synaptic signaling (Ferreira et al. 2015).  
Abeta appears to have intrinsically unstructured N- and C-termini with some 
secondary structure in the middle regions of the protein. Studies have found that the 
central hydrophobic cluster (CHC, residues 17-21) plays an important role in forming 
amyloid plaques (Wurth et al. 2002). Residues 24-26 and 31-34 appear to be important for 
fibrillization of Abeta40 (Williams et al. 2004). While it has been suggested that Abeta 
monomers in solution do not have secondary structure, there are studies that suggest 
Abeta does have secondary structure that is critical for amyloid formation (Chen and Glabe 
2006). Although Abeta has been extensively studied, there is a lot of variability in 
experimental results possibly due to differences in experimental conditions. Therefore, 
examining amyloidogenic proteins for similarities using a novel computational approach 
could provide insights into structural features that other methods could not address. 
 
Other Amyloidoses of the CNS. The brains of Parkinson’s disease patients have 
cytoplasmic inclusions known as Lewy bodies (LBs) (Braak et al. 2003). LBs are mainly 
composed of α-syn (Tu et al. 1998), a 140 amino acid protein that forms alpha-helices 
when in a hydrophobic, membrane-like environment (Ulmer et al. 2005). While α-syn can 
form fibrils, it is thought that oligomers are the most toxic form of the protein (Conway et 
al. 2000). The α-syn protein has been shown to inhibit synaptic transmission through a 
variety of mechanisms (Stefanis 2012), including altering the distribution of SNARE 
proteins (Garcia-Reitböck et al. 2010) and decreasing the release of neurotransmitters 
(Nemani et al. 2010).  
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Human prion protein is an infectious protein that is the cause of TSEs. There are 
several types of TSEs that involve the conversion of the cellular form of the prion protein 
(PrPC) to the infectious form (PrPSC) (Colby and Prusiner 2011). The concept of infectious 
proteins was proposed by Prusiner in 1982 (Prusiner 1982). While hPrP often forms 
amyloids in vivo (Colby et al. 2007), amyloid formation is not required to cause disease 
(Wille et al. 2000). Like α-syn and Abeta, there is evidence that oligomeric PrP species are 
more toxic than fibrils for pathogenesis (Sokolowski et al. 2003). Because both α-syn and 
hPrP can form amyloids, they are included in the group of amyloidogenic proteins studied 
in Chapter 3. 
 
Lysozyme Amyloidosis as a Model for General Amyloidosis. Lysozyme is a 14.7 kDa 
antimicrobial protein discovered by Alexander Fleming (Fleming 1922) and found in 
secretions such as tears (McDermott 2013) and saliva (van’t Hof et al. 2014). While wild 
type (WT) lysozyme does not form amyloids in vivo, rare amyloidogenic mutants of 
lysozyme exist and are known to cause human disease (Granel et al. 2006). Because 
lysozyme is a well-studied protein and single amino acid substitutions can cause lysozyme 
to form amyloids, it is a useful model for studying the general process of amyloidogenesis 
(Merlini and Bellotti 2005). Several lysozyme point mutations are catalogued in the 
database Online Mendelian Inheritance in Man (OMIM 153450). These include I56T (Pepys 
et al. 1993), D67H (Pepys et al. 1993), W64R (Valleix et al. 2002), and F57I (Yazaki et al. 
2003). It is generally thought that these mutations cause regions of instability between the 
alpha and beta domains, leading to unfolding (Booth et al. 1997). As the lysozyme 
molecules unfold, new intermolecular interactions can form between them, allowing 
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lysozyme to form amyloid plaques. While regions of instability have been clearly 
demonstrated to be involved (Booth et al. 1997), there may be other factors involved in 
amyloidogenesis. Applying residue interaction network analysis to lysozyme structures 
available in the Protein Data Bank (PDB) may yield new insights into the primary 
nucleation of lysozyme amyloids. Since lysozyme is a model for general amyloidogenesis, 
understanding the residue interaction network changes that occur in amyloidogenic 
variants of lysozyme could provide insight into the primary nucleation of other proteins as 
well. A better understanding of the amyloidogenic process could lead to more effective 
pharmacological interventions. 
 
Residue Interaction Networks Provide a Novel Perspective into Protein Structure and 
Function 
Complex networks analysis is a growing field that applies network science to a 
variety of systems (Estrada 2012). Proteins can be abstracted into a network of interacting 
amino acid residues where a node is represented by an amino acid and an edge represents 
a likely connection between amino acid residues (Di Paola et al. 2013; Yan et al. 2014). 
Conceptualizing a protein’s structure as a network has proven to be a powerful technique 
that has provided several insights into protein structure (Dokholyan et al. 2002; Amitai et 
al. 2004; Brinda and Vishveshwara 2005; Liu and Hu 2011; Hu et al. 2014; Emerson and 
Louis 2015; Di Paola and Giuliani 2015). There are a variety of metrics available to describe 
a network (Junker and Schreiber 2008). These include global network measures such as 
average clustering coefficient, average shortest pathlength, average degree, and number of 
nodes and edges. There also exist local measures of a network such as clustering 
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coefficient, degree of a node, betweenness, and stress. Both global and local metrics have 
proven useful for protein network analysis. Network metrics applied to residue interaction 
networks (RINs) have been associated with features of proteins such as folding dynamics 
(Dokholyan et al. 2002) and active sites (Amitai et al. 2004). RINs are most useful for 
analyzing protein structure when combined with traditional 3D structural data and 
sequence data. 
As described above, the 3D structures and sequences of monomeric and soluble 
amyloidogenic proteins are generally very well studied, but there have been no strong 
sequence or structural similarities found among them that suggest common features 
involved in amyloidogenesis (Knowles et al. 2014). Adding RIN data could better identify 
common features in amyloidogenic proteins. RINs provide a novel perspective of 
amyloidogenic proteins that could lead to the generation of information useful in further 
refining the current model of primary nucleation of amyloid fibrils.  
As mentioned previously, Abeta plaques are a hallmark of AD. One of the hypotheses 
for the toxic effects of Abeta focuses on the potential of Abeta to cause oxidative damage 
(Smith et al. 1994; Smith et al. 1998; Rottkamp et al. 2001; Boyd-Kimball et al. 2005; Boyd-
Kimball et al. 2006). Oxidative damage is increased in those with AD (Castegna et al. 2003; 
Perluigi et al. 2009) and in animal models of AD (Praticò et al. 2001). One of the enzymes 
especially sensitive to oxidative inactivation is glutamine synthetase (GLUL) (Butterfield et 
al. 1997), an enzyme that ligates ammonia and glutamate to produce glutamine. GLUL is 
oxidized in vitro after Abeta42 treatment (Boyd-Kimball et al. 2005) and has been shown 
to be oxidized in patients with mild cognitive impairment (MCI) (Butterfield et al. 2006) 
and in a mouse model of AD (Shen et al. 2015). Because of the sensitivity of GLUL to 
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oxidative inactivation and the potential effects on ammonia metabolism due to oxidative 
damage, I expanded my research to examine the role of ammonia metabolism enzymes on 
blood ammonia levels and the potential neurotoxicity when enzyme activity is altered in 
disease conditions. 
 
Specific Aim 2 
To create a mathematical model to determine if the amount of dietary protein and 
degree of liver function interact to affect blood ammonia levels and to determine if the 
predicted changes could affect neuron health. This aim addresses hypothesis (B) and 
investigates the potential role of ammonia metabolism in neural function using an 
organismal and tissue level approach. 
 
Urea Cycle, CPS1, GLS, and GLUL in Ammonia Metabolism 
 Ammonia is a toxic byproduct of amino acid catabolism (Auron and Brophy 2012) 
that is processed in mammals into the relatively nontoxic molecule urea by enzymes of the 
urea cycle. The urea cycle is composed of a series of enzymes located mainly in the liver, 
but also in the kidneys and small intestine. The first committed step of the urea cycle is 
catalyzed by the enzyme carbamoyl phosphate synthetase 1 (CPS1), a mitochondrial 
protein that synthesizes carbamoyl phosphate from ammonia, carbonic acid, and ATP. CPS1 
deficiency, a disease caused by mutations in the CPS1 gene that reduce the enzyme’s 
activity, results in increased systemic ammonia levels (Klaus et al. 2009). Severe CPS1 
deficiency typically leads to death at an early age due to the sensitivity of the brain to high 
ammonia levels. 
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Many other enzymes exist that are involved in ammonia metabolism but are not 
part of the urea cycle. These include glutamine synthetase (GLUL), as mentioned earlier, 
and glutaminase (GLS). Glutamine is relatively inert as a signaling molecule (Albrecht et al. 
2010). However, glutamine can be broken down into ammonia and glutamate by the 
enzyme glutaminase (Albrecht and Norenberg 2006). Glutamate is an important 
neurotransmitter involved in synaptic function (Zhou and Danbolt 2014) and is discussed 
in more detail below. GLUL has a very low Km (high affinity for substrate) (Listrom et al. 
1997), so it efficiently processes free ammonia into glutamine when glutamate is present. 
The interplay among these ammonia metabolism enzymes has important implications for a 
variety of diseases. 
 
Liver Physiology and Hepatic Encephalopathy 
The liver carries out a variety of critical physiological functions. One of the most 
important functions is the removal of ammonia from the blood to create urea for excretion. 
This is carried out through a series of enzymes that are spatially separated in the acinus, 
the functional unit of the liver. Briefly, the hepatic portal vein carries blood from the small 
intestine to the liver. The blood then diffuses across about 22 hepatocyte cell layers in the 
acinus and then collects in a branch of the central vein. The hepatocytes of the acinus are 
divided into three zones which each express a set of enzymes to metabolically process the 
compounds in the blood coming from the small intestine (Häussinger et al. 1992; Brosnan 
and Brosnan 2009; Lautt 2009). Zone 1 is closest to the hepatic portal vein. These 
hepatocytes express the enzymes CPS1 (Moorman et al. 1989) and GLS (Moorman et al. 
1994). Zone 2 largely contains the same ammonia metabolism enzymes as zone 1 but with 
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lower levels of GLS (Moorman et al. 1989; Moorman et al. 1994). Zone 3, however, is 
closest to the central vein and contains GLUL instead of CPS1 and GLS (Gebhardt and 
Mecke 1983). The separation of these enzymes makes ammonia metabolism more efficient. 
Liver damage causes changes in the metabolic functions of the liver (Gebhardt and 
Reichen 1994; Fleming and Wanless 2013). Hepatic encephalopathy is a condition where 
liver damage leads to an accumulation of potentially neurotoxic factors in the blood, 
impairing cognitive function (Butterworth 2015). Liver cirrhosis has been shown to cause 
changes in the activities of CPS1 and GLUL (Gebhardt and Reichen 1994; Fleming and 
Wanless 2013). When these enzyme activities are altered, the rate at which ammonia 
metabolism occurs is altered as well, leading to higher levels of ammonia in the blood of 
patients with liver damage (Butterworth 2003). The higher levels of blood ammonia in 
those with hepatic encephalopathy cause neural dysfunction, leading to the clinical 
symptoms of disease. 
 
Effects of Blood Ammonia on Neural Cells 
 Most ammonia (NH3) becomes protonated at physiological pH and is present in the 
body as the ammonium ion (NH4+). For simplicity, “ammonia” is used in this dissertation to 
include both chemical species unless otherwise noted. Uncharged ammonia can passively 
cross the blood-brain barrier (BBB), while the charged ammonium ion cannot (Auron and 
Brophy 2012). Because the brain has a lower pH than blood, once ammonia passes through 
the BBB and becomes protonated, it does not pass back through so easily, leading to a 
higher concentration of ammonium ions in the brain compared to the blood (Auron and 
Brophy 2012). Once in the brain, ammonia can cause damage to neural cells and interrupt 
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cognitive function in a variety of ways. First, ammonia can directly exert toxicity on 
neurons and glia. Studies have demonstrated that increased ammonia levels cause 
increased reactive oxygen and nitrogen species production (Bobermin et al. 2015), leading 
to oxidative damage. Furthermore, ammonium ions compete with potassium for transport 
into astrocytes and neurons, leading to problems with inhibitory neurotransmission in the 
cortex (Rangroo Thrane et al. 2013). Next, high ammonia levels disrupt the glutamate-
glutamine balance in the brain (Braissant et al. 2013). Glutamate is an excitatory 
neurotransmitter involved in learning and memory (Esposito et al. 2013). Disruption of 
glutamate metabolism and signaling by high ammonia levels could lead to some of the 
symptoms of neurological diseases. Either too much or too little glutamate signaling has 
been shown to have negative effects on the brain (Myhrer 1998). The results of Specific 
Aim 2 add further evidence that increased ammonia levels resulting from 
pathophysiologically relevant enzyme activity changes are directly toxic to neurons. 
Because of these results and the established role of glutamate signaling in neuronal 
function and AD, I investigated a potential connection between ammonia metabolism genes 
and three neurological and metabolic diseases: AD, major depressive disorder (MDD), and 
type-2 diabetes (T2D). 
 
Specific Aim 3 
To determine if there is an association between single nucleotide polymorphisms 
(SNPs) in the GLS, CPS1, and GLUL genes and AD, MDD, and T2D, and to predict the effects 
of any associated SNPs in the disease processes. This aim addresses hypothesis (B) where I 
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suggest that altered ammonia metabolism stimulates neuropathology on a molecular and 
cellular level. 
 
Ammonia Metabolism Could Play a Common Role in AD, T2D, and MDD 
Proper organismal ammonia metabolism is critical for normal physiology, but it is 
especially important for brain function. Because of its very high toxicity and its production 
by a central metabolic pathway, ammonia metabolism may be altered in a variety of 
diseases where central metabolism is altered. Therefore, we hypothesized that ammonia 
and glutamate metabolism may play a role in the pathogenesis of AD, MDD, and T2D. While 
these diseases have many differences, cortical thinning has been associated with all three 
diseases (Du et al. 2007; Tu et al. 2012; Yoon et al. 2017). Memantine is one of the handful 
of drugs available for the treatment of AD. It is an NMDA receptor antagonist, so it reduces 
glutamate excitotoxicity in neurons. Overactivation of NMDA receptors results in the 
excessive opening of plasma membrane calcium channels, resulting in calcium-induced cell 
death. Memantine has been shown to slightly slow the progression of AD, reinforcing that 
glutamate signaling is important in AD pathogenesis. However, memantine administration 
has also been shown to have positive effects in patients with MDD (Amidfar et al. 2017) 
and in a mouse model of T2D (Iwanami et al. 2014; Huang et al. 2017). Since memantine 
may be effective against all three of these diseases, there are likely common features of 
pathogenesis among them. Exploring common disease features may lead to better 
treatments for patients with a variety of diseases. This suggests that drugs targeting 
ammonia and glutamate metabolism and signaling may be worthwhile pharmacological 
interventions.  
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In addition to the link between AD, MDD, and T2D and glutamate and ammonia 
metabolism and signaling, the comorbidity of the three diseases suggests a possible link 
among them. For example, T2D nearly doubles the risk of developing MDD (Anderson et al. 
2001; Ali et al. 2006), and those with a history of depression have an increased risk of 
developing AD (Geerlings et al. 2008). Furthermore, a strong link between T2D and AD 
appears to be established (Ott et al. 1999; Luchsinger et al. 2005; Gudala et al. 2013; Li et 
al. 2015). Ammonia metabolism and its role in glutamate signaling may partially explain 
the comorbidity, the benefit of NMDA receptor antagonists, and the similar tissue 
pathology of these diseases with neurological components. Furthermore, since each of 
these diseases has a heritable component (Gatz et al. 1997; Sullivan et al. 2000; Willemsen 
et al. 2015), investigating genetic abnormalities in ammonia metabolism genes in 
individuals with these diseases may further support a causative role for dysfunctional 
ammonia and glutamate metabolism in the onset and progression of the disorders. 
 
Amino Acid and Ammonia Metabolism in AD. Since 1992, Abeta has been a major 
focus of AD research (Hardy and Higgins 1992). However, Abeta is likely not the only factor 
involved in AD pathogenesis. The year after the amyloid hypothesis was proposed, Seiler 
proposed the ammonia hypothesis of AD (Seiler 1993). However, due to the popularity of 
the amyloid hypothesis, it has received little attention although the data that support it are 
strong. In light of the numerous failed AD drug trials that sought to prevent Abeta 
fibrilization or remove fibrils that were already present, many researchers have suggested 
that the investigation of other hypotheses of AD pathogenesis is warranted (Herrup 2015).  
Of the drugs currently approved to treat AD, none of them targets Abeta, but memantine 
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alters glutamate signaling. Therefore, strategies targeting ammonia and glutamate 
metabolism may lead to more effective treatments. Seiler has reviewed the body of 
evidence that supports the role of ammonia in AD (Seiler 2002). Briefly, subjects with AD 
tend to have high levels of ammonia in their plasma (Fisman et al. 1985), cerebrospinal 
fluid (CSF), and autopsied brains than age-matched controls (Hoyer et al. 1990). The 
cognitive symptoms of those with CPS1 deficiency or hepatic encephalopathy (although not 
identical with AD) demonstrate the effects of hyperammonemia on the CNS (Raabe 1987). 
Together, this evidence warrants further research. 
 In addition to increased ammonia levels in AD patients, amino acid level changes in 
those with AD have also been thoroughly investigated. Several amino acids have altered 
concentrations in blood, CSF, or autopsied brain tissue of AD patients (Chapter 5). Because 
amino acids release ammonia when catabolized and are precursors for the synthesis of a 
variety of metabolites, their altered levels in AD patients could lead to a variety of disease 
symptoms. The changes in amino acid levels in AD patients and animal models are 
thoroughly reviewed in Chapter 5. 
 
Ammonia Metabolism in MDD and T2D. Ammonia and glutamate metabolism have 
also been linked to MDD and T2D. In addition to the positive effects of memantine on the 
symptoms of MDD patients and in a mouse model of T2D, some studies have reported 
associations between ammonia metabolism genes and MDD and T2D. Changes in the 
activity of GLS in a diabetes rat model were found (Ardawi 1987), and it is also known that 
glutamate signaling pathways are altered in those with MDD (Bernard et al. 2011).  
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Overview of the Dissertation 
 In the first part of this dissertation, I discuss the results of studies seeking to find 
similarities among amyloidogenic proteins by combining 3D structural analysis with RIN 
analysis. Amyloidogenic lysozyme was used as a model of an amyloidogenic protein to 
demonstrate the usefulness of combining 3D structural data and RIN data in the study of 
primary nucleation (Chapter 2). Next, a group of amyloidogenic proteins was compared to 
random network controls and a group of real proteins to detect similarities among the 
amyloidogenic proteins (Chapter 3). Then, Abeta, as an example from a prevalent disease, 
was explored in more detail to find novel residue interactions that may be involved in 
primary nucleation of amyloid fibrils (Chapter 3).  
In the second part of this dissertation, the results of the studies aimed at 
investigating the potential role of ammonia in a variety of neurological diseases are 
discussed. First, a computational model was built to investigate the interactions among the 
activities of enzymes involved in ammonia metabolism, dietary protein intake, and blood 
ammonia levels and their potential role in hepatic encephalopathy (Chapter 4). Next, the 
literature on amino acid and ammonia metabolism changes that occur in AD was 
thoroughly reviewed (Chapter 5). Finally, single nucleotide polymorphisms (SNPs) in 
ammonia metabolism genes were found to be linked to AD, MDD, and T2D, suggesting the 
potential for altered ammonia metabolism to play an important role in a variety of diseases 
with neurological symptoms (Chapter 6). By combining the study of amyloid forming 
proteins such as Abeta in Alzheimer’s disease and ammonia metabolism in hepatic 
encephalopathy, AD, MDD, and T2D, a more complete understanding of diseases with 
neurological and metabolic components has been obtained. 
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Abstract 
  Amyloidogenic proteins are most often associated with neurodegenerative diseases 
such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, but there are 
more than two dozen human proteins known to form amyloid fibrils associated with 
disease. Lysozyme is an antimicrobial protein that is used as a general model to study 
amyloid fibril formation. Studies aimed at elucidating the process of amyloid formation of 
lysozyme tend to focus on partial unfolding of the native state due to the relative instability 
of mutant amyloidogenic variants. While this is well supported, the data presented here 
suggest the native structure of the variants may also play a role in primary nucleation. 
Three-dimensional structural analysis identified lysozyme residues 21, 62, 104, and 122 as 
displaced in both amyloidogenic variants compared to wild type lysozyme. Residue 
interaction network (RIN) analysis found greater clustering of residues 112-117 in 
amyloidogenic variants of lysozyme compared to wild type. An analysis of the most 
energetically favored predicted dimers and trimers provided further evidence for a role for 
residues 21, 62, 104, 122, and 112-117 in amyloid formation. This study used lysozyme as a 
model to demonstrate the utility of combining 3D structural analysis with RIN analysis for 
studying the general process of amyloidogenesis. Results indicated that binding of two or 
more amyloidogenic lysozyme mutants may be involved in amyloid nucleation by placing 
key residues (21, 62, 104, 122, and 112-117) in proximity before partial unfolding occurs. 
Identifying residues in the native state that may be involved in amyloid formation could 
provide novel drug targets to prevent a range of amyloidoses. 
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Background 
Amyloidoses are a group of diseases defined by the formation of protein aggregates 
characterized by stacks of cross-beta sheets (Greenwald and Riek 2010).  There are dozens 
of different amyloid diseases caused by a variety of both wild type (WT) and mutant forms 
of proteins (Knowles et al. 2014). Some of the most well-known amyloidoses are 
neurodegenerative diseases such as Alzheimer’s disease (involving amyloid-beta peptide) 
and Parkinson’s disease (involving alpha-synuclein protein). However, not all amyloid 
diseases affect the brain. Lysozyme amyloidosis is a rare disease characterized by the 
deposition of amyloid fibrils of the enzyme lysozyme. Lysozyme was discovered by 
Alexander Fleming in 1922 (Fleming 1922) and is an antimicrobial enzyme synthesized by 
hepatocytes, cells of the gastrointestinal system, and macrophages (Granel et al. 2006). 
Lysozyme amyloidosis has no known effective treatment and leads to lysozyme amyloid 
deposits typically concentrated in the liver (Harrison et al. 1996), spleen, gastrointestinal 
tract (Granel et al. 2002), and kidneys (Gillmore et al. 1999). Lysozyme amyloidosis is 
thought to be largely caused by subtle structural changes of the protein caused by genetic 
mutations that lead to pockets of local instability and a greater likelihood of partial 
unfolding (Canet et al. 1999). The Online Mendelian Inheritance in Man (OMIM) database 
(Amberger et al. 2015) entry for lysozyme (OMIM ID 153450) reports four lysozyme 
variants that are associated with the disease: I56T (Pepys et al. 1993), D67H (Pepys et al. 
1993), W64R (Valleix et al. 2002), and F57I (Yazaki et al. 2003).  
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Lysozyme has long been used as a model for studying protein structure and folding. 
Since lysozyme is structurally and functionally well-characterized, the protein provides a 
useful model for understanding the complex process of amyloid fibril formation (Merlini 
and Bellotti 2005). Several studies have investigated the role of amyloidogenic mutations 
on lysozyme amyloid formation with a focus on the first identified mutations, I56T and 
D67H. Studies that examined the crystal structure of the WT and I56T variant suggest very 
little difference in the native structure of these enzymes (Funahashi et al. 1996). The D67H 
variant, however, destroys the hydrogen bonds that stabilize the beta domain, leading to 
the displacement of a long loop of residues (Booth et al. 1997). Because the obvious loop 
displacement between the WT and D67H mutant is not present in the I56T mutant, it is 
thought that this change is not responsible for amyloidogenesis. Instability of the I56T 
variant may be caused by subtle changes in bonding between alpha and beta domains of 
lysozyme; similar bonding changes are also evident in the D67H variant (Booth et al. 1997).  
Since the structure of proteins in amyloid plaques are different from the native 
structure, amyloidogenic proteins must at least partially unfold during amyloidogenesis. 
Most studies focus on the unfolding process of lysozyme instead of differences in the native 
structure. The amyloidogenic proteins likely spend more time partially unfolded, providing 
more opportunities for unfolded segments to interact and aggregate in the form of amyloid 
plaques (Canet et al. 1999). The importance of the partially unfolded state for lysozyme 
amyloidosis has been demonstrated in vitro with the use of antibodies that stabilize the 
protein (Dumoulin et al. 2003; Chan et al. 2008). Studies have also shown that both the 
I56T and D67H mutants are less stable than WT lysozyme when heated (Booth et al. 1997), 
and the I56T mutant is also less stable than WT at low pH (Funahashi et al. 1996; Booth et 
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al. 1997; Morozova-Roche et al. 2000; Buell et al. 2011), further supporting a role for 
instability. However, other factors besides regions of protein instability may be involved in 
amyloidogenesis. Further studies that examine primary nucleation from different 
perspectives could provide more insight into this important process that is associated with 
a variety of diseases. 
Residue interaction networks (RIN) abstract protein structure into a network of 
likely side-chain interactions with residues represented as nodes and interactions 
represented as edges, the connections between the nodes (Di Paola et al. 2013). Several 
metrics are available for studying networks and identifying subnetworks of interest 
(Junker and Schreiber 2008; Estrada 2012; Scardoni and Laudanna 2012). Many network 
features have been associated with and applied to protein structural and functional 
characteristics (Liu and Hu 2011; Scardoni and Laudanna 2012; Hu et al. 2014; Emerson 
and Louis 2015), demonstrating the relevance of RINs to structural biology. Clusters are 
particularly interesting in RIN analysis because they identify areas with many chemical 
interactions, suggesting structural rigidity or functional importance (Vishveshwara et al. 
2002). RIN analysis is most useful when combined with 3D structural analysis (Amitai et al. 
2004). This study uses the two-pronged approach of combining 3D structural analysis with 
RIN analysis to identify residues in the native structure that are likely involved in amyloid 
formation. 
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Methods 
Three-Dimensional Structure Visualization and Structure Comparison 
The Online Mendelian Inheritance in Man (OMIM) database (Amberger et al. 2015) 
was searched for mutations in lysozyme that have been associated with amyloidosis. The 
Protein Data Bank (PDB) (Berman et al. 2000) was then searched for human lysozyme 
structures with these mutations, resulting in a dataset of WT human lysozyme (PDB ID: 
1REX, (Muraki et al. 1996)) and two amyloidogenic variants, I56T (PDB ID: 1LOZ, (Booth et 
al. 1997)) and D67H (PDB ID: 1LYY, (Booth et al. 1997)). The 3D protein structure 
coordinates were downloaded from the PDB and visualized using UCSF Chimera v1.11.2 
software (Pettersen et al. 2004). The 3D structures were overlapped using the MatchMaker 
application (Meng et al. 2006) in UCSF Chimera with default settings, and the root mean 
square deviations (RMSDs) for the full residues from the wild type (1REX) structure of 
lysozyme were calculated in the Multialign Viewer (Meng et al. 2006). Side chains that had 
a different location when compared to WT lysozyme in both amyloidogenic variants were 
selected for further study. Because the resolution of the PDB files used for the comparison 
was less than or equal to 1.8 angstroms, only residues with a RMSD from WT greater than 
or equal to 1.9 angstroms were considered. 
 
Generating Residue Interaction Networks and Calculating Clusters and Metrics 
 To detect network clusters in the proteins, the PDB files were converted to GML 
format using the Protein Graph Converter software from the Protein Graph Repository 
(PGR) (Dhifli and Diallo 2016). Each alpha carbon was considered a node, and an edge was 
drawn between every alpha carbon within seven angstroms of another. The GML files were 
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then analyzed for clusters using the MCODE application in the network analysis software 
Cytoscape v3.4.0 (Shannon et al. 2003). Only clusters with MCODE scores greater than or 
equal to 5.00 were selected for further analysis. The residues involved in the clusters in the 
amyloidogenic mutants were compared to those identified in WT lysozyme. As with the 3D 
structure comparison, cluster changes that are in common between the amyloidogenic 
mutants and different from WT lysozyme were selected for further analysis. UCSF Chimera 
was used to calculate the average residue B-factor for each of the clusters. The Pearson 
correlation of MCODE scores for the selected clusters of each of the lysozyme PDB files with 
the average B-factor for the clusters was calculated using GraphPad Prism 7, and a p-value 
of < 0.05 was considered significant. 
 
Generating Predicted Dimer and Trimer Structures and Calculating Interprotein Bond 
Number and Energies 
 ClusPro v2.0 software (Kozakov et al. 2017) was used to generate predicted 
structures of homodimers, homotrimers, and heterodimers for WT lysozyme and the 
amyloidogenic variants. After multimer generation, the resulting PDB files for the top 
predicted dimer and trimer structures were edited so that each lysozyme protein was 
given a unique name. Next, the edited PDB files were uploaded to the Residue Interaction 
Network Generator (RING) v2.0 software (Piovesan et al. 2016), and residue interaction 
networks were created using a strict distance threshold between the closest atoms of 
residues separated by at least two other residues. Multiple edges per residue pair were 
allowed but only one edge per interaction type. The resulting graph files were analyzed for 
the number of interactions and overall bonding energy occurring between lysozyme 
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proteins in dimers or trimers. The number and bond energies of the interprotein 
interactions were analyzed for the whole complexes and the residues of interest to provide 
information about the relative importance of the residues of interest to the formation of 
dimers and trimers. 
 
Results 
Three-Dimensional Structural Comparison of Lysozyme 
Three-dimensional structure overlaps from the MatchMaker software revealed 
residues of the amyloidogenic variants that differed from WT lysozyme. The D67H variant 
diverges more from WT lysozyme than the I56T variant. However, there are only four 
residues with a RMSD greater than or equal to 1.9 angstroms that were shared by both the 
I56T and the D67H amyloidogenic lysozyme variants: residues 21, 62, 104 and 122. In all 
four cases, the structural changes are in proximity to each other in the 3D structure (Figure 
2.1).  
 
Figure 2.1: Three-dimensional overlap of lysozyme structures 1REX (WT, tan), 1LOZ (I56T, 
orange), and 1LYY (D67H, blue). The side chains of residues 21, 62, 104, 112-117, and 122 
are shown and outlined in green. 
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Residue Interaction Network Clustering Analysis of Lysozyme Structures 
 The 3D structure of lysozyme and its resulting PGR residue interaction network 
(RIN) representation are shown in Figure 2.2. The MCODE application in Cytoscape 
revealed four clusters in each of the lysozyme structures that had an MCODE score of 
greater than 5.00. Some of the clusters in each of the lysozyme variants involved similar or 
identical sets of residues. As before, we focused on the differences from the WT clusters 
that were present in both amyloidogenic proteins. The most robust and consistent 
difference was the cluster around residues 112-117. The MCODE score for the cluster 
containing these residues in WT lysozyme was 5.11, but it increased in both amyloidogenic 
variants to 6.00. Residues 104 and 106-108 are clustered with 112-117 in WT lysozyme 
but not in I56T and D67H. The average B-factors of the clusters containing residues 112-
117 also decreased in both amyloidogenic variants compared to WT lysozyme. These 
results are shown in Table 2.1. Residues 112-117 are shown in Figure 2.1. There was a 
statistically significant negative correlation (r2 = 0.44, p = 0.0184) between MCODE scores 
for the top four clusters in each of the three lysozyme network structures and the average 
B-factor for each cluster. The residues are in proximity to the other residues of interest as 
shown in Figure 2.1. 
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Figure 2.2: Three-dimensional and network structures of lysozyme. A) The three-
dimensional structure of WT lysozyme, PDB 1REX. B) Network representation of WT 
lysozyme with amino acids represented as nodes and edges drawn between alpha carbons 
within seven angstroms of each other. Residue numbering starts at zero only for this image. 
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Table 2.1: RIN clusters in WT and amyloidogenic variants of lysozyme 
Lysozyme 
Structure 
Cluster 
Rank 
MCODE Score Residues Involved Average Residue 
B-Factor 
WT    14.88 
 1 6.36 92-103 12.35 
2 6.00 32-37 11.71 
3 5.60 7-13, 19, 23-29, 31 9.72 
4 5.11 104, 106-108, 112-117 19.09 
I56T    16.06 
 1 6.00 112-117 17.53 
2 6.00 92-98 10.54 
3 5.60 7-13, 19, 23-29, 31 10.39 
4 5.00 122-126 29.15 
D67H    13.24 
 1 6.50 92-100 7.83 
2 6.00 112-117 14.99 
3 6.00 32-37 8.21 
4 5.75 7-13, 17-19, 23, 25-29, 31 8.12 
 
 
 
Interprotein Bonds Involving Residues 21, 62, 104, 112-117, and 122 in Predicted 
Lysozyme Dimers and Trimers 
 The top-rated ClusPro models of dimer and trimer structures for each of the 
variants of lysozyme are shown in Figure 2.3 (homodimers), Figure 2.4 (homotrimers), and 
Figure 2.5 (heterodimers). The number of interprotein residue interactions and the 
strength of the bonding energy for these interactions for all residues and for the residues of 
interest were quantified using RING 2.0 software, and the results are shown in Table 2.2 
(homodimers), Table 2.3 (homotrimers), and Table 2.4 (heterodimers).  
 
50 
 
 
 
Figure 2.3: Predicted 3D structures of WT or mutant lysozyme homodimers. A) WT: WT, B) 
I56T: I56T, and C) D67H: D67H. The side chains of residues 21, 62, 104, 112-117, and 122 
are shown and outlined in green. 
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Figure 2.4: Predicted 3D structures of WT or mutant lysozyme homotrimers. A) WT: WT: 
WT, B) I56T: I56T: I56T, and C) D67H: D67H: D67H. The side chains of residues 21, 62, 
104, 112-117, and 122 are shown and outlined in green. 
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Figure 2.5: Predicted 3D structures of heterodimers of each of the amyloidogenic lysozyme 
variants with WT lysozyme. A) WT: I56T, B) WT: D67H. The side chains of residues 21, 62, 
104, 112-117, and 122 are shown and outlined in green. 
 
 
53 
 
Table 2.2 ClusPro predicted interprotein binding energies for WT and mutant lysozyme homodimers 
Lysozyme 
Structure 
Number of Interprotein Residue Interactions Interprotein Bond Energy (kJ/mol) 
Total Residues of Interest  
(% of Total) 
Total Residues of Interest 
(% of Total) 
WT 100 36 (36 %) 1019 398 (39.1 %) 
I56T 71 35 (49.3 %) 768 442 (57.6 %) 
D67H 61 18 (29.5 %) 594.6 246 (41.4 %) 
 
 
Table 2.3 ClusPro predicted interprotein binding energies for WT and mutant lysozyme homotrimers 
Lysozyme 
Structure 
Number of Interprotein Residue Interactions Interprotein Bond Energy (kJ/mol) 
Total Residues of Interest     
(% of Total) 
Total Residues of Interest 
(% of Total) 
WT 89 2 (2.2 %) 824.8 12 (1.5 %) 
I56T 133 74 (55.6 %) 1392.8 817 (58.7 %) 
D67H 108 24 (22.2 %) 1060.8 320 (30.2 %) 
 
 
Table 2.4 ClusPro predicted interprotein binding energies for WT and mutant lysozyme heterodimers 
Lysozyme 
Structures 
Number of Interprotein Residue Interactions Interprotein Bond Energy (kJ/mol) 
Total Residues of Interest     
(% of Total) 
Total Residues of Interest 
(% of Total) 
WT: I56T 48 25 (52.1 %) 481 238 (49.5 %) 
WT: D67H 49 27 (55.1 %) 482.6 289.6 (60.0 %) 
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For homodimers, residues of interest made up 36% of the number of interprotein 
residue interactions in WT lysozyme, contributing to 39.1% of the predicted interprotein 
bonding energy. The overall number of interprotein residue interactions increased to 
49.3% of the total in the I56T variant, but it decreased to 29.5% of the total number in the 
D67H variant. However, the total percentage of interprotein bonding energy contributed by 
the residues of interest increased for both amyloidogenic variants even though the total 
interprotein bonding energy for dimers was less than WT dimers. 
Trimers showed different trends from the homodimers (Table 2.3). The total 
number of interprotein residue interactions increased for I56T (133 interactions) and 
D67H (108 interactions) compared to WT (89 interactions). The contribution of the 
residues of interest to the total number of interprotein residue interactions increased from 
2.2% for the WT to 55.6% for the I56T variant and 22.2% for the D67H variant. 
Interprotein bonding energy showed similar trends. The total interprotein bonding energy 
increased from 824.8 kJ/mol in the WT to 1392.8 kJ/mol in the I56T variant and 1060.8 
kJ/mol in the D67H variant. Residues of interest contributed 1.5% of the total interprotein 
bonding energy in the WT but 58.7% in the I56T variant and 30.2% in the D67H variant. 
 Heterodimers (WT: I56T and WT: D67H) showed fewer and less energetic 
interprotein interactions than homodimers (Table 2.4). The WT: I56T variant heterodimer 
had 48 interprotein interactions and 481 kJ/mol interprotein bonding energy, and the WT: 
D67H variant heterodimer had 49 interprotein interactions and 482.6 kJ/mol bonding 
energy. In both cases, there was a high reliance on the residues of interest for the bonding. 
The residues of interest made up more than 50% of the number of interprotein bonding 
interactions and nearly 50% of the interprotein bonding energies of both heterodimers. 
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Discussion 
Three-Dimensional Structural Comparison Suggests Residues 21, 62, 104, and 122 May Be 
Involved in Lysozyme Amyloidogenesis 
 Comparing 3D protein structures revealed that both amyloidogenic variants of 
lysozyme analyzed differ from WT lysozyme in the location of residues 21, 62, 104, and 
122. Following the reasoning of Booth and colleagues (Booth et al. 1997), because these 
differences are common to both amyloidogenic variants, they suggest these residues may 
play a role in the formation of amyloid fibrils. The four residues (21, 62, 104, and 122) are 
in proximity to each other in all three variants (Figure 2.1). As discussed above, the 
prevailing hypothesis for lysozyme amyloidosis is that the mutations disrupt the hydrogen 
bonds near the residues between alpha and beta domains, leading to partial unfolding 
followed by fibril formation (Canet et al. 1999; Johnson et al. 2005; Buell et al. 2011); 
interprotein interactions between the native structures are not thought to play a large role 
in unfolding. However, the consistency of the structural changes observed in both 
amyloidogenic variants compared to WT hints at a role for these residues in amyloidosis. 
We hypothesized that these residues may facilitate an interprotein interaction between 
native state amyloidogenic lysozyme proteins, contributing to the first steps of amyloidosis. 
To gather further support for this hypothesis, we examined the structures for network 
cluster changes. 
 
Residues 112-117 May Also Be Involved in Lysozyme Amyloidogenesis 
 In addition to the 3D structural changes described above, amyloidogenic variants of 
lysozyme were associated with changes in network clusters. The network cluster 
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consisting of residues 112-117 in the I56T and the D67H variants had the greatest and 
most consistent cluster changes, showing an increased MCODE score in both variants 
compared to WT (Table 2.1). Residues 104 and 106-108 were included in the cluster 
containing residues 112-117 in WT lysozyme only, so the loss of this part of the cluster may 
also be important for the structural changes observed. More clustering has been shown to 
be associated with greater structural stability (Kannan and Vishveshwara 2000; 
Vishveshwara et al. 2002), so we hypothesized that residues 112-117 have greater 
structural stability in the amyloidogenic variants compared to WT lysozyme. To test this 
hypothesis, we used UCSF Chimera to calculate the average B-factor for each of the residues 
in each of the PDB files. The B-factor is a measure of flexibility where a lower B-factor 
indicates greater stability (Yuan et al. 2005). Even in our relatively small data set of three 
lysozyme structures, we found a statistically significant negative correlation (r2 = 0.44, p = 
0.0184) between MCODE scores and average B-factors for the top four clusters of each of 
the PDB files shown in Table 2.1. Consistent with the hypothesis of greater cluster stability, 
residues 112-117 had smaller average B-factors in amyloidogenic variants compared to the 
cluster containing these residues in WT lysozyme. Because most studies focus on the 
instability caused by amyloidogenic mutations, disrupting this cluster while stabilizing 
other regions may provide a novel therapeutic approach. The side chains of residues 112-
117 are shown in Figure 2.1 along with the other residues of interest (21, 62, 104, and 122) 
from the 3D structural comparison. Residues 112-117 are in proximity to the residues 
identified through the 3D structural comparison. Therefore, residues 112-117 may also be 
involved in facilitating interactions between different lysozyme molecules and possibly 
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contribute to the primary nucleation of amyloid fibrils. To test this hypothesis, we 
simulated intermolecular interactions between native state structures. 
 
Predicted Dimer and Trimer Structures Provide Further Evidence for the Involvement of 
Residues 21, 62, 104, 112-117, and 122 in Lysozyme Amyloidogenesis 
 To test the hypothesis that residues 21, 62, 104, 112-117, and 122 in the structure 
of amyloidogenic lysozyme variants are involved in primary nucleation, we used ClusPro 
docking software to predict the 3D structure of dimers and trimers of lysozyme for the PDB 
files. While ClusPro generates the structures of many predicted dimers and trimers, we 
only analyzed the top-ranked structures. Visual inspection of the predicted homodimers 
(Figure 2.3) suggested some of the residues of interest may be involved in dimer 
interactions. To test this hypothesis, we examined the number and strength of interprotein 
residue interactions (Table 2.2). The number of interprotein bonds was less for 
amyloidogenic variant homodimers, and there was no consistent trend with the percent 
contribution of the residues of interest to the number of interprotein bonds in the dimers. 
Both amyloidogenic variant homodimers had overall less bonding energy. However, the 
residues of interest contributed to a greater degree to the interprotein bonding energy 
compared to WT lysozyme. Overall, the contribution of the residues of interest to lysozyme 
homodimer formation in amyloidogenic variants was not as convincing as the evidence for 
their role in simulated trimer formation. 
Visual inspection of the predicted trimer structures of lysozyme suggested a greater 
role for the residues of interest in interprotein interactions of amyloidogenic variants than 
WT lysozyme (Figure 2.4). When examined quantitatively, both amyloidogenic variants 
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had stronger and more numerous bonds between proteins compared to WT (Table 2.3). 
This suggests the residues of interest may be largely facilitating the predicted sharp 
increase in interprotein interactions, supporting the important role predicted for these 
residues by 3D structural analysis and network analysis.  
 
A Role for Mutant Native Structure in Enhancing Lysozyme Amyloid Fibril Formation? 
Taken together, these data support the hypothesis that residues 21, 62, 104, 112-
117, and 122 in the mutant native states are involved in lysozyme amyloid primary 
nucleation. While the instability of amyloidogenic variants of lysozyme is almost certainly 
the most important factor for fibril formation (Dumoulin et al. 2005), it may not be the only 
factor involved. The greater interprotein interactions predicted to occur between trimeric 
amyloidogenic mutants compared to WT lysozyme may lead to amyloidogenic variants 
oligomerizing more readily before unfolding. We hypothesize these aggregates are 
composed of mostly mutant proteins because heterodimers with WT lysozyme have less 
interprotein bonding energies than mutant homodimers. This suggests when one of the 
lysozyme variants partially unfolds, it may already be in proximity to or bound by another 
mutant molecule, leading to a greater probability of amyloid nucleation. The sequence of 
events of the unfolding process for WT lysozyme and the I56T variant are consistent with 
our hypothesis. It has been demonstrated that lysozyme alpha helices A, B, and D 
(Moraitakis and Goodfellow 2003) are some of the last regions to unfold (Dhulesia et al. 
2010). All the residues identified in this report except residue 62 are in or near regions of 
the protein that unfold later in the unfolding process, so these positions have a greater 
chance of maintaining their structure to facilitate intermolecular interactions during this 
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process. Residues 21, 62, 104, and 122 do not appear to be involved in increasing the 
flexibility of lysozyme in the amyloidogenic mutants because the total predicted bond 
energies from RING analysis for monomers do not suggest consistent and structurally 
important differences when compared to WT. Furthermore, the average B-factors for these 
residues in mutant lysozyme do not consistently differ from WT. It has been suggested that 
residues not present in the partially unfolded region can be altered without affecting the 
process of amyloid fibril formation (Ahn et al. 2012), but our data challenge this 
suggestion. It has been noted that lysozyme amyloid plaques are nearly entirely composed 
of the amyloidogenic variant free from WT protein (Morozova-Roche et al. 2000). This may 
be due not only to the greater instability of amyloidogenic proteins, but also due to the 
predicted favored intermolecular interactions of mutant homodimers and homotrimers 
compared to heterodimers with WT molecules (Table 2.4). A better understanding of the 
process of amyloidogenesis for lysozyme could yield insights into treatments for many 
different types of amyloidoses. 
 
Study Limitations and Future Studies 
Data from various computational approaches in this study support a role for 
lysozyme residues 21, 62, 104, 112-117, and 122 in lysozyme amyloidosis. However, this 
study has several limitations. The most obvious limitation is the small sample size of 3D 
structures used. Unfortunately, the study is limited by the availability of PDB files of human 
amyloidogenic lysozyme variants. We draw our conclusions from three PDB files, making 
this a preliminary study. The findings reported here may not be shared by all 
amyloidogenic variants of lysozyme. To increase confidence in our conclusions, further 
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studies should explore the structures of WT and amyloidogenic lysozyme under various 
experimental conditions. Furthermore, these hypotheses need to be experimentally tested 
to verify the importance of these residues for amyloidogenesis. Lysozyme mutants with 
smaller side chains or nonpolar side chains at the residues of interest could be created and 
the fibril formation kinetics studied. Data from studies of double mutants may also be 
useful. Future studies could be performed where residues 21, 62, 104, 112-117, or 122 are 
mutated in combination with I56T or D67H and tested for altered fibril formation kinetics. 
However, it may be most useful to mutate residue 21 and a residue in 112-117 or 122 
because residues 32 through 108 have been shown to form the core of the lysozyme fibril 
(Frare et al. 2006). Therefore, mutating these residues may interfere with amyloid 
formation after unfolding. 
 
Conclusions and Testable Hypotheses Generated 
This preliminary study used a combination of 3D structural and residue interaction 
network analyses to support roles for residues 21, 62, 104, 112-117, and 122 in lysozyme 
amyloidosis. By comparing two amyloidogenic variants to WT lysozyme, we were able to 
identify network and 3D structural changes that were shared between the amyloidogenic 
variants. Modeling dimer and trimer interactions further supported a role for these 
residues. These residues appear to be especially important for trimer formation. This study 
generates several hypotheses that can be experimentally tested. 1) Residues 112-117 are 
less flexible in amyloidogenic variants of lysozyme than in the WT. 2) Residues 21, 62, 104, 
112-117, and 122 are involved in the primary nucleation of lysozyme by facilitating 
intermolecular interactions between mutant lysozyme molecules. 3) Trimers of lysozyme 
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are more stable than dimers. 4) Lysozyme mutant molecules favor self-interactions over 
interactions with WT molecules. 5) Interprotein interactions in or close to the native state 
likely play a larger role in amyloid formation in general than previously hypothesized. This 
study demonstrates the utility of combining 3D structural and network analysis for 
understanding amyloid formation. Furthermore, it provides insight into lysozyme amyloid 
formation that may be applicable to the study of many other amyloidoses. 
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Abstract 
 Amyloid plaques are known to contribute to the pathogenesis of a variety of 
diseases, but few 3D structural or sequence similarities among these proteins have been 
found.  Here we report similarities in the residue interaction networks (RINs) of unrelated 
non-amyloid forms of amyloidogenic proteins.  RINs for amyloidogenic proteins, non-
amyloidogenic proteins, and random network controls were created, and various network 
metrics were calculated to test for differences in network structures.  After finding 
differences in the RINs between a set of control proteins and a set of amyloidogenic 
proteins, we found differences in network structures when comparing amyloidogenic 
variants to non-amyloidogenic variants of the same proteins.  Next, we focused on amyloid-
beta (1-42) (Abeta42) because of its likely involvement in the pathogenesis of Alzheimer’s 
disease (AD).  Abeta42 is more amyloidogenic and therefore more likely to form amyloid 
plaques in aqueous environments than nonpolar environments that resemble cell 
membranes.  We examined the network and structural differences in Abeta42 in a more 
polar versus a relatively nonpolar solvent and found some of the network features of 
amyloids were only present when Abeta was in the more polar environment.  Insights from 
the combined use of network analysis and structural data suggest that the interaction 
between Val24 and Ile31 in Abeta42 in more nonpolar environments may be involved in 
preventing amyloidogenesis.  This in silico study generates hypotheses that could provide 
insight into amyloid primary nucleation. 
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Background 
 In many neurodegenerative diseases such as Alzheimer’s disease (AD) and 
Parkinson’s disease, specific proteins are known to aggregate into cross-β sheet structures 
called amyloid fibrils (Makin and Serpell 2005).  There are dozens of these diseases, 
collectively called amyloidoses, that affect several physiological systems (Greenwald and 
Riek 2010).  Amyloid fibrils are thought to contribute to disease processes (Knowles et al. 
2014).  The protein monomers that form fibrils associated with diseases are diverse, and 
there are few structural and sequence similarities among them (Tzotzos and Doig 2010).  
Further understanding the similarities among amyloidogenic proteins that are present 
could provide insight into the first steps of nucleation, when two or three molecules of the 
same protein interact to form oligomers that may continue aggregating to form fibrils 
(Knowles et al. 2014).  To investigate the molecular properties of amyloidogenic proteins 
that lead to plaque formation, we examined the residue interaction networks (RINs).  RINs 
represent the residue interactions that are likely to occur as determined by the protein 
structure and are reviewed by Di Paola et al. (Di Paola et al. 2013).  Each amino acid is 
represented as a node, and edges are drawn between residues that are likely to interact 
(Figure 3.1).  Various metrics have been devised to mathematically describe the network 
size and the connections within a network (Estrada 2012), and many of these metrics have 
biological interpretations useful for analyzing protein structure (Amitai et al. 2004; 
Scardoni and Laudanna 2012) (Table 3.1).  It has even been found that 3D structural 
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analysis techniques such as normal mode analysis reveal features that are largely 
determined by RINs (Bahar et al. 2010). RINs are powerful tools because they examine 
proteins from the perspective of a whole system rather than using a reductionist approach.  
This information complements more traditional structural and sequence studies, adding 
another layer to the understanding of protein function. RIN observations indicate residues 
that are important to the network (Estrada 2012); if a residue is important to the network, 
it is likely important to the 3D structure of the protein. This study investigates associations 
between RINs and amyloidogenicity to provide novel insights into common 3D structural 
features of non-amyloid forms of amyloidogenic proteins. If the non-amyloid forms of 
amyloidogenic proteins have similar features distinct from nonamyloidogenic proteins, 
these features may predispose the proteins to nucleate and fibrillize into amyloids. 
 
Figure 3.1: Three-dimensional and network structures of β-2-microglobulin. Residue 
interaction networks (RINs) abstract a 3D protein structure (left) into a network (right) of 
nodes (representing residues) and edges (representing potential residue bonds).  This 
structure and network is for β-2-microglobulin (PDB ID: 5CSB). The numbering of residues 
in the network begins at zero in this figure only. 
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Table 3.1: Network metrics and their interpretations 
Metric Interpretation of Metric 
Average Clustering Coefficient Average connectedness of a node’s neighbors 
 
Centralization 
 
Describes how much the network relies on hubs 
 
Average Shortest Path Length Mean minimum number of edges between one node 
and any other node 
 
Density 
 
Describes how connected the network is compared to a 
fully connected network 
 
Average Number of Neighbors Mean number of edges connected to a node 
 
Highest MCODE Score Describes the “strength” of the top cluster 
 
Average of Top 3 MCODE 
Scores 
Describes the average “strength” of the top three 
clusters 
 
Clusters per Node How many clusters are in a network (corrected for 
network size) 
 
Number of Nodes Total number of nodes in a network 
 
Betweenness Describes the extent to which a node is in the shortest 
path between other node pairs 
 
Residue Centrality Change in mean shortest path length after removing a 
node and its edges 
 
 
 Amyloid-beta (1-42) (Abeta42) is a 42 amino acid peptide that is hypothesized to be 
a causative factor in Alzheimer’s disease (Hardy and Higgins 1992).  As discussed above, 
Abeta42 forms amyloid fibrils and plaques in the brains of AD patients.  Many drug 
candidates have been designed to reduce the amount of amyloid plaques in the AD brain, 
but these efforts have been largely ineffective in treating AD in human trials (Herrup 
2015).  If blocking oligomerization and amyloidogenesis of Abeta42 can lead to treatments 
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for AD, a better understanding of the primary nucleation of this peptide could lead to more 
effective drugs.   
 Abeta is a well-studied peptide, and there are many reports describing the 
relationship between fibrillization and the Abeta sequence.  However, Abeta contains 
amino and carboxyl terminal regions of intrinsic disorder, and therefore detailed structural 
studies of the full-length peptide have proven challenging.  The central hydrophobic cluster 
(CHC), consisting of residues 17-21, has been shown to be important for fibrillization 
(Wurth et al. 2002).  Studies with fragments containing the CHC reveal that replacing any of 
the five residues prevents fibrillization (Wood et al. 1995).  Several other studies have also 
found the CHC to be important for fibrillization (Hilbich et al. 1991; Hilbich et al. 1992; 
Esler et al. 1996; Wurth et al. 2002).  However, the CHC is not the only region suspected to 
be involved in fibril formation.  Scanning proline mutagenesis of Abeta40 identified 
residues 24-26 and 31-34 as important for fibrillization (Williams et al. 2004).  The N-
terminal 10 to 15 residues have not been found to have much effect on amyloid formation 
(Sánchez De Groot et al. 2005).   
While some amyloidogenic proteins have regions that lack clearly defined structure, 
there is much evidence using different experimental conditions that Abeta is not 
completely disordered, and that the structured regions that are present play a role in 
nucleation and fibril formation. Studies have detected secondary structure in Abeta40 or 
Abeta42 dissolved in hexafluoroisopropanol (HFIP) (Crescenzi et al. 2002; Tomaselli et al. 
2006), aqueous solvent with and without trifluoroethanol (TFE) (Soto et al. 1995), 
aqueous sodium dodecyl sulfate (SDS) micelles (Coles et al. 1998; Shao et al. 1999), 
aqueous urea solutions (Chen and Glabe 2006), and aqueous glycine solutions (Kirkitadze 
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et al. 2001). HFIP and aqueous SDS micelles are used to model a phospholipid membrane 
environment (Shao et al. 1999; Crescenzi et al. 2002), so protein structures in these 
solutions are likely similar to the in vivo membrane structures. Studies have shown that 
some secondary structure is necessary for Abeta amyloid formation because Abeta 
fibrillization was decreased following the near complete denaturation of Abeta by urea 
(Chen and Glabe 2006).  
While the presence of secondary structure in Abeta dissolved in several different 
solvents has been described, there is not much consensus on the structural details. For 
example, while several studies have provided support for the existence of a turn region in 
Abeta, there are conflicting reports about where the turn occurs and even how many turns 
there are.  These inconsistencies are likely due to different solvent conditions and peptide 
fragments used for these experiments.  Williams et al. report two turn regions around 
residues 22-23 and 29-30 (Williams et al. 2004), whereas Morimoto et al. report only one 
turn around residues 22-23 (Morimoto et al. 2004), and Lazo et al. found evidence of one 
turn near residues 24-28 (Lazo et al. 2009).  More data will likely help clarify these 
inconsistencies reported for Abeta structure, allowing for more precise drug targeting. 
In this study we used both RINs and structural data to provide novel insights into 
the primary nucleation of Abeta42 and the role of solvent polarity in nucleation. We found 
that amyloidogenic proteins tend to be smaller, denser, and more centralized when 
compared to non-amyloidogenic controls.  These features indicate networks that are more 
reliant on hubs.  Potential binding pockets including these hub amino acids could prove 
useful as drug targets.  Furthermore, our data suggest that when Abeta42 is present in a 
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more nonpolar solvent or membrane environment the interactions between Val24 and 
Ile31 in Abeta42 may play a role in preventing primary nucleation. 
 
Methods 
Creating Residue Interaction Networks from PDB Files 
 3D structure files for amyloidogenic proteins available in the Protein Data Bank 
(PDB) (Berman et al. 2000) (Table 3.2) and proteins not known to form amyloid fibrils in 
disease (Real Protein Controls, Table 3.3) were downloaded.  The PDB files were uploaded 
to the Protein Graph Repository Converter (PGR Converter) (Dhifli and Diallo 2016 Jan 24) 
and used to create RINs.  A node was considered to be the alpha carbon and an edge was 
drawn between every alpha carbon within 7 Å.  The networks were exported from PGR 
Converter as GML files and then imported into Cytoscape v3.4.0 (Shannon et al. 2003) for 
visualization and network analysis. 
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Table 3.2: Network metrics of amyloidogenic proteins 
PDB 
ID 
Name SCOP Class Closest 
Match 
Nodes Density Clusters 
per Node 
Centralization 
1ZEH Insulin Small Protein α 102 0.074 0.069 0.056 
1IYT Amyloid-β (1-42) Peptide α 42 0.168 0.119 0.054 
1QLX Human Prion Protein α+β α+β 104 0.070 0.115 0.047 
1XQ8 α-Synuclein Coiled Coil α 140 0.046 0.100 0.019 
2KB8 Amylin NA α 37 0.188 0.108 0.095 
1LOZ Lysozyme (I56T) α+β α+β 130 0.060 0.092 0.049 
4IP8 Serum Amyloid-α α α 420 0.021 0.074 0.015 
5CSB β-2-Microglobulin 
(D76N) 
NA β 100 0.073 0.090 0.049 
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Table 3.3: Network metrics of real protein controls  
SCOP Protein 
Class 
Control 
Number 
PDB IDa Nodes Density Clusters 
per Node 
Centralization 
α 1 1A6M 151 0.052 0.073 0.028 
 2 1ALL 321 0.026 0.059 0.015 
 3 1B33 2060 0.004 0.064 0.002 
 4 1C75 71 0.114 0.099 0.103 
 5 1DLW 116 0.067 0.086 0.038 
 6 1DO1 153 0.052 0.092 0.034 
 7 1DWT 152 0.052 0.079 0.035 
 8 1FPO 499 0.015 0.060 0.009 
 9 1FXK 349 0.023 0.049 0.012 
 10 1G08 572 0.014 0.068 0.009 
 11 1H97 294 0.028 0.071 0.017 
 12 1HBR 572 0.014 0.072 0.009 
 13 1IDR 253 0.030 0.087 0.022 
 14 1IRD 287 0.028 0.077 0.017 
 15 1KR7 110 0.070 0.091 0.041 
 16 1KPT 334 0.025 0.078 0.014 
 17 1LIA 664 0.012 0.062 0.009 
 18 1MWC 306 0.026 0.059 0.017 
 19 1NEK 1068 0.008 0.073 0.005 
 20 1PHN 334 0.024 0.072 0.015 
α+β 21 1ALC, 1AVP 168.5 0.051 0.105 0.036 
 22 1BRN, 1CNS 351 0.026 0.081 0.016 
 23 1CQD, 1EUV 582 0.018 0.079 0.013 
 24 1F13, 1GCB 946.5 0.012 0.082 0.008 
 25 1GOU, 1IWD 216.5 0.036 0.081 0.027 
 26 1K3B, 1LNI 272 0.031 0.098 0.025 
 27 1LSD, 1ME4, 
1MZ8, 1PPN 245 0.039 0.101 0.031 
 28 1QMY, 1QSA, 
1UCH, 2ACT 377.5 0.026 0.084 0.019 
β 29 1AUN, 1BEH, 
1BHU, 1DMH, 
1DO6 308.6 0.039 0.090 0.030 
 30 1F35, 1F86, 
1G13, 1HOE, 
1I9R 569 0.038 0.091 0.023 
 31 1IAZ, 1IFR, 
1JK6, 1KCL, 
1KNB 299 0.041 0.097 0.030 
 32 1SFP, 1SHS, 
1SLU, 2MCM, 
2HFT 338.4 0.042 0.082 0.033 
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Creating Real Protein Controls 
The proteins selected for the real protein controls were based on the protein control 
groups created by Bagler (Bagler and Sinha 2005; Bagler 2006) and Sinha (Bagler and 
Sinha 2005).  The Bagler and Sinha protein library consists of 20 proteins each of the α, β, 
α+β, and α/β structural classes as defined by the Structural Classification of Proteins 
(SCOP) (Murzin et al. 1995) for a total of 80 protein control entries.  We searched the 
amyloidogenic proteins in SCOP, and, if they were assigned to a protein structure class that 
was not α, β, α+β, or α/β, we classified them as α, β, α+β, or α/β based on the closest best 
fit determined by visual inspection (Table 3.2).  If a protein was not included in SCOP, we 
searched for structural matches in SCOP and used the class of the closest match.  The 
resulting amyloidogenic group was 62.5 % α-class, 12.5 % β-class, 25 % α+β-class, and 0 % 
α/β class.  The real protein control group was adjusted to reflect the structural class 
composition of the amyloidogenic group by averaging metrics from random subgroups of 
real protein control entries in the same class to condense the 20 protein entries in each 
group so we could create a control group with 20 entries from the α-class, 4 entries from 
the β-class, and 8 entries from the α+β-class.  This method yielded a control group with the 
same percent composition of protein classes as the amyloidogenic protein group.  The 
averaged random subgroups and the resulting control group are included in Table 3.3. 
 
Creating Random RIN Controls 
The RIN metrics from the amyloidogenic proteins were compared to the real protein 
controls.  However, the real protein controls generally consisted of larger networks (Table 
3.3).  To determine if differences between groups are due to network size or network 
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connections, we created a random network control group of the amyloidogenic proteins 
(Table 3.4).  To create the random protein controls, we retained the number of nodes and 
edges from each RIN for the amyloidogenic proteins, but the connections between them 
were randomized using the Network Randomizer application (Tosadori et al. 2016) in 
Cytoscape.  For each amyloidogenic protein RIN, fifty random networks were created.  The 
RIN metrics were calculated for each of the networks, and then the mean of the fifty 
resulting metric values for each type of metric was used as the randomized metric value for 
the random control of a single amyloidogenic protein.  This process was repeated for each 
amyloidogenic protein. 
 
Table 3.4: Average metrics of randomized networks of amyloidogenic proteins 
PDB 
ID 
Name Nodes Density Clusters 
per Node 
Centralization 
1ZEH Insulin 102 0.074 0.033 0.074 
1IYT Amyloid-β (1-42) 42 0.168 0.056 0.142 
1QLX Human Prion Protein 104 0.070 0.031 0.070 
1XQ8 α-Synuclein 140 0.046 0.019 0.051 
2KB8 Amylin 37 0.188 0.056 0.154 
1LOZ Lysozyme (I56T) 130 0.060 0.028 0.062 
4IP8 Serum Amyloid-α 420 0.021 0.011 0.024 
5CSB β-2-Microglobulin (D76N) 100 0.073 0.033 0.071 
 
 
Calculating RIN Metrics 
Local RIN metrics were calculated in Cytoscape using the Network Analyzer 
application (Assenov et al. 2008).  The MCODE application (Bader and Hogue 2003) in 
Cytoscape was used to calculate the number of clusters in a network.  Centrality measures 
of Abeta42 included betweenness and residue centrality.  Residue centrality was calculated 
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as by Hu et al. (Hu et al. 2014) by taking the average path length for the whole Abeta42 
network, deleting a single node, recalculating the average path length for the resulting 
network, and then finding the absolute value of the change in average path length from the 
whole network.  This was repeated for every node in the Abeta42 network.  These values 
were used to determine which nodes have the highest betweenness values and which 
nodes are the most critical for maintaining the average path length.  We then calculated 
betweenness values for residues in Abeta42 and Abeta40 in more polar and more nonpolar 
solvents (PDB structure files 1IYT (Crescenzi et al. 2002); 1Z0Q (Tomaselli et al. 2006); 
1BA4 (Coles et al. 1998); 2LFM (Vivekanandan et al. 2011)).  Next, we averaged the 
betweenness values for residue regions of interest in Abeta and compared them across all 
four structures. 
 
Overlapping Abeta42 Structured Regions and Analyzing Residue Interactions 
 The PDB files for Abeta42 were visualized using UCSF Chimera v1.11.2 (Pettersen et 
al. 2004).  The unstructured regions of each of the PDB files as determined by visual 
inspection (residues 1-9 and 33-42) were trimmed off, and then the two structures were 
overlapped using the MatchMaker application (Meng et al. 2006) in UCSF Chimera.  The 
structural data for the PDB files for Abeta42 are from NMR experiments, so there is 
information for multiple models in each file.  To determine the residue interactions 
occurring in each model, each chain was individually input into the Residue Interaction 
Network Generator (RING) (Piovesan et al. 2016), and networks were created using the 
alpha carbons as nodes and by drawing a single undirected edge for each type of 
interaction between two residues.  The resulting networks were each analyzed for the 
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presence of edges between the residues of interest identified from the betweenness and 
residue centrality measures. 
 
Analyzing Predicted Abeta42 Trimer Interactions 
To determine the potential differences of contributions of the residues of interest to 
the energy of interpeptide bonding in a solvent, we used ClusPro (Kozakov et al. 2017) to 
predict the trimer structure of Abeta42 in a nonpolar or a polar solvent. The resulting PDB 
file for the ClusPro top-rated predicted structure was input into RING, and networks were 
created as described above. Bonding information was exported to Microsoft Excel and the 
predicted bond energies for interpeptide interactions were summed for each condition. 
 
Statistical Analysis of Data 
All statistical analyses were completed with GraphPad Prism v7.0, and p-values < 
0.05 were considered significant. 
 
Comparing Amyloidogenic Proteins, Real Protein Controls, and Random Network 
Controls. The data was tested for normality using the D’Agostino-Pearson normality test.  
When the data distribution was normal, and the groups had equal variance as determined 
by Bartlett’s test, a one-way ANOVA with Tukey’s post hoc test was performed.  This was 
the case for comparing the RIN metric clusters per node.  If data was not normally 
distributed but had equal variance, the Kruskal-Wallis test with Dunn’s multiple 
comparisons was performed.  This was the case for number of nodes and centralization.  If 
data was not normal and did not have equal variance, it was transformed by taking the 
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square root of each value and then rechecked for normality.  We then performed a one-way 
ANOVA with Tukey’s post hoc test.  This was the case for network density. 
 
Analyzing Abeta42 Centrality Metrics. To determine which residues had high 
centrality values, we checked the data for normality using the D’Agostino-Pearson 
normality test before calculating the z-score for each of the residues.  Betweenness values 
were normalized by taking the square root of each value, and residue centrality values 
were normalized by taking the cube root.  Z-score absolute values ≥ 2 were considered 
statistically significant.  For both betweenness and residue centrality, Val24 and Ile31 had 
z-score absolute values ≥ 2. 
 
Comparing Average Betweenness Values of Regions in Abeta. The arithmetic mean 
for betweenness was calculated for regions of interest of different lengths across several 
PDB structures of Abeta.  These average betweenness values of regions were compared to 
the average betweenness of the entire structure using a paired one-way ANOVA with 
Tukey’s post hoc test. 
 
Results 
RINs of Amyloidogenic Proteins Have Unique Features Compared to Controls 
Of the RIN metrics analyzed (average clustering coefficient, centralization, average 
shortest path length, density, average number of neighbors, highest MCODE cluster score, 
average of top 3 MCODE cluster scores, clusters per node, and number of nodes), four 
metrics showed significant differences when comparing amyloidogenic proteins to the 
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controls (Figure 3.2).  The eight amyloidogenic proteins in our data set are shown in Table 
3.2.  If the amyloidogenic protein group differs from the real protein controls in the same 
direction and magnitude as the random controls, then the differences are due to network 
size and not wiring (the specific connections between nodes).  If both the amyloidogenic 
protein group and the random control group differ from the real protein controls and differ 
from each other, then at least some of the differences are due to network wiring.  First, 
compared to real protein controls, amyloidogenic proteins tend to have fewer nodes 
(Figure 3.2A) and a higher density (Figure 3.2B).  These metrics are a measure of network 
size rather than connections.  However, some measures related to network wiring also 
showed significant differences.  Amyloidogenic proteins had 1) slightly greater numbers of 
clusters per node (Figure 3.2C) compared to real protein controls or random networks.  
Furthermore, 2) the centralization of amyloidogenic RINs was greater than real protein 
controls but less than random network controls (Figure 3.2D). 
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Figure 3.2: Comparing network metrics for amyloidogenic proteins (APs), real protein 
controls (Real Protein Ctrl), and random network controls (Random Ctrl).  # indicates p ≤ 
0.05, ## indicates p ≤ 0.01, ### indicates p ≤ 0.001, and #### indicates p ≤0.0001 when 
compared to Real Protein Ctrl. 
 
 
RINs of Amyloidogenic Variants of Proteins Show Similar Patterns as When Comparing 
Amyloidogenic RINs to Real Protein Controls 
We compared the RINs of wild type (WT) variants to amyloidogenic variants of the 
same proteins. The findings are reported in Table 3.5 for lysozyme (an α+β class protein) 
and Table 3.6 for β-2-microglobulin (a β-class protein).  Lysozyme and β-2-microglobulin 
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were chosen because they both had WT and amyloidogenic variant structures available in 
the Protein Data Bank (Muraki et al. 1996; Booth et al. 1997).  For centralization but not for 
density or clusters per node the amyloidogenic lysozyme variants I56T and D67H showed 
similar differences from the WT protein as the group of amyloidogenic proteins showed 
when compared to real protein controls.  For centralization and density only D76N β-2-
microglobulin showed similar differences from the WT protein as the group of 
amyloidogenic proteins showed when compared to real protein controls. 
 
 
Table 3.5: Effects of amyloidogenic mutations of lysozyme (α+β class) on RIN   
                  metrics 
Network Metric WTa I56Tb D67Hc Consistent with Group Trends? 
Centralization 0.049 0.049 0.050 Yes 
Density 0.0604 0.0602 0.0598 No 
Clusters per Node 0.108 0.092 0.115 No 
aPDB ID 1REX 
bPDB ID 1LOZ 
cPDB ID 1LYY 
 
 
Table 3.6: Effects of amyloidogenic mutations of β-2-microglobulin (β-class) on RIN   
                  metrics 
Network Metric WTa D76Nb Consistent with Group Trends? 
Centralization 0.040 0.049 Yes 
Density 0.072 0.073 Yes 
Clusters per Node 0.10 0.09 No 
aPDB ID 5CS7 
bPDB ID 5CSB 
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RINs of Abeta40 and Abeta42 Show Similar Patterns as When Comparing Amyloidogenic 
RINs to Real Protein Controls 
We compared the RINs from Abeta42 in 20% H2O, 80% hexafluoroisopropanol 
(v/v) (Crescenzi et al. 2002), a more nonpolar solvent (predicted to make Abeta less 
amyloidogenic), to those in 70% H2O, 30% hexafluoroisopropanol (v/v) (Tomaselli et al. 
2006), a more polar solvent (predicted to make Abeta more amyloidogenic), and found that 
the centralization was different and changed in a direction consistent with the trends 
described above for real protein controls versus amyloidogenic proteins.  However, 
clusters per node or density did not follow these trends (Table 3.7).  We found similar 
results when comparing the RINs of Abeta40 in nonpolar and polar solvents (Table 3.8).  
 
Table 3.7: Effects of solvent conditions on amyloid-beta (1-42) RIN metricsa 
Network Metric Nonpolarb Polarc Consistent with Group Trends? 
Centralization 0.054 0.063 Yes 
Density 0.168 0.159 No 
Clusters per Node 0.119 0.095 No 
a Amyloid-beta (1-42) tends to form amyloid plaques in polar solvents 
(Crescenzi et al. 2002). 
b PDB ID 1IYT 
c PDB ID 1Z0Q 
 
Table 3.8: Effects of solvent conditions on amyloid-beta (1-40) RIN metricsa 
Network Metric Nonpolarb Polarc Consistent with Group Trends? 
Centralization 0.069 0.086 Yes 
Density 0.165 0.123 No 
Clusters per Node 0.125 0.125 No 
a Amyloid-beta (1-42) tends to form amyloid plaques in polar solvents 
(Crescenzi et al. 2002). 
b PDB ID 1BA4 
c PDB ID 2LFM 
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RINs of Abeta40 and Abeta42 Reveal Higher Mean Betweenness Values for the CHC 
The central hydrophobic cluster (CHC) in the Abeta40 and Abeta42 peptides spans 
residues 17-21.  Compared to the average betweenness of each of the entire structures, the 
CHC had a significantly higher average betweenness (Figure 3.3).  Because betweenness 
can indicate structurally important residues, this agreed with the visual examination of the 
3D structure of Abeta40 and Abeta42 in each solvent where it is visually evident that the 
CHC largely retains its structure. 
 
 
 
Figure 3.3:  Average betweenness of regions of Abeta40 and Abeta42 compared to the 
average betweenness of the entire node set.  # indicates p ≤ 0.05 and ## indicates p ≤ 0.01. 
 
 
Val24 and Ile31 Have Significantly Higher Centrality Values 
The betweenness (Figure 3.4A) and residue centrality (Figure 3.4B) measures for 
each residue in Abeta42 in the more nonpolar solvent are shown.  In each case, the values 
for Val24 and Ile31 were higher than the value for the average node in the network, and 
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each has a z-score absolute value of ≥ 2.0, so they were significantly different from the 
values of the other residues.  Structural data indicated that Val24 and Ile31 were likely to 
form hydrophobic interactions in 3 of 10 NMR models in the PDB 1IYT structure file (more 
nonpolar solvent), but no hydrophobic interactions between these residues were predicted 
in any of the 30 models in the PBD 1Z0Q structure file (more polar solvent).  The structures 
in the more nonpolar and more polar environments for representative NMR models are 
shown in Figure 3.5. 
 
 
 
 
Figure 3.4:  Betweenness and residue centrality values for each residue in Abeta42 in a 
more nonpolar solvent (1IYT). * indicates a z-score ≥ 2.0. 
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Figure 3.5: Structured regions of Abeta42 in a more nonpolar solvent (tan, 1IYT) and a 
more polar solvent (blue, 1Z0Q). The side chains of Val24 and Ile31 are shown highlighted 
in green in each case. 
 
 
 
 
 
Predicted Trimers of Abeta42 Suggest Greater Interpeptide Bonding Energy in More Polar 
Solvents 
The PDB files of the predicted trimers with the top ClusPro ranking for 1IYT 
(showing the possible Val24-Ile31 hydrophobic interaction) and 1Z0Q (showing no Val24-
Ile31 hydrophobic interaction) were used to generate RINs, and the predicted bonding 
energies were analyzed (Figure 3.6).  The total bonding energy between chains was larger 
for the predicted trimer with no hydrophobic Val24-Ile31 interaction (1Z0Q PDB file). 
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Figure 3.6:  Predicted trimer structures of Abeta42. UCSF Chimera predictions of trimer 
formation for Abeta42 in a more nonpolar solvent (left, 1IYT) and a more polar solvent 
(right, 1Z0Q). The side chains of Val24 and Ile31 are shown highlighted in green in each 
case. 
 
 
Discussion 
RINs From Amyloidogenic Proteins Suggest Similarities in Structure 
By comparing non-amyloidogenic protein RINs to those of amyloidogenic proteins, 
differences unique to amyloidogenic proteins were detected. When interpreted in the light 
of structural data, the results could be important for understanding the amyloidogenic 
process and developing strategies to prevent it. RIN metrics have important biological 
interpretations, allowing for structural and functional predictions (Amitai et al. 2004; 
Scardoni and Laudanna 2012).  Compared to real protein controls, amyloidogenic proteins 
tended to be more centralized, smaller, denser, and had more clusters per node (Figure 
3.2).  The network metric differences due to differences in network wiring provide novel 
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insight into the structure of amyloids.  Amyloidogenic proteins had more clusters per node.  
A cluster is a group of nodes that is highly connected (Bader and Hogue 2003), indicating 
the potential for many residue interactions.  This suggests a greater number of local areas 
of higher stability in amyloidogenic proteins compared to non-amyloidogenic proteins. 
This does not contradict the well-established finding that destabilizing mutations increase 
amyloidogenesis because the amyloidogenic proteins could be globally less stable while 
having a few local areas of higher stability. Amyloidogenic proteins were also more 
centralized. Centralization describes the “star-like” character of a network (Pavlopoulos et 
al. 2011), which can also be described as reliance on hubs.  A reliance on hubs makes 
proteins more robust against random “attacks” such as random amino acid substitutions 
caused by DNA mutations, but it leaves them more susceptible to targeted attacks (Albert 
et al. 2000; Oltvai et al. 2000), such as those that can occur when groups of amino acids 
including hubs are targeted by rational drug design.  Drugs targeting these hub regions are 
more likely to greatly disrupt or stabilize peptide structure than drugs targeting other 
regions of the protein.  Network metrics revealed common features in amyloidogenic 
proteins that have not previously been described.  These common features may enhance 
our understanding of the pathogenesis of amyloidoses. 
 
Some of the Network Differences Observed for Amyloidogenic Proteins as a Group Are 
Robust Enough to Be Observed in Mutant Variants of the Same Protein 
This study reports significant network differences between an amyloidogenic 
protein group and a group of non-amyloidogenic proteins. We also investigated whether 
the differences between amyloidogenic proteins and real protein controls held when 
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examining different mutant variants of the same protein.  Lysozyme (an α+β class protein) 
has been extensively studied as a model of amyloidogenesis because it has mutant variants 
that differ by a single residue that are much more likely to form amyloid plaques 
(Swaminathan et al. 2011).  We compared WT lysozyme network metrics to those of two 
different amyloidogenic variants and observed similar changes in centralization as when 
comparing amyloidogenic proteins to real protein controls (Table 3.5).  The protein β-2-
microglobulin (a β-class protein) also had a WT structure and an amyloidogenic variant for 
comparison. The expected trends held for centralization and density for β-2-microglobulin 
(Table 3.6). The network metric differences were understandably small because we 
analyzed networks that only had a single amino acid change. Because increased 
centralization was present in the amyloidogenic variants of proteins from these two 
classes, increased centralization may be a more robust difference between amyloidogenic 
proteins and non-amyloidogenic proteins than other network metrics tested. Therefore, 
drugs could be designed to target the regions of the peptide that include the hubs that 
amyloidogenic proteins appear to rely on most heavily for network structure. 
 
Network Variations Can Be Observed for the Same Protein in Different Solvents 
Some of the differences observed when comparing amyloidogenic proteins to real 
protein controls were observed even when comparing the networks of the same protein in 
different solvents. Abeta42 structures in HFIP were used because HFIP is a model for 
hydrophobic membrane environments (Crescenzi et al. 2002). While HFIP likely 
exaggerates the alpha helicity of Abeta (Pachahara et al. 2015), it is still a relevant model 
for Abeta structure in vivo because alpha helical Abeta likely plays a role in 
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amyloidogenesis (see Background). The two concentrations of HFIP used for structural 
studies also allow for a direct comparison to determine the effects of solvent polarity on 
Abeta structure. We examined network properties of Abeta42 dissolved in a more nonpolar 
solvent where it is less amyloidogenic and those present when it is dissolved in a more 
polar solvent where it is more amyloidogenic (Crescenzi et al. 2002).  Interestingly, we 
found the Abeta42 network when the more polar solvent was used to be more centralized 
than that for Abeta42 when the more nonpolar solvent was used (Table 3.7). We observed 
the same trend when comparing Abeta40 dissolved in the more nonpolar and more polar 
solvents (Table 3.8). Because this trend was also found when comparing the amyloidogenic 
variants of lysozyme and β-2-microglobulin with their WT variants, increased 
centralization appears to be a consistent feature of amyloidogenic proteins. As discussed 
above, increased centralization could indicate the presence of effective drug targets in 
amyloidogenic proteins because of the increased reliance on hubs.   
 
Results from RIN Metrics Support a Role for the CHC in Abeta Fibrillization 
Amyloid-beta is a well-studied protein with much known about its structure.  The 
CHC has been identified as an important region of Abeta for fibrillogenesis (Wurth et al. 
2002).  Consistent with these studies, we found that the CHC has significantly higher 
average betweenness values compared to the average betweenness values of the entire 
networks (Figure 3.3).  Betweenness describes the frequency with which a node occurs in 
the shortest path length between any two other nodes (Chakrabarty and Parekh 2016).  
Betweenness is used as a metric to identify residues that are important for the overall 
network (Steuer and Lopez 2008) and therefore for the 3D structure.  The significantly 
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higher average betweenness values for the CHC indicate that it is an important region for 
the structure of Abeta monomers.  This agrees well with several other studies (Hilbich et al. 
1991; Hilbich et al. 1992; Esler et al. 1996; Wurth et al. 2002), providing support for the 
usefulness of RINs in the study of protein structure and function. 
 
Disrupting the Predicted Interaction Between Val24 and Ile31 in Abeta42 in a More 
Nonpolar Solvent May Facilitate Primary Nucleation 
Because increased centralization suggests reliance on hubs, we analyzed network 
and structural data to identify the key residues for network structure of Abeta42 when 
dissolved in a more nonpolar solvent where it is less amyloidogenic. We calculated the 
betweenness and residue centrality values for each residue in the structure (Figure 3.4), 
and residues Val24 and Ile31 were shown to have significantly higher values than the other 
residues. Therefore, two separate methods for identifying key residues support the 
conclusion that the interaction between Val24 and Ile31 is important for overall network 
structure in Abeta42 when it is dissolved in a more nonpolar solvent. 
Residue interaction network data is most useful when combined with sequence and 
structural data (Amitai et al. 2004), so we examined the 3D structure of Abeta42 when it is 
dissolved in a more nonpolar solvent to determine the effects that these residues may exert 
on the overall structure (Figure 3.5).  When dissolved in the more nonpolar solvent, 
Abeta42had a noticeable turn near Val24 and Ile31, so we hypothesized the presence of a 
hydrophobic interaction between them.  To test this hypothesis, we uploaded the PDB file 
to RING which predicted the interactions that occur within the structures.  The predicted 
interaction between Val24 and Ile31 in a nonpolar environment may be important for 
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maintaining the less-amyloidogenic structure of Abeta42.  The involvement of Val24 and 
Ile31 in Abeta fibrillization has previously been identified by scanning proline mutagenesis 
(Williams et al. 2004). To our knowledge, we are the first to predict an interaction between 
Val24 and Ile31 in Abeta42 to be important for preventing fibrillization. 
To further determine why Abeta42 is more likely to engage in primary nucleation in 
more polar solvents compared to more nonpolar solvents, software was used to predict 
Abeta42 trimer formation under both solvent conditions, and interpeptide bonding energy 
was calculated (Figure 3.6).  Evidence has shown that oligomers are the form of Abeta that 
is most toxic to neurons (Sakono and Zako 2010), so even if trimers only exist transiently 
on the path to fibril formation, structural studies of trimers are important. However, there 
is experimental evidence that relatively stable trimers and tetramers of Abeta exist (Chen 
and Glabe 2006). The interpeptide bonding energy was much higher for Abeta42 when 
dissolved in the more polar solvent.  Increased bonding energy suggests tighter binding 
between the individual components of an Abeta42 trimer when dissolved in the polar 
solvent compared to the nonpolar solvent.  We hypothesize that the lack of an interaction 
between Val24 and Ile31 allows for a more linear conformation, facilitating tighter bonding 
and primary nucleation.  Therefore, drugs designed to stabilize the interaction between 
Val24 and Ile31 may prevent primary nucleation and reduce the number of toxic Abeta42 
oligomers. 
 
Study Limitations 
 While there are several dozen amyloidogenic proteins in the human proteome, our 
experimental group only contained eight due to the limited availability of PDB data files.  
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The relatively small size of the amyloidogenic protein group is a limitation of this study.  
Second, our conclusions regarding Abeta42 structural differences are based on only two 
structures.  More structural data for Abeta42 in monomeric form in different solvent 
conditions would increase our confidence in the conclusions.  Third, some of the effect sizes 
are relatively small.  It is not entirely clear if these small effects could lead to functional 
differences between the groups.  Finally, the hypotheses generated from the data presented 
here need to be experimentally tested to verify the validity of our conclusions.  Sciarretta 
and colleagues created a lactam link between two different residues of Abeta40 to test the 
effects of conformational changes on the nucleation of beta-amyloid (Sciarretta et al. 2005).  
A similar method covalently linking Val24 to Ile31 in an aqueous solvent and comparing 
nucleation to an unlinked peptide could be used to test our hypothesis.  However, the 
predicted Val24-Ile31 interaction is likely only one of several interactions necessary to 
prevent oligomerization. 
 
Conclusions 
 Metrics from residue interaction network structures of amyloidogenic proteins 
were statistically different from those of a group of non-amyloidogenic control proteins.  
These differences included increased centralization and clusters per node.  Increased 
centralization implies the presence of residues that act as hubs in the network, making the 
protein more susceptible to targeted attacks such as those occurring from rationally 
designed drugs.  Some of these differences were observed even when comparing 
amyloidogenic variants to the WT non-amyloidogenic variant of the same protein.  
Furthermore, increased centralization was observed when comparing the structure of 
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Abeta42 in a more nonpolar solvent to that in the more amyloid-friendly polar solvent.  The 
local RIN metrics of betweenness and residue centrality identified residues 24 and 31 as 
hubs.  Combining this data with structural analysis suggests stabilizing the interaction 
between Val24 and Ile31 may help prevent oligomerization of Abeta42.  Combining the use 
of network analysis and structural data produces novel insight that can be used for the 
design of drugs for the treatment of amyloidoses. 
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Abstract 
After proteolysis, the majority of released free amino acids from dietary protein are 
transported to the liver for gluconeogenesis or to peripheral tissues where they are used 
for protein synthesis and eventually catabolized, producing ammonia as a byproduct.  High 
ammonia levels in the brain are a major contributor to the decreased neural function that 
occurs in several pathological conditions such as hepatic encephalopathy. Therefore, it is 
important to gain a deeper understanding of human ammonia metabolism.  The objective 
of this study was to predict changes in blood ammonia levels resulting from alterations in 
dietary protein intake or from liver disease and to determine the toxicity of ammonia on 
differentiated SH-SY5Y neuroblastoma cells.  A simple mathematical model was created 
using MATLAB SimBiology and data from published studies. Simulations were performed 
and results analyzed to determine steady state changes in ammonia levels resulting from 
varying dietary protein intake and varying liver enzyme activity levels to simulate liver 
disease.  As a toxicity reference, viability was measured in SH-SY5Y neuroblastoma cells 
following differentiation and ammonium chloride treatment.  Results from simulations 
yielded physiological steady state blood ammonia levels and reasonably approximated 
pathophysiological steady state levels resulting from liver cirrhosis or a genetic carbamoyl 
phosphate synthetase I (CPS1) deficiency.  A pathophysiological level of ammonium 
chloride (90 µM) decreased the viability of differentiated SH-SY5Y cells by 14%.  Data from 
the model suggest decreasing protein consumption may be one simple strategy to decrease 
blood ammonia levels and minimize the risk of developing encephalopathy for some liver 
disease patients. 
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Background 
Protein is an abundant part of the human diet.  It is recommended that humans 
consume 0.8 g of protein per kg body mass per day.  For a male of average weight (88.7 kg) 
(Fryar et al. 2012), this is equivalent to 71 g of protein per day.  When amino acids are 
consumed at a faster rate than they are used for protein synthesis, they are metabolized as 
an energy source, typically accounting for roughly 15%-20% of the energy supply.  The 
liver breaks down nearly half of the amino acids in the human diet as substrates for 
gluconeogenesis (Jungas et al. 1992).  Amino acid catabolism first relies upon the transfer 
of the amino group by aminotransferases to a ketoacid, often to alpha-ketoglutarate to form 
glutamate, and then by the deamination of glutamate by glutamate dehydrogenase which 
produces ammonia (NH3).  Roughly 12.5% of nitrogen intake is excreted from the digestive 
tract (Tome and Bos 2000).  Because ammonia is relatively toxic (Auron and Brophy 2012),  
systems such as the urea cycle are in place primarily in the liver to convert it into a less 
toxic form that can be readily removed from the circulation and excreted.   
The liver is the main organ responsible for filtering ammonia and other nitrogen 
sources such as glutamine from the blood to synthesize urea, the major form of excreted 
nitrogen in mammals.  Urea is a relatively nontoxic waste product that safely stores 
nitrogen until it can be removed from the body.  However, when ammonia is not 
successfully removed from the blood due to impaired or overwhelmed removal 
103 
 
mechanisms, the plasma ammonia concentration increases, which may cause deleterious 
effects such as neural impairment (Ott and Vilstrup 2014).  As part of the process of 
nitrogenous waste removal, nitrogen-rich blood enters through the hepatic portal vein and 
is eventually filtered through the acinus, the functional unit of the liver, before draining out 
of the central vein.  The acinus is divided into three zones (Brosnan and Brosnan 2009).  
Zone 1 is the closest to the hepatic portal vein, and zone 3 is the closest to the central vein.  
The hepatocytes spanning these three zones do not all perform the same metabolic 
functions (Häussinger et al. 1992); rather, different branches of nitrogen metabolism are 
localized to specific zones.  Zones 1 and 2 contain the enzymes of the urea cycle (Moorman 
et al. 1989) as well as glutaminase (Moorman et al. 1994), an enzyme that removes 
nitrogen from glutamine to yield ammonia and glutamate.  However, zone 2 has less 
glutaminase activity than zone 1. Zone 3 contains glutamine synthetase (Gebhardt and 
Mecke 1983), an enzyme that combines ammonia and glutamate to produce glutamine and 
is also called glutamate-ammonia ligase (GLUL). 
Liver disease can change the activities of several key enzymes involved in nitrogen 
metabolism.  For example, liver cirrhosis results in decreased expression of GLUL and the 
urea cycle enzyme CPS1 (Gebhardt and Reichen 1994; Fleming and Wanless 2013).  
Mutations in the CPS1 gene can lead to individuals born with a deficiency in mitochondrial 
carbamoyl phosphate synthetase activity (Klaus et al. 2009).  Because CPS1 catalyzes the 
first committed step of the urea cycle, this can have serious consequences on nitrogen 
metabolism.  The increase in the number of individuals with liver disease in recent years 
(Mokdad et al. 2014) combined with an average protein intake in the U.S. that is about 40% 
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above the recommended value (NHAHES 2006) creates the need for understanding the 
effects of increased protein intake on blood ammonia levels.  
Increased blood ammonia levels are a causative agent in hepatic encephalopathy 
(HE) (Butterworth 2003), but increased ammonia levels have also been implicated in other 
neural disorders such as Alzheimer’s disease (Seiler 2002), amyotrophic lateral sclerosis 
(Parekh 2015), and Huntington’s disease (Chen et al. 2015).  HE results from liver damage 
leading to cognitive impairment. Liver disease also increases the blood levels of other 
potentially neurotoxic factors such as manganese and pro-inflammatory cytokines 
(Butterworth 2015) that may contribute to the encephalopathy as well.  Between 30% and 
45% (Poordad 2007) of the more than 600,000 patients (Scaglione et al. 2015) with liver 
cirrhosis each year will develop hepatic encephalopathy, resulting in a cost of nearly $1 
billion per year (Poordad 2007).  Most treatments aim to reduce the level of circulating 
ammonia (Butterworth 2003).  Due to challenges in reliably assaying ammonia due to its 
reactivity (Goggs et al. 2008; Blanco Vela and Bosques Padilla 2011), there are not many 
studies that measured the effects of dietary alterations on blood or tissue ammonia levels.  
Our model provides further insight into how changes in dietary protein intake may affect 
blood ammonia levels to better direct these treatment strategies. 
We used data from the literature to create a computational model that simulates 
ammonia metabolism and predicts blood ammonia levels based upon the amount of 
protein consumed and upon the degree of liver dysfunction.  Results from the model agree 
relatively well with measured physiological and pathophysiological steady state metabolite 
levels, and several insights were made from varying our initial conditions to investigate the 
role of key enzymes in human organismal nitrogen metabolism.  Cell culture studies were 
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used to extend the model and establish the toxicity of pathophysiological concentrations of 
ammonia on differentiated SH-SY5Y neuroblastoma cells in culture. 
 
Methods 
Description of the Model 
This model describes the changes in ammonia, urea, and glutamine in the blood with 
the following ordinary differential equations: 
 
            
𝑑[𝑁𝐻3]
𝑑𝑡
= 𝑉𝑁𝐻3 𝑎𝑏𝑠 + 𝑉𝐺𝐿𝑆 − 𝑉𝑈𝑟𝑒𝑎 𝑓𝑜𝑟 𝐵𝑎𝑙𝑎𝑛𝑐𝑒 − 𝑉𝐶𝑃𝑆1 − 𝑉𝑁𝐻3 𝑒𝑥 − 𝑉𝐺𝐿𝑈𝐿             (1)  
            
𝑑[𝑈𝑟𝑒𝑎]
𝑑𝑡
= 𝑉𝐶𝑃𝑆1 − 𝑉𝑈𝑟𝑒𝑎 𝑒𝑥                                                                                       (2) 
            
𝑑[𝐺𝑙𝑛]
𝑑𝑡
= 𝑉𝐺𝐿𝑈𝐿 − 𝑉𝐺𝐿𝑆                                                                                               (3) 
 
The overall reaction scheme is shown in Figure 4.1.  Equations for reaction velocities 
in Equations 1, 2, and 3 are shown in Table 4.1.  Carbamoyl phosphate synthetase 1 (CPS1) 
catalyzes the first committed step in the urea cycle, so this is the only enzyme of the cycle 
incorporated into the model for simplicity.  Other model parameters are shown in Table 
4.2.  Mammalian enzymes from liver tissue were used when the data was available (see 
Table 4.1).  No distinction is made between NH3 and NH4+ in this study unless otherwise 
noted.  N-acetyl-glutamate (NAG) is a CPS1 activator that increases in concentration when 
more protein is consumed (Morimoto et al. 1990).  To model the effects of NAG on CPS1 
activity, we interpolated data on CPS1 activity changes from a study that included the 
effects of changes in hepatic mitochondrial NAG levels due to diet (Morimoto et al. 1990) 
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(about 11% in this study).  The maximally activated activity of CPS1 (Pierson and Brien 
1980) was adjusted to reflect the reduced activity at physiological NAG concentrations 
(McGivan et al. 1976; Caldovic and Tuchman 2003) for all the protein diets and liver 
conditions used in the study.  The adjusted CPS1 values for individuals on the three diets of 
differing protein content are as follows: 71 g protein per day, 8.05 mmoles/min; 100 g 
protein per day, 8.47 mmoles/min; 122 g protein per day, 8.78 mmoles/min.  Adjustments 
for liver conditions are described below. 
 
 
 
 
Figure 4.1:  Model of nitrogen metabolism and excretion.  NH3 in the figure includes both 
ammonia and ammonium ions.  Circles represent reactions (see Table 4.1 for reaction 
equations) and ovals represent reactants and products. A) Conceptual framework of the in 
vivo physiology simulated including the many tissues and subcellular compartments 
involved.  B) The system is modeled in silico considering only the concentrations of 
metabolites in the blood.  Abbreviations are as follows: GLUL, glutamine synthetase; Gln, 
glutamine; GLS, glutaminase; CPS1, carbamoyl phosphate synthetase 1; Urea ex, urea 
excreted; NH3 abs, ammonia absorbed; NH3 ex, ammonia excreted. 
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Table 4.1 Values for reaction velocities scaled to average healthy male liver mass with healthy 
protein diet 
Reaction Velocities Parameters from the 
Literature 
Organism and 
Tissue 
Parameters Scaled 
to Liver 
  
VNH3 abs = 0.492 mmol/mina 
 
 
 
 
VGLS = (Vmax GLS[Gln])/ 
              (Km Gln + [Gln]) 
Vmax GLS = 91.4 
nmole/min per mg 
(McGivan et al. 1991)  
 
Km Gln = 4.0 mM 
(DeLaBarre et al. 2011)  
Rat Liver 
 
 
 
Human 
Recombinant 
Vmax GLS = 28.54 
mmol/min 
 
 
 
Km Gln = 4.0 mM 
 
VCPS1 = (Vmax CPS1[NH3])/ 
             (Km NH3 + [NH3]) 
 
Vmax CPS1 = 45 
nmole/min per mg 
(Pierson and Brien 
1980)  
 
Km NH3 = 0.35 mM 
(Ahuja and Powers-Lee 
2008)  
 
Human Liver 
 
 
 
 
Human 
Recombinant 
 
Vmax CPS1 = 8.05 
mmol/minab 
 
 
 
 
Km NH3 = 0.35 
mM 
VNH3 ex = 0.004 mmol/mina 
   
 
VGLUL = (Vmax GLUL[NH3])/ 
           (Km NH3{1 + ([Gln]/Ki Gln)} 
           + [NH3]) 
 
Vmax GLUL = 0.47 
µmole/15 min per mg 
(Tate et al. 1972)  
 
Km NH3 = 0.15 mM 
(Listrom et al. 1997)  
 
Ki Gln = 0.6 mM (Wray 
and Fisher 2005)  
 
Rat Liver 
 
 
 
Human 
Recombinant 
 
Bacillis 
subtilis 
 
Vmax GLUL = 12.3 
mmol/minb 
 
 
 
Km NH3 = 0.15 
mM 
 
 
Ki Gln = 0.6 mM 
 
VUrea ex = 0.244 mmol/mina 
   
aThese values change with protein diet.  See methods and discussion for details. 
bThese values change with liver condition.  See methods and discussion for details. 
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Table 4.2 Parameter values used in nitrogen metabolism model 
Parameter Name Value References 
Blood Volume 6.59 La  
Average Liver Mass 1561 g (Molina and DiMaio 2012)  
Average Human Mass, Male 88.7 kg (Fryar et al. 2012)  
Time Through Sinusoid 4.3 s (Schwen et al. 2015)  
Initial Urea 5.5 mM  
Initial Ammonia 0 µM  
Initial Glutamine 0 mM  
Recommended Daily Protein 71 g (2005)  
aBlood volume is about 5.2 L for a 70 kg individual (Wicker 2015).  The value used above was 
determined by assuming a linear relationship of blood volume with body mass for an individual 
weighing 88.7 kg.  This is the volume of the blood compartment used to calculate metabolite 
concentrations. 
 
 
Because all the chemical species under consideration are present in the blood 
compartment, it is the only compartment where the volume affects simulation results.  The 
other compartments in Figure 4.1 are used to organize the model components for 
conceptualization.  We assume free diffusion across membranes.  The volume was 
determined by assuming a linear relationship between body mass and blood volume and 
taking 5.2 liters to be the blood volume of a 70 kg male (Wicker 2015).  Blood in the model 
is assumed to be well mixed.  Published enzyme activities were scaled up to the average 
liver size (1561 g, see Table 4.2) by adjusting the units to mmol/(min*1561 g).  For 
example, McGivan et al. (McGivan et al. 1991) report glutaminase activity as 91.4 nmoles 
per minute per mg protein, which converts to 0.0914 mmoles per minute per g protein.  If 
we assume 20% protein content in the cultured hepatocytes, it takes 5 g of tissue to yield 1 
g protein.  Adjusting for protein content and multiplying by a liver weight of 1561 g yields 
an enzyme activity of 28.54 mmoles/min/liver.  Because of the slightly higher protein 
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content of liver tissue compared to isolated hepatocytes (Berry et al. 1991), we used a 
tissue protein content value of 25% when scaling up parameters from a study that reports 
enzyme activity from liver tissue.  Similar calculations were performed for each of the liver 
enzymes.  Changes in enzyme activity due to diet and liver conditions are summarized in 
Table 4.3. 
 
Table 4.3 Parameter changes with protein diet and liver condition 
Parameter 
Name 
Protein Diet    
(g per day) 
Healthy 
(mmoles/min) 
Early Cirrhosis 
(mmoles/min) 
Late Cirrhosis 
(mmoles/min) 
Urea ex 71 0.244 
    No change with liver condition 
100 0.343 
122 0.417 
NH3 ex 71 0.004 
100 0.008 
122 0.012 
NH3 abs 71 0.492 
100 0.693 
122 0.845 
Vmax CPS1 71 8.05 5.64 5.64 
100 8.47 5.93 5.93 
122 8.78 6.146 6.146 
Vmax GLUL No change 
with diet 
12.3 2.46 0.246 
 
 
The complete urea cycle uses two nitrogen atoms to synthesize each molecule of 
urea in one turn of the cycle.  However, CPS1 incorporates one nitrogen atom per turn of 
the cycle.  A second nitrogen enters into the cycle from aspartate when argininosuccinate 
synthetase catalyzes the reaction of aspartate with citrulline.  To balance the stoichiometry 
of the reaction series and to simplify the model, a second reaction equal to CPS1 was 
created with the product not considered in the simulation results (“Urea for Balance” in 
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Figure 4.1).  Therefore, two nitrogen atoms per unit time are used to produce one urea 
molecule, satisfying the stoichiometry of the overall reaction series for this simplified 
model.  The rate of nitrogen absorption is based upon the daily amount of nitrogen 
consumed.  The mass of protein ingested is adjusted to the molar amount of nitrogen 
ingested (16% of the mass of protein ingested) and for the 12.7% loss of nitrogen in feces 
(Tome and Bos 2000).  The remaining molar amount of nitrogen is assumed to be absorbed 
linearly over a period of 24 h.  For example, if 71 grams of protein is ingested, 16% of that 
amount (11.36 grams) is nitrogen.  Assuming a 12.7% loss in feces, this leaves 9.92 grams 
of nitrogen available for absorption.  Because there are 14 grams of nitrogen per mole, 
there are 0.708 moles of nitrogen available for absorption per day, or 0.49 millimoles of 
nitrogen per minute.  The absorption rate was recalculated using the same method for each 
of the three protein diets modeled.  The ranges of the amounts of ammonia and urea 
excreted in urine over a 24 h period have been reported (Bingham et al. 1988; Bankir et al. 
1996), and in the model we assumed the average values to be excreted linearly over the 24 
h period.  When modeling altered protein intake, the rates of ammonia and urea excretion 
were adjusted as well.  For the high protein diet, we used the upper values of the reference 
ranges reported for the amounts of ammonia and urea excreted instead of the average 
values.  This was accomplished by assuming daily nitrogen balance and using calculations 
similar to those used above to equate molar amounts of nitrogen to grams of protein.  For 
example, using the lower values for the reference ranges of daily ammonia and urea 
excretion and assuming daily nitrogen balance suggest a dietary intake of about 60 g of 
protein per day.  Ammonia and urea excretion rates were scaled to the dietary protein 
intake by assuming a linear relationship between the two.  Excretion rates that were used 
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in the model are as follows: for the 71 g per day protein diet, 0.004 mmoles ammonia are 
excreted per minute and 0.244 mmoles urea are excreted per minute; for the 100 g per day 
protein diet, 0.008 mmoles ammonia are excreted per minute and 0.343 mmoles urea are 
excreted per minute; and for the 122 g per day protein diet, 0.012 mmoles are ammonia 
excreted per minute and 0.417 mmoles urea are excreted per minute.  Changes with 
protein diet are summarized in Table 4.3. 
We modelled the spatial separation of enzymes by acinus zones by translating 
spatial separation into temporal separation.  The time a red blood cell takes to travel 
through a sinusoid has been calculated to be 4.3 seconds (Schwen et al. 2015).  Assuming a 
constant rate and equal division of zones, this is about 1.43 s per zone.  By using event 
functions in the SimBiology software, the enzyme activities of CPS1 and glutaminase were 
turned on for 2.87 s and then off for 1.43 s while GLUL was turned on.  This change in 
enzyme activities combined with the well-mixed assumption approximates the spatial 
enzyme separation found in the liver because blood is exposed to CPS1 and glutaminase for 
twice as long and just prior to exposure to GLUL activity before repeating the cycle.  This 
cycling was repeated for 774 seconds during simulations (Figure 4.2A), yielding a pattern 
of peaks and valleys in the simulation results that is a mathematical artifact of modeling 
spatial separation as temporal separation. 
Steady state levels for ammonia were calculated following model simulations for 
different levels of protein in the diet (healthy, 71 g per day; average, 100 g per day; high, 
122 g per day) and liver conditions (healthy, “early cirrhosis”, “late cirrhosis”, and 50% 
CPS1 activity) for 12 conditions total.  Simulation results were exported to Microsoft Excel, 
and steady state levels were determined from the data points corresponding to the top of 
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the resulting ammonia concentration curve.  Steady state was defined as the concentration 
when blood ammonia levels were changing less than 0.002% per second.   
Several assumptions and simplifications were used in the model.  The urea cycle is 
simplified to the first committed step and an extra CPS1 reaction was added to maintain the 
stoichiometry of the entire urea cycle (“Urea for Balance” in Figure 4.1).  Other molecular 
species involved in the included reactions that are not included in the model are assumed 
to be in abundance, blood is assumed to be well-mixed, and we used temporal separation of 
enzymes to model spatial separation of enzymes in the liver acinus.  Furthermore, GLS 
activity is the same in zones 1 and 2 in the model, but it may be slightly decreased in zone 2 
in vivo. We recognize that blood is heterogeneous and blood ammonia levels may be 
concentrated in some compartments compared to others.  For example, arterial blood has 
been shown to have higher ammonia levels than venous blood in dogs with liver disease 
(Rothuizen and van den Ingh 1982).  This difference of concentrations could limit systemic 
effects of blood ammonia.  However, this was not included in the model.  We also assume a 
continuous nutritional supply for simplicity.  Furthermore, the model does not account for 
the activities of transporters but often assumes free passage of small molecules.  There is 
also evidence for positive cooperativity for the binding of some of the species to enzymes in 
the model.  For example, there is evidence of cooperativity for glutamine binding (Hill 
coefficient of 1.8) in the kinetics of the glutaminase enzyme (Szweda and Atkinson 1989) 
and possible glutaminase upregulation by a high protein diet (Ewart and Brosnan 1993) 
that was not included in the model.  However, sensitivity analysis suggests that increases in 
glutaminase and GLUL activity will not have much effect on ammonia steady state levels.  
Even with these simplifying assumptions, the model results agree relatively well with the 
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available clinical data.  However, the available clinical data is sometimes incomplete, so 
further validation is not currently possible. 
 
Sensitivity Analysis 
To determine the relative effects of altering enzyme kinetic parameters on the 
steady state blood ammonia levels, each of the parameters was individually increased or 
decreased by 50% under the normal simulation conditions for a healthy liver and a protein 
diet of 71 g per day. The simulations were run under these altered conditions and the 
steady state levels of ammonia were compared to those under normal conditions.  Results 
are reported in Table 4.4 as percent change. 
 
 
Table 4.4 Sensitivity analysis for kinetic parameters. 
Enzyme Parameter Percent Parameter 
Change 
Blood Ammonia 
Percent Change 
CPS1 Vmax 150% -35.4 
50% 110.3 
Km 150% 52.6 
50% -50.3 
Glutaminase Vmax 150% 0.6 
50% -2.9 
Km 150% -1.1 
50% 1.1 
Glutamine 
Synthetase 
Vmax 150% 4.6 
50% -4.6 
Km 150% -2.9 
50% 7.4 
Ki 150% 0.6 
50% -0.6 
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SH-SY5Y Culture, Differentiation, and Treatment 
SH-SY5Y cells were cultured in a 1:1 mixture of DMEM (high glucose) and Ham’s F-
12 medium.  The medium contained 2.44 g/L sodium bicarbonate, 30 mg/L penicillin, 50 
mg/L streptomycin, and 10% FBS.  The cells were seeded at a concentration of 1,000 cells 
per well in 96-well plates and treated with retinoic acid (10 µM) for 4 days with the 
medium changed every two days.  Next, ammonium chloride was added to the medium at 
the indicated concentrations and the cells were incubated for 24 additional hours. 
 
Protein Assay 
After 24 h of treatment with ammonium chloride, the cells were washed in PBS and 
then lysed with RIPA buffer (50 µl per well for three wells per condition).  The lysate was 
pooled in a microcentrifuge tube and the Pierce BCA Protein Assay was performed in 
triplicate per manufacturer’s instructions.   
 
Software and Statistical Methods 
The model was built and simulated using the MATLAB R2016a SimBiology software 
package.  Data was analyzed using Microsoft Excel and GraphPad Prism v7.0.  For cell 
culture studies, three independent experiments were performed and data was analyzed 
with a repeated measures one-way ANOVA with Fisher’s post hoc test. 
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Results 
Model Results Approximated Physiological Steady State Ammonia Levels 
A computational model estimating blood ammonia levels in healthy individuals and 
those with liver disease was constructed.  The model was first simulated using the 
parameters for a healthy liver and a healthy, moderate protein diet to determine if the 
resulting steady state levels were consistent with clinical data.  The healthy protein diet 
was taken to be 71 g per day.  The reference range for healthy blood ammonia levels was 
taken to be 11-32 µM (Hawke 2012).  Healthy blood urea levels are considered to be 3.6-
7.1 mM (Pagana and Pagana 2009).  The initial conditions in this study are 0 µM ammonia 
and 5.5 mM urea.  Figure 4.2A shows the results of 774 s of simulation of our model.  The 
steady state ammonia level was 17.5 µM (Figure 4.2A), and the steady state urea level 
remained around 5.5 mM (Figure 4.2A), both values well within the healthy range. 
 
Enzyme Activity Changes Had Different Effects on Ammonia and Urea Levels 
To investigate the relative influences of CPS1 and GLUL on blood ammonia levels, 
enzyme activities were individually varied stepwise in the model for a healthy individual 
on a healthy protein diet, and steady state levels of ammonia were determined.  The results 
show an inverse, non-linear relationship between CPS1 activity and ammonia levels (Figure 
4.2B).  The steady state urea level did not show much change under any conditions tested 
likely because much larger changes are necessary to cause differences in the millimolar 
concentrations of urea compared to the micromolar concentrations of ammonia.  
Decreasing GLUL activity had almost no effect on steady state levels of ammonia (Figure 
4.2B).  However, decreasing GLUL activity does affect the kinetics of ammonia formation.  
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Eliminating GLUL activity caused the simulation to reach steady state ammonia levels much 
more quickly.  In a healthy individual, the rate of ammonia formation for the first 12.9 
seconds of the simulation was 0.55 µmoles per second, but this rate increased to 0.83 
µmoles per second when GLUL activity was inactivated (Figure 4.2C).  A sensitivity analysis 
(Table 4.4) of the kinetic parameters revealed that, as expected, changes in CPS1 activity 
have by far the strongest effect on blood ammonia levels of any enzyme in the model. 
 
Figure 4.2:  Model simulation results for a healthy individual on a healthy protein diet.  A) 
Simulation results for a healthy individual with the recommended daily protein intake.  
Note the break in the scale of the y-axis.  B) Ammonia steady state levels from simulations 
varying enzyme activities of CPS1 and GLUL.  C) Simulation results showing changes in 
ammonia kinetics with changes in GLUL activity. 
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Changes in Enzyme Activities Caused by Liver Cirrhosis Affected Blood Ammonia Levels 
Liver cirrhosis has been shown to decrease the activities of two of the enzymes in 
the model, so decreasing the Vmax values accordingly can create a simple model of liver 
cirrhosis at different stages.  As mentioned above, a healthy, moderate protein diet for a 
typical adult male is 71 g of protein per day.  The average American diet is about 100 g of 
protein per day, and a high protein diet in our model was taken to be 122 g of protein per 
day.  The amount of protein in the high protein diet was calculated by using the highest 
values of ammonia and urea excretion in the published reference ranges (Bingham et al. 
1988; Bankir et al. 1996) and assuming nitrogen balance (see Methods).  To model early 
stage liver cirrhosis, the Vmax of CPS1 was reduced to 70% of the normal value and the Vmax 
of GLUL was reduced to 20% of the normal value (Gebhardt and Reichen 1994).  Late stage 
liver cirrhosis was modeled by changing the Vmax values for CPS1 and GLUL to 70% and 2% 
of the normal values, respectively (Fleming and Wanless 2013).  Following simulation, the 
steady state ammonia and urea levels were determined as described above.  The steady 
state ammonia levels under the various conditions are shown in Figure 4.3A.  Ammonia 
levels progressively increased with increased dietary protein intake and with decreased 
liver function. 
 
Decreased CPS1 Activity Led to Increased Blood Ammonia Levels 
Based upon the population frequency of the genetic disorder CPS1 deficiency, there 
are likely many heterozygous individuals with decreased CPS1 activity (see Discussion).  
To investigate the consequences of decreased CPS1 activity on blood ammonia and urea 
levels, the Vmax for CPS1 was reduced by 50% and different protein levels in the diet were 
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compared (Figure 4.3B).   Decreased CPS1 activity (50% below normal, as present in a 
heterozygous individual with a complete loss of function from one of the two alleles) led to 
about a 20 µM increase in blood ammonia levels, greater than the levels present in the early 
or late stage liver cirrhosis models for each of the diets examined. 
 
 
 
Figure 4.3:  Ammonia levels changed with dietary protein levels, progression of liver 
cirrhosis, and CPS1 activity.  A) The steady state ammonia concentration in the blood 
increases with increased ammonia absorption due to increases in dietary protein (See 
Table 4.1) and declining liver function.  B) When CPS1 activity is reduced by half, steady 
state ammonia levels are higher than those in a healthy individual.  This effect increases 
with increased ammonia absorption due to increased dietary protein levels (See Table 4.1).  
Cirr-E, early liver cirrhosis; Cirr-L, late liver cirrhosis. 
 
 
Ammonium Chloride Treatment Decreased Viability of Differentiated SH-SY5Y Cells 
To test whether the increased ammonia levels observed in the simulations could be 
neurotoxic in vitro, we administered ammonia to differentiated human neuroblastoma 
cells.  Retinoic acid-treated SH-SY5Y cells treated with 90 µM ammonium chloride showed 
14% decreased viability as measured by protein content from cells attached to the plate 
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after a PBS wash.  Ammonium chloride concentrations of 30 µM or 60 µM showed no 
statistically significant effect on viability (Figure 4.4).   
 
 
 
Figure 4.4:  Ammonium chloride (90 µM) decreased the viability of retinoic acid-
differentiated SH-SY5Y neuroblastoma cells in culture. * indicates that p = 0.01 compared 
to 0 µM NH4Cl added.  Bars represent mean ± SEM, and n = 3 independent experiments. 
 
 
Discussion 
A simple mathematical model of human organismal nitrogen metabolism is 
presented that uses published parameters for physiological inputs to give physiologically 
relevant outputs consistent with the available experimental data.  While other models exist 
for ammonia metabolism in humans (Ohno et al. 2008; Drasdo et al. 2014; Schliess et al. 
2014), this is the first to model the effects of altered levels of dietary protein intake on 
blood ammonia levels.  Increased protein intake led to increased blood ammonia levels 
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across all conditions.  However, blood ammonia levels remained in the healthy range when 
simulating a healthy liver.  The simulation results showed that low GLUL activity can lead 
to more rapid changes in blood ammonia levels.  The model highlights the effects of diet on 
ammonia levels in disease conditions.  Our results indicate that increased protein intake 
likely causes blood ammonia to rise above healthy levels in some patients with cirrhosis.   
 
Altering Dietary Protein Consumption in Cirrhosis Patients 
Because relative energy expenditure per kg body mass is increased in some cirrhotic 
patients (Merli et al. 1985), some sources recommend a high protein diet (1.8 g/kg per 
day) for these patients to maintain muscle mass if they do not already have HE (Nielsen et 
al. 1995). Others suggest a normal, moderate intake of 0.8 g to 1.0 g of protein per kg per 
day (Riordan and Williams 1997).  Data has shown that high protein intake exacerbated 
encephalopathy in 35% of patients with cirrhosis (Seymour and Whelan 1999).  Reduced 
protein intake was first shown to protect from encephalopathy in cirrhotic patients in 1952 
(Phillips et al. 1952).  In 2004, a study was performed with cirrhosis patients where 
protein was completely removed from the diet for three days and then slowly increased 
over 12 days back to the normal level (Córdoba et al. 2004).  At the end of the study, blood 
ammonia levels were non-significantly 17% lower in the patients with the restricted 
protein diet compared to patients on a normal protein diet of 1.2 g/kg per day, roughly 
equivalent to the average American protein diet in this model.  However, the methods used 
in that study have been critiqued and questioned (Nguyen and Morgan 2014).  A larger 
patient group size and earlier measurements of blood ammonia levels would help to clarify 
if blood ammonia levels are indeed decreased by a low protein diet.  If the findings of no 
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significant effects do prove to be robust and highly reproducible, this leaves the possibility 
that a high protein diet may play a role in the development of HE, but a low protein diet is 
not normally helpful in its resolution.  Even though several studies have suggested that 
restricting dietary protein intake below the recommended amount for a healthy individual 
may not be therapeutic for the roughly 60% of cirrhosis patients who suffer from 
malnutrition, other studies over the past 65 years on HE patients who can maintain a 
proper energy balance have consistently shown benefits of protein restriction (Nguyen and 
Morgan 2014).  We acknowledge the large heterogeneity in patient responses to changes in 
the level of dietary protein (Gheorghe et al. 2005) and suggest that monitoring the 
cirrhosis patient’s energy balance will help determine the proper dietary protein level for 
that individual.  
Previous research has shown that there was an 80% reduction in GLUL activity and 
a 30% reduction in CPS1 activity in a rat model of liver cirrhosis (Gebhardt and Reichen 
1994).  As the disease progressed, GLUL activity dropped even further (Fleming and 
Wanless 2013).  Results from adjusting the model to these parameters suggest that 
ammonia levels will increase as liver cirrhosis develops.  Furthermore, a high protein diet 
may exacerbate these effects.  We recognize that liver cirrhosis is a complex disease with 
many changes besides altered CPS1 and GLUL activity, so this model is a simplified 
representation of liver cirrhosis.  Using an upper limit of 32 µM for the reference range of 
healthy blood ammonia levels, the model indicates that a high protein diet with early or 
late cirrhosis will result in blood ammonia levels that are at least 20% higher (40.3 µM and 
41.3 µM, respectively) than the upper limit for the healthy range (32 µM).  These elevations 
may contribute to HE.  The model suggests that controlling protein intake could be one 
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method to slightly reduce the likelihood of developing HE in some patients with liver 
cirrhosis. 
 
Plasma Ammonia Levels Likely Rise in Healthy Individuals After a Meal 
Our model predicts that blood ammonia levels will rise slightly by consumption of a 
high protein diet.  Surprisingly, we could not find many studies in the literature examining 
dietary-induced changes in blood ammonia levels in healthy humans.  One study found 
increased blood ammonia levels in women following consumption of a test drink 
containing whey protein.  The ammonia level peaked at a value 20% higher than the initial 
level at 90 minutes after consumption (Chungchunlam et al. 2015).  Another study found 
increasing breath ammonia levels after a high protein challenge; ammonia levels plateaued 
roughly 5 hours after the dietary challenge (Spacek, M.L. Mudalel, et al. 2015).  However, 
breath ammonia levels do not always correlate well with blood ammonia levels (Spacek, M. 
Mudalel, et al. 2015).  A further study using Huntington’s disease patients who were put on 
a high (26.3%) protein diet did not find any association between the high protein diet and 
blood ammonia levels (Chen et al. 2015). 
In studies with mice placed on a high protein diet ammonia levels increased from 
210 µM to 245 µM at night when the mice were active and feeding.  Likewise, a high fat/low 
protein diet decreased ammonia levels from 170 µM to 130 µM when measured at night 
(Nohara et al. 2015).  When rats were switched from a 20% protein diet to a 58% protein 
diet, colonic venous ammonia maximally increased from 100 µM to 340 µM two days after 
the switch in diet, which dropped to 170 µM after a week on the diet (Mouillé et al. 2004). 
Another study using rats trained on a 6% protein diet showed that blood ammonia levels 
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increased from 60 µM to 120 µM when they were given a 44% protein meal, and ammonia 
levels were maintained at that elevated level for at least 24 hours (Semon et al. 1988). 
There is also evidence of increases in blood ammonia levels in pigs after a protein meal 
(Welters et al. 1999; Liu et al. 2015).  The limited data above suggest that systemic 
ammonia levels likely increase slightly following a meal, especially if the meal is high in 
protein, but more experiments should be performed to verify these initial findings and to 
determine the extent of brain ammonia level changes under the same conditions.  In 
addition, more detailed studies using human subjects would help to better characterize the 
time dependency of elevated ammonia levels as well as to discern differential effects in 
patients with liver disease. 
 
Variability in the Correlation between Blood Ammonia Levels and the Severity of HE 
While there is a correlation between blood ammonia levels and HE severity (Ong et 
al. 2003), the exact blood concentration that leads to impairment may be different for 
individuals based on their specific nitrogen balance and the release of other neurotoxic 
factors from the liver.  Some patients with hyperammonemia present with 100-200 µM 
blood ammonia levels and remain asymptomatic, while others such as infants with GLUL 
deficiency have severe encephalopathy with blood ammonia levels fluctuating between 100 
and 150 µM (Häberle 2013).  However, decreased blood glutamine levels may also 
contribute to the encephalopathy in GLUL deficiency.  Maintained blood ammonia levels 
over 300 µM are considered severe and invariably lead to encephalopathy.  However, some 
newborns have been shown to have no lasting impairment by temporary blood ammonia 
concentrations up to 2 mM for a day or two (Whitelaw et al. 2001).  In contrast with this 
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data, blood ammonia levels (< 50 µM) that border the healthy range have also been linked 
to HE (Ong et al. 2003).  These variabilities do not affect the validity of the model because 
the model represents the blood ammonia level changes for an average person.  
To investigate the roles of CPS1 and GLUL in ammonia metabolism, enzyme 
activities were varied in the model with otherwise healthy parameters (Figure 4.2B, Table 
4.4).  CPS1 activity levels relevant to the model had a non-linear effect on ammonia 
concentrations.  GLUL activity, however, had very little effect on ammonia steady state 
levels.  Simulating early liver cirrhosis (70% CPS1, 20% GLUL) resulted in an average 
ammonia increase of 43% across all diets.  Simulating late liver cirrhosis (70% CPS1, 2% 
GLUL) resulted in an average ammonia increase of 47%.  GLUL activity appears to slow 
changes in blood ammonia levels.  Since muscles may help metabolize some ammonia 
(Dejong et al. 1992), slowing the rate of change may give the body time to adapt to the 
larger ammonia levels.  These results are consistent with the known role of CPS1 together 
with the rest of the urea cycle to be a low affinity, high capacity system for removing 
ammonia, while GLUL is a high affinity, low capacity enzyme for removing ammonia 
(Häussinger 1986). 
 
Ammonia Levels in Individuals Deficient in GLUL 
Human subjects with decreased GLUL activity have been shown to have blood 
ammonia levels of 100-150 µM (Häberle 2013), while mice with liver-specific GLUL 
knockout showed a blood ammonia level of roughly 150 µM (Qvartskhava et al. 2015).  Our 
model, under otherwise normal healthy conditions, shows no change in ammonia steady 
state levels when GLUL is reduced (Figure 4.2B).  This is a limitation of the study possibly 
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due to the enzyme kinetics data available, but it could also be due to the way we have 
modeled the hepatic acinus, the functional unit of the liver.  The ratio of CPS1 to GLUL 
activity or the amount of time that ammonia is associated with CPS1 activity compared to 
GLUL activity may be too high in our model, resulting in deviations from in vivo results. 
This suggests that some of the changes in ammonia levels observed in our model may be 
too conservative.  
 
Ammonia Levels in Individuals Deficient in CPS1 
CPS1 deficiency is a rare autosomal recessive genetic disorder that results in very 
little CPS1 activity (McReynolds et al. 1981).  Individuals experience extreme 
hyperammonemia and the many detrimental effects that come with it (Klaus et al. 2009).  
The prevalence of CPS1 deficiency is about 1 in 800,000 (Nagata et al. 1991).  Assuming 
strict Mendelian inheritance, if a mother and father each are heterozygous and have 
decreased CPS1 activity, there is a 1 in 4 chance that their children will have CPS1 
deficiency.  Working backwards from this assumption, the odds that both parents are 
heterozygous are 1 in 200,000.  The odds that one parent is heterozygous is roughly 1 in 
447.  Therefore, heterozygosity for disease-causing CPS1 mutations is almost as prevalent 
as liver cirrhosis.   However, regulatory effects may partially compensate for CPS1 
heterogeneity, a scenario not explored is this study.  The model predicts that individuals 
with CPS1 activity 50% of normal levels (currently thought to have no detrimental effect) 
will have high blood ammonia levels.  Many people may be unaware that they carry a 
mutation in one CPS1 allele that likely results in higher than normal levels of blood 
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ammonia.  Lifelong exposure to high levels of blood ammonia may have unknown, 
deleterious effects on neural function. 
 
Relatively Low (90 µM) Brain Ammonia Levels May Affect Neural Cell Viability or Function 
It is hypothesized that the increased levels of ammonia in liver disease interfere 
with the glutamine-glutamate balance involved in neurotransmission (Butterworth 2014), 
which can lead to increased production of reactive oxygen and nitrogen species (Bobermin 
et al. 2015).  Increased brain ammonia levels also block potassium uptake in astrocytes, 
which causes increased potassium uptake in neurons that compromises inhibitory 
neurotransmission in the cortex, leading to seizure (Rangroo Thrane et al. 2013).   
Cell culture experiments using retinoic acid-differentiated SH-SY5Y cells revealed 
that viability was decreased by relatively low concentrations (90 µM) of ammonium 
chloride.  The ability of such a low concentration of brain ammonia to cause toxicity was 
surprising given that most cells (Schneider et al. 1996) including rodent primary cortical 
and cerebellar granule cells and undifferentiated human SH-SY5Y cells require low (1-10) 
millimolar concentrations of ammonium chloride before toxicity is observed (Bobermin et 
al. 2015).  Ammonia has been reported to be slightly more toxic to neuroblastoma cells 
than to primary neurons (Haghighat et al. 2000), partially accounting for the lower toxicity 
threshold.  Furthermore, the retinoic acid-mediated differentiation procedure we used 
likely sensitized the cells to ammonia toxicity as it is known to increase reactive oxygen 
species production (Kunzler et al. 2016).   
The ability of uncharged NH3 to cross the blood brain barrier and the limited ability 
of the charged, protonated form NH4+ to cross the barrier combined with the difference in 
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pH between the brain and the blood allows higher total ammonia levels to accumulate in 
the brain (Auron and Brophy 2012).  The model predicts serum (pH ~ 7.4) levels of 
ammonia/ammonium in healthy individuals will be 17.5 µM; since the brain has a pH of 
about 7.0 (Shi et al. 2014; Ren et al. 2015), applying the Henderson-Hasselbalch equation 
implies a total ammonia/ammonium concentration in the brain of 44 µM for a healthy 
individual on a healthy protein diet, more than twice the blood ammonia/ammonium 
concentration.  The following diet combinations and liver conditions are predicted from the 
model results to have brain ammonia/ammonium concentrations of > 90 µM: high protein 
diet/early cirrhosis (101 µM), high protein diet/late cirrhosis (104 µM), healthy protein 
diet/decreased CPS1 activity (92 µM), average protein diet/decreased CPS1 activity (127 
µM), and high protein diet/decreased CPS1 activity (152 µM).  Combining the experimental 
data with the computational results suggests that many of the diet and liver condition 
combinations could negatively affect neuronal function.  Mouse studies showing that high 
protein diets are associated with decreased lifespan (Solon-Biet et al. 2014) should 
stimulate further research into the mechanisms involved. Adhering to the recommended 
protein diet may help cirrhosis patients and CPS1 heterozygotes avoid high blood and brain 
ammonia levels and any associated cognitive problems. 
 
Conclusions 
The following testable hypotheses have been generated using this model: 1) 
Increasing dietary protein consumption increases blood ammonia levels in healthy 
individuals.  2) A low protein diet is beneficial for liver cirrhosis patients who have a 
normal energy balance.  3) Heterozygosity for CPS1 complete loss of function mutations 
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leads to elevated blood ammonia levels.  4) Chronic but low-level hyperammonemia has 
negative effects on neurons and astrocytes such as sensitizing them to further toxic insults.  
5) Increased blood ammonia levels contribute to the decreased lifespan of mice on a high 
protein diet (Solon-Biet et al. 2014). 
This model describes physiological and pathophysiological human nitrogen 
metabolism in blood and liver using published parameters.  It suggests that the diet and the 
level of progression of liver cirrhosis contribute to blood ammonia levels, and experimental 
results suggest that these blood ammonia levels could affect neural functioning.  Since high 
blood ammonia levels are associated with diseases such as HE, the model can be used to 
predict the conditions in which HE may develop.  Furthermore, the model predicts that a 
50% reduction in CPS1 activity, an activity level likely present in thousands of individuals 
worldwide, can lead to high blood ammonia levels.  Limiting protein intake may be one 
effective way for some of these individuals to decrease blood ammonia levels and possible 
associated pathologies. 
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Abstract 
 There is a dire need to discover new pathways to target for Alzheimer’s disease 
(AD) drug development.  The decreased neuronal glucose metabolism that occurs in AD 
brain could play a central role in disease progression.  Little is known about the 
compensatory neuronal changes that occur to attempt to maintain energy homeostasis.  In 
this review using the PubMed literature database, we summarize evidence that amino acid 
oxidation can temporarily compensate for the decreased glucose metabolism, but 
eventually altered amino acid and amino acid catabolite levels likely lead to toxicities 
contributing to AD progression.  Because amino acids are involved in so many cellular 
metabolic and signaling pathways, the effects of altered amino acid metabolism on AD are 
far-reaching.  Possible effects resulting from changes in the levels of several important 
amino acids are discussed.  Urea cycle function may be induced in endothelial cells of AD 
patient brains, possibly to remove excess ammonia produced from increased amino acid 
catabolism.  Studying AD from a metabolic perspective provides new insights into AD 
pathogenesis and may lead to the discovery of dietary metabolite supplements that can 
partially compensate for alterations of enzymatic function to delay AD or alleviate some of 
the suffering caused by the disease. 
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Background 
 There are currently about 24 million cases of Alzheimer’s disease (AD) worldwide, 
and that number is expected to continue to increase for at least the next few decades as 
better treatments for other diseases such as heart disease and cancer extend average 
human longevity (Reitz et al. 2011).  In addition to human suffering, Alzheimer’s disease 
and other dementias cost the United States about $172 billion in 2010 (2010).  To date, 
most research has focused on the amyloid cascade hypothesis that emphasizes the role of 
amyloid-β protein aggregation in the pathogenesis of AD.  However, growing evidence 
suggests that the amyloid cascade hypothesis does not encapsulate the complex 
symptomology of AD (Herrup 2015).  Two decades of researching the amyloid cascade 
hypothesis have not yielded the treatments that were predicted in the early 1990s. The 
other major histological hallmark of AD in addition to amyloid plaques is the 
neurofibrillary tau tangle pathology present in neurons (Herrup 2015).  It is possible that 
tau-based therapies will not fare better in clinical trials than amyloid-based therapies.  
Another promising alternative is to view Alzheimer’s disease as a metabolic disease in 
attempt to shed novel insight into its etiology.  In this regard, it is known that neurons in 
AD brain show large deficits in glucose metabolism, so alternative energy sources may help 
to prevent the neuronal death characteristic of the disease.  Treating AD as a metabolic 
disorder would lead to further research into dietary supplementation of metabolites and 
enzyme cofactors that show depletion in AD brain as possible treatments.  Neurons lack the 
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enzymes for beta-oxidation of fatty acids, but other possible neuronal energy sources 
include amino acids, ketone bodies, citric acid cycle intermediates, pyruvate, and lactate.  
Because many recent metabolomics investigations have shown large changes in the levels 
of several amino acids in AD brain and plasma, it is important to consider whether changes 
in amino acid metabolism are a driving force for AD progression. 
Amino acids in the form of proteins are a large part of the human diet.  The 
recommended daily allowance of protein is 0.8 grams per kilogram body mass (2005); in 
an average adult this amounts to roughly 71 grams of protein per day.  This high protein 
consumption dictates that amino acids will be present at levels that far exceed their 
requirements as the building blocks for protein synthesis, and that much of the protein 
consumed will be broken down for energy generation.  Processing these amino acids for 
energy generation requires the disposal of nitrogenous waste, a process carried out mostly 
in the liver and small intestine by the urea cycle.  Disrupted amino acid and nitrogen 
metabolism is associated with neurological defects and in some cases dementia (Wiesinger 
2001; Gropman et al. 2007; Coloma and Prieto-Gonzalez 2011; Esposito et al. 2013; P. Liu 
et al. 2014).  In addition to these primary routes of amino acid usage, amino acids and their 
metabolic derivatives are also involved to a lesser extent in cell signaling and in many 
diverse metabolic pathways. 
 
Amino Acid Metabolism in the AD Brain 
Many studies have shown altered amino acid levels in serum and brain in AD 
patients or in AD model mice, but whether these changes contribute to disease 
pathogenesis is not yet known.  Because glutamate is an excitatory neurotransmitter and 
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two of its metabolites, gamma-aminobutyric acid (GABA) and glycine, are inhibitory 
neurotransmitters (Esposito et al. 2013), changes in glutamate metabolism in AD brain 
could greatly affect neural functioning.  GABA can also be synthesized from arginine in 
astrocytes and increased GABA levels synthesized through this pathway have been shown 
to play a role in cognitive dysfunction in an AD mouse model (Jo et al. 2014).  Changes in 
the levels of enzymes involved in amino acid metabolism have also been observed in AD 
brain (Jęśko et al. 2016), further suggesting a role for metabolic dysregulation in AD 
pathogenesis.  For example, alterations in the levels of glutamine synthetase and urea cycle 
enzymes and intermediates have been observed in AD brain.  This is of concern because 
nitrogenous waste in the form of ammonia from amino acid catabolism has adverse effects 
on neural cells if not properly cleared from the brain.   
 A healthy individual is able to process the excess amino acids consumed into other 
useful metabolites or oxidize them for energy production.  To use them as fuel, the carbon 
skeletons are oxidized in the citric acid cycle to produce carbon dioxide, and the excess 
nitrogen is disposed of as the relatively non-toxic nitrogenous waste product urea.  
However, when neurons cannot catabolize glucose efficiently such as during AD, they likely 
become partly reliant upon amino acid oxidation for energy. If neuronal amino acids 
become depleted or if the machinery used to metabolize amino acids becomes 
dysregulated, the neurons may die, contributing to disease progression.  However, even if 
amino acid oxidation is able to maintain neuronal energy levels, the increased amounts of 
ammonia released during amino acid catabolism could lead to neuronal cell death because 
a complete urea cycle that is needed to detoxify ammonia is not present in neurons.  
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Instead, astrocytes contain the glutamine synthetase enzyme to sequester ammonia into 
glutamine, which can be released from the brain.  
 
Amino Acid Level Changes Examined in Control, MCI, and AD Populations 
 Identifying amino acid changes in patients with mild cognitive impairment (MCI) is 
important as these changes may be upstream changes leading to the onset of AD, and the 
downstream changes that occur during AD may be a result of the body adapting to the 
insults that occurred during MCI.  In one report, a metabolomics analysis was performed on 
the cerebralspinal fluid (CSF) of patients with mild cognitive impairment (MCI), AD, or 
healthy aged-matched controls.  Results showed that the metabolites dimethylarginine, 
arginine, valine, proline, serine, histidine, choline, creatine, carnitine, and suberylglycine 
were possible disease progression biomarkers (Ibáñez et al. 2012).  Another group 
studying potential CSF biomarkers for AD concluded that changes in methionine, 
tryptophan, tyrosine, and purine metabolism pathways occurred in both MCI and AD 
subjects.  Methionine levels increased in MCI while tryptophan levels decreased 
(Kaddurah-Daouk et al. 2013).  Levels of the tripeptide glutathione also decreased in AD.  
Another study found increased cysteine levels in CSF from AD subjects (Czech et al. 2012) 
while another identified altered tryptophan and phenylalanine levels in plasma from both 
MCI and AD subjects compared to controls; tryptophan levels were also distinct when 
comparing MCI to AD subjects (Y. Liu et al. 2014).  A further metabolomics study of plasma 
found altered arginine metabolism and polyamine metabolism in MCI and AD subjects 
(Graham et al. 2015).  Another study found that glycine and valine levels were altered in 
AD plasma (Klavins et al. 2015), but the authors warned that plasma amino acid levels 
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show large variability depending upon the amount of fasting the subjects had undergone 
prior to donating blood (Mathew et al. 2014) and that phospholipids may be more reliable 
plasma biomarkers. 
A comprehensive metabolomics study of both plasma and CSF from control, MCI, 
and AD subjects found that tryptophan and arginine metabolism were altered in both CSF 
and plasma from MCI subjects (Trushina et al. 2013).  Lysine metabolism was decreased in 
the CSF, but not plasma, from the MCI subjects.  This study also found increased methionine 
levels in the CSF of MCI subjects.  Methionine, histidine, and lysine levels were increased in 
AD plasma.  The pathways affected in AD in both CSF and plasma included beta-alanine, 
aspartate and asparagine, alanine, cysteine, methionine, methionine-cysteine-glutamate, 
and arginine and lysine metabolism. Phenylalanine, lysine, and leucine were three of six 
metabolites in plasma that could be used to discriminate between the MCI subjects and 
controls (Trushina et al. 2013).  A salivary metabolomics analysis found that taurine and 
several dipeptides including Ser-Ser, Phe-Pro, and Arg-Leu were decreased in abundance in 
MCI patients (Zheng et al. 2012).  From the summation of these results one can discern that 
there are many alterations in amino acid metabolism in MCI and AD patients, but the 
results are not very consistent from study to study likely due to the different 
methodologies and instrumentation used. 
 
An Overview of Select Amino Acids by Class 
 In AD and MCI patients, some amino acids showed increased levels while most 
showed decreased levels, especially in the brain, consistent with their oxidation as a 
neuronal energy source.  This information is summarized in Table 5.1.  There are several 
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possible connections described in detail below through which disruption of normal amino 
acid metabolism may lead to pathogenicity. 
 
Table 5.1: Amino acids of interest in neurodegeneration 
Amino Acids 
of Interest 
Tissue Increase or 
Decrease in 
AD 
Points of Interest Effects of 
Addition 
DataWarrior 
Drug Score* 
Leucine 
  
Led to persistent 
mTOR activation 
(Lynch and Adams 
2014); Metabolites 
led to metabolic 
dysfunction 
(Amaral et al. 
2010; Lynch and 
Adams 2014; 
Wisniewski et al. 
2016) 
 
Metabolite led to 
mitochondrial 
dysfunction in rat 
neurons (Amaral et 
al. 2010); BCAAs 
increased mean 
lifespan in male 
mice (D’Antona et 
al. 2010) 
 
0.592 
Valine Plasma 
(Gonzalez-
Dominguez 
et al. 2015) 
Decrease 
(Gonzalez-
Dominguez et 
al. 2015) 
Led to persistent 
mTOR activation 
(Lynch and Adams 
2014); Metabolites 
led to metabolic 
dysfunction 
(Lynch and Adams 
2014) 
 
BCAAs increased 
mean lifespan in 
male mice 
(D’Antona et al. 
2010) 
0.559 
Isoleucine 
  
Led to persistent 
mTOR activation 
(Lynch and Adams 
2014); Metabolites 
led to metabolic 
dysfunction 
(Lynch and Adams 
2014) 
 
BCAAs increased 
mean lifespan in 
male mice 
(D’Antona et al. 
2010) 
0.684 
Phenylalanine Serum 
(Gonzalez-
Dominguez 
et al. 2015); 
Brain 
(Nilsen et al. 
2014; Xu et 
al. 2016) 
Decrease 
(Gonzalez-
Dominguez et 
al. 2015); 
Increase 
(Nilsen et al. 
2014; Xu et al. 
2016) 
 
Metabolized in 
absence of tyrosine 
(Fernstrom and 
Fernstrom 2007) 
 
0.579 
Tryptophan Serum 
(Gonzalez-
Dominguez 
et al. 2015); 
Brain (Xu et 
al. 2016) 
Decrease 
(Gonzalez-
Dominguez et 
al. 2015); 
Increase (Xu 
et al. 2016) 
Metabolites led to 
metabolic 
dysfunction 
(Bonda et al. 2011) 
Metabolite 
increases nitric 
oxide synthetase in 
cell culture (Pérez-
Severiano et al. 
1998) 
0.661 
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Tyrosine Serum 
(Gonzalez-
Dominguez 
et al. 2015) 
Decrease 
(Gonzalez-
Dominguez et 
al. 2015) 
 
 
 
Decreases could 
disrupt 
catecholamine 
production 
Improved memory 
and cognitive 
function in humans 
(van de Rest et al. 
2013) 
0.584 
Glutamine Serum 
(González-
Domínguez 
et al. 2015); 
Brain (Gueli 
and Taibi 
2013) 
Decrease 
(González-
Domínguez et 
al. 2015); 
Increase 
(Gueli and 
Taibi 2013) 
 
  0.573 
Aspartic Acid Brain (Gueli 
and Taibi 
2013; Xu et 
al. 2016); 
Serum 
(Gonzalez-
Dominguez 
et al. 2015) 
 
Decrease 
(Gueli and 
Taibi 2013; 
Gonzalez-
Dominguez et 
al. 2015; Xu et 
al. 2016) 
  
0.593 
Glutamic 
Acid 
Serum (G. 
Wang et al. 
2014); Brain 
(Gueli and 
Taibi 2013; 
Xu et al. 
2016) 
 
Increase (Xu 
et al. 2016); 
Decrease 
(Gueli and 
Taibi 2013; G. 
Wang et al. 
2014) 
Excitotoxicity led 
to neuronal death 
(Mattson et al. 
1992; Hynd et al. 
2004) 
 
0.531 
Lysine Brain (Xu et 
al. 2016) 
 
Decrease (Xu 
et al. 2016) 
  
0.499 
Histidine Serum 
(Gonzalez-
Dominguez 
et al. 2015) 
 
Decrease 
(Gonzalez-
Dominguez et 
al. 2015) 
  
0.835 
Cysteine Serum 
(González-
Domínguez 
et al. 2014; 
Hu et al. 
2016); Brain 
(Hu et al. 
2016; Xu et 
al. 2016); 
CSF (Czech 
et al. 2012) 
 
Decrease (Hu 
et al. 2016); 
Increase 
(Czech et al. 
2012; 
González-
Domínguez et 
al. 2014; Xu et 
al. 2016) 
Involved in 
glutathione 
synthesis 
Decrease in mTOR 
activity in rats 
(Gomez et al. 2015) 
0.493 
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Methionine Serum 
(González-
Domínguez 
et al. 2014) 
Decrease 
(González-
Domínguez et 
al. 2014) 
 
Increased amyloid-
beta and p-tau in 
mice (Tapia-Rojas 
et al. 2015) 
0.578 
*Structures were drawn using DataWarrior software using their most prevalent charge states at pH 7.4. A 
higher Drug Score value indicates a better drug candidate. 
 
Branched Chain Amino Acids, mTOR, and AD 
 The branched chain amino acids (BCAAs) include leucine, valine, and isoleucine.  
BCAAs compete with the aromatic amino acids phenylalanine, tyrosine, and tryptophan for 
entry into the brain.  Therefore, altering plasma BCAA levels can affect the levels of the 
neurotransmitters serotonin, dopamine, epinephrine, and norepinephrine in the brain 
(Fernstrom 2005).  Unlike most amino acids which are metabolized to a large extent by 
first pass hepatic metabolism, BCAAs are not metabolized there to a large degree, so their 
concentration in blood often directly reflects the level of dietary consumption.  Protein 
restriction has been shown to decrease tau hyperphosphorylation and increase cognition in 
an AD mouse model (Parrella et al. 2013).  A BCAA-restricted diet has been shown to 
induce similar protective metabolic effects on peripheral glucose and insulin levels as a 
protein restricted diet (Fontana et al. 2016).  However, whether the neuroprotective effects 
of protein restriction are mediated by decreased BCAA levels is not yet known because 
methionine restriction can also induce protective metabolic effects (Sanchez-Roman and 
Barja 2013). 
Some researchers suspect a link between increased BCAA levels and AD 
pathogenesis (Morabito et al. 2014).  Increasing BCAA levels through dietary 
supplementation in rats led to a decrease in neural growth factor (NGF) in the 
hippocampus (Scaini et al. 2013), a part of the brain involved in memory formation and 
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known to shrink due to neuronal loss in AD patients.  Administration of the leucine 
metabolite α-ketoisocaproic acid also decreased NGF as well as brain-derived neurotrophic 
factor (BDNF) (Wisniewski et al. 2016).  However, the role of BCAAs in AD is not clear-cut.  
The level of one of the BCAAs, valine, was found to be decreased in the plasma of AD 
patients (Gonzalez-Dominguez et al. 2015).  Furthermore, there are several studies that 
link increased levels of BCAAs to indicators of increased health such as increased muscle 
protein synthesis (Rennie et al. 2006), mitochondrial biogenesis (D’Antona et al. 2010), 
and mTOR signaling (Tokunaga et al. 2004).  A beneficial role of mTOR signaling in AD has 
been hypothesized due to the fact that insulin is neuroprotective (Felice 2013; Cai et al. 
2015), and insulin can activate mTOR kinase through PI3K (Um et al. 2006; Vergès and 
Cariou 2015).  mTOR activity has also been found to be neuroprotective under other 
experimental conditions.  For example, increased mTOR activation was associated with 
decreased Aβ pathology in brains from the 5XFAD mouse model (Avrahami et al. 2013).  
However, these effects may be related to the particular model or to the length of time of 
mTOR activation.  In the short term, it appears mTOR activation can lead to improved 
insulin secretion (Rachdi et al. 2008), whereas chronic mTORC1 activation may lead to 
exhaustion of β-cells in the pancreas (Shigeyama et al. 2008), decreasing the levels of 
neuroprotective insulin.  Somewhat contrary to the findings of mTOR being 
neuroprotective is the finding that increased mTOR activation is frequently found in the 
brains of AD model mice (Caccamo et al. 2011) and human AD patients (Li et al. 2005). 
Increased amyloid-beta levels lead to increased mTOR activation which increases protein 
translation to increase levels of tau protein, the main component of the neurofibrillary 
tangles pathologically found in AD neurons (Jahrling and Laberge 2015).  The increased 
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rate of translation induced by mTOR activation may be partially responsible for the 
decreased levels of amino acids measured in AD brain.  Increased mTOR activity can also 
stimulate mitochondrial electron transport chain activity (Schieke et al. 2006), perhaps 
leading to increased mitochondrial catabolism of amino acids.  The increased mTOR 
activity also decreases the rate of autophagy, leading to the build-up of toxic amyloid-beta 
peptides.  Consistent with these findings, treatment of PDAPP or 3xTg-AD mice with 
rapamycin, an mTOR inhibitor, reduced amyloid-beta and tau levels and restored cognitive 
function (Caccamo et al. 2010; Spilman et al. 2010).  These data suggest that diets 
containing low protein levels or low levels of the potent mTOR activators leucine and 
arginine may prove beneficial for AD patients (Hara et al. 1998), although decreasing the 
levels of all three BCAAs together was more potent than decreasing only leucine levels on 
enhancing peripheral metabolism in mice (Fontana et al. 2016). 
 Since a portion of the protective effects of mTOR inhibition by rapamycin treatment 
in AD model systems is likely caused through a decreased rate of translation, other 
therapies which decrease the rate of translation in the hippocampus may also be 
therapeutic.  With this in mind, decreased or unbalanced amino acid levels have also been 
shown to decrease the rate of translation through the general control nonderepressible 2 
(GCN2)-eIF2α kinase pathway.   GCN2 kinase senses uncharged tRNAs and then 
phosphorylates the translation initiation factor eIF2α to slow the rate of translation.  Many 
amino acids, for example BCAAs and aromatic amino acids, share the same amino acid 
transporter for transport across the blood brain barrier. Therefore, supplementation with 
high levels of one particular amino acid may competitively decrease the rate of transport of 
others into the brain to decrease the levels of one or more of these other amino acids.  This 
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could create imbalanced amino acid levels in the brain to activate GCN2 and inhibit mTOR, 
decreasing global translation rates and increasing autophagy to protect AD brains.  Not all 
mRNA transcripts show decreased translation under amino acid limitation. Some 
transcripts, such as ATF4, show increased translation to mediate protective compensatory 
responses.  ATF4 is a transcription factor involved in the ER stress response that has been 
shown to be upregulated during five conditions that extended mouse longevity (Li et al. 
2014). 
There are two prevalent hypotheses linking BCAAs to metabolic disease (Lynch and 
Adams 2014).  First, BCAAs, especially leucine, may directly lead to persistent activation of 
mTORC1.  Second, hyper-activation of BCAA catabolism can lead to increased BCAA 
metabolites which lead to metabolic dysfunction.  For example, adding the α-keto acid 
catabolite of leucine, α-ketoisocaproic acid, to rat neurons led to mitochondrial dysfunction 
(Amaral et al. 2010).  The conflicting results of studies attempting to find correlations 
between BCAA levels and disease suggest a complex role for BCAA levels in metabolism 
that may vary depending on the model organism, disease state, and the length of time of 
elevated BCAA and BCAA catabolite levels. 
Few studies have examined the levels of BCAAs specifically in postmortem AD brain, 
but it appears increasing certain BCAAs may be beneficial for the aging brain in specific 
model systems.  A diet high in BCAAs has even been shown to increase the mean lifespan of 
male mice (D’Antona et al. 2010).   Research into the role of BCAAs in AD is far from 
complete.  For example, there has been little study of the effects of isoleucine or valine 
supplementation in AD patients or animal models.  Since isoleucine and valine do not 
stimulate mTOR activity as potently as leucine does (Xu et al. 1998) and are not broken 
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down into neurotoxic α-ketoisocaproic acid, supplementation with these amino acids could 
provide energy for the brain without activating potentially pathogenic signaling pathways.  
Given the links between BCAAs, mTOR signaling, aging, and neurodegeneration, further 
research will likely clarify these complex interactions.  Furthermore, many of the same 
correlations observed for BCAAs in insulin resistant individuals have also been observed 
for aromatic amino acids, highlighting a complementary role for both of these classes of 
amino acids in metabolism and disease (Newgard 2012). 
 
Aromatic Amino Acids 
 Several studies have found that the levels of aromatic amino acids are frequently 
altered in AD serum or brain.  One research group found a decrease in all three aromatic 
amino acids in the serum of AD patients (Gonzalez-Dominguez et al. 2015), while others 
reported an increase in both phenylalanine and tryptophan in the brains of AD patients (Xu 
et al. 2016).  Researchers using AD model rats found an increase in phenylalanine in 
different regions of the brain (Nilsen et al. 2014).  Tryptophan has two different neural 
fates; it can be metabolized into serotonin or it can enter the kynurenine pathway (KP) 
where it is degraded to α-amino-β-carboxymuconate-ε-semialdehyde (ACMS) which can 
either be metabolized into quinolinic acid for NAD synthesis or into 2-aminomuconate for 
entry into the TCA cycle.  Serotonin plays a role in learning and cognition (Geldenhuys and 
Van Der Schyf 2011), but enzymes involved in the KP are upregulated in AD (Bonda et al. 
2011).  There is evidence that quinolinic acid (QUIN) and other metabolic intermediates in 
the KP pathway cause oxidative damage to the brain (Bonda et al. 2011).  Increased QUIN 
led to a concentration-dependent increase in ROS in the synaptosomes of rat brains and 
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lipid peroxidation in the hippocampus (Santamaría et al. 2001).  Researchers have also 
shown that QUIN can increase nitric oxide synthase activity more than three-fold (Pérez-
Severiano et al. 1998).  This enzyme produces nitric oxide, a vaso-relaxing free radical.  
Amyloid-beta production increased the concentration of QUIN (Guillemin et al. 2003), 
linking AD more directly to oxidative damage from amino acid metabolites.  Moreover, a 
shift in tryptophan degradation to the KP pathway diverts tryptophan from the serotonin 
synthesis pathway.  This could deprive the AD brain of serotonin, contributing to the 
pathogenesis of AD.    However, knowledge of aromatic amino acid metabolism and 
signaling in AD brain is far from complete.  Dietary tryptophan restriction has been shown 
to extend the lifespan of rodents (Segall 1977), but the mechanism has not been 
investigated.  Acute tryptophan depletion leads to memory impairment (Riedel et al. 2002). 
The amino acid tyrosine is important for synthesizing catecholamines, but there are 
only a few studies measuring tyrosine levels specifically in AD brain, although several 
studies have found that oral tyrosine administration improves memory and cognitive 
function (van de Rest et al. 2013).  Phenylalanine can be metabolized through the same 
metabolic pathways as tyrosine but only when tyrosine levels are low (Fernstrom and 
Fernstrom 2007), preventing firm conclusions regarding changes in phenylalanine levels in 
AD brain until changes in tyrosine levels are measured as well.  As a class, aromatic amino 
acid metabolism is especially important for neural functioning, and more research is 
needed to elucidate the relevance of the changes that occur in AD. 
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Charged Amino Acids 
The charged amino acids include the acidic (aspartate and glutamate) and basic 
(arginine, lysine, and histidine) amino acids.  Each of these appears to be decreased in AD 
patient brain or plasma, with the possible exception of glutamate where the direction of 
change may depend upon the brain region assayed.  Glutamate (G. Wang et al. 2014), 
histidine, and aspartate levels were decreased in serum from AD patients (Gonzalez-
Dominguez et al. 2015), while aspartate and glutamate levels were decreased in the 
temporal lobe of the cerebral cortex of AD patients (Gueli and Taibi 2013). Xu et al. 
measured a decrease in both lysine and aspartate levels in the brains from autopsied AD 
patients, while glutamate levels increased (Xu et al. 2016).  Glutamate’s interaction with 
the NMDA receptor is critical for learning and memory formation (Esposito et al. 2013), but 
glutamate excitotoxicity also leads to neuronal death in AD (Mattson et al. 1992; Hynd et al. 
2004).  As discussed below, aspartate and glutamate also play a role in transamination 
reactions such as those occurring upstream of the urea cycle.  As a group, the levels of 
charged amino acids are altered in AD, suggesting  specific perturbations in metabolism, 
but more research needs to be done to determine the cause of the changes in amino acid 
levels and the effects these have on the brain.  Examining the activity of more enzymes 
involved in amino acid metabolism and building computational models of amino acid 
metabolism could help explain the alterations in amino acid levels in AD. 
 
Glutamine 
 Glutamine is the most prevalent amino acid in plasma and, together with glutamate, 
the most prevalent amino acids in human brain (Cooper and Jeitner 2016).  Glutamate 
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supplementation decreases tau phosphorylation and has shown other protective effects in 
a mouse model of AD (Chen and Herrup 2012).  It has been found that glutamine, 
glutamate, aspartate, alanine, and purines are likely degraded as the top alternative energy 
sources in neurodegenerative diseases such as AD when glucose metabolism is disturbed 
(Kori et al. 2016).  These amino acids are readily broken down because high levels of 
aminotransferases for the initial step in the catabolism of alanine, aspartate, and glutamate 
are present in brain (Cooper and Jeitner 2016).  In AD patients, glutamine levels have been 
shown to decline in the serum (González-Domínguez et al. 2015) but increase in the 
temporal cortex of the brain (Gueli and Taibi 2013).  Glutamine and alanine levels have 
also been found to be decreased in the blood in transient global amnesia (Sancesario et al. 
2013). 
 There has not been much data generated on how the brain maintains balances in 
amino acid and total nitrogen levels during times of neuronal amino acid catabolism, but it 
is likely that BCAAs can be taken up through the blood-brain barrier (BBB) and glutamate 
can be released to maintain nitrogen balance (Hawkins and Viña 2016).  BCAA-derived 
carbons can then be fed into the citric acid cycle to form alpha-ketoglutarate, and then the 
alpha-ketoglutarate can be transaminated to glutamate to maintain glutamate levels.  
During times when ammonia levels increase in the brain, exporting a glutamine (containing 
two nitrogen atoms) from the brain for every BCAA (or other amino acid containing a 
single nitrogen atom) taken up would allow for a net efflux of nitrogen to lower the brain 
ammonia levels (Cooper and Jeitner 2016). 
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Sulfur-Containing Amino Acids 
 The sulfur containing amino acids are cysteine and methionine.  Much research has 
been performed on supplementation with cysteine and the more membrane permeable 
form N-acetylcysteine (NAC) as cysteine levels limit the synthesis of glutathione, one of the 
most important antioxidants in the body.  NAC appears to cross the blood-brain barrier 
slowly, so other therapies are under development to increase brain glutathione levels 
(Bavarsad-Shahripour et al. 2014).  There have been three small clinical trials of NAC 
supplementation to AD patients with mixed results (Deepmala et al. 2015).  Therefore, 
more research is needed to clarify the effects of NAC on AD.  There seems to be a disruption 
in sulfur-containing amino acid metabolism in AD as serum and brain homocysteine levels 
increase (Hu et al. 2016).  Cysteine levels were also shown to be increased in the 
hippocampus of autopsied AD patients (Xu et al. 2016).  Homocysteine-cysteine disulfide 
levels were also found to increase in AD patient serum while methionine levels decreased 
(González-Domínguez et al. 2014).  Increased homocysteine levels in the plasma is a known 
risk factor for AD and other dementias (Seshadri et al. 2002).  Dietary methionine 
supplementation caused increased amyloid-beta and phosphorylated tau levels in brain 
and cognitive impairment in wild-type mice (Tapia-Rojas et al. 2015).  Dietary methionine 
restriction led to decreased amyloid-beta levels and neuroprotection in APP-PS1 AD mice 
(Sambamurti et al. 2015) and decreased mitochondrial complex I-mediated superoxide 
production and increased lifespan in rats (Orentreich et al. 1993) while cysteine 
supplementation led to a slight decrease in mTOR activity (Gomez et al. 2015).  However, 
cysteine supplementation prevented the decreased ROS production in methionine 
restricted animals.   
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Amino Acids as an Energy Source in AD Neurons 
 One of the hallmarks of AD is dysfunctional energy metabolism.  Mitochondrial-
derived oxygen free radicals produced in AD brain are known to damage glycolytic 
enzymes such as enolase (Butterfield and Lange 2009) and glyceraldehyde-3-phosphate 
dehydrogenase (Butterfield et al. 2010), slowing glycolysis.  This damage, combined with 
decreased insulin signaling in AD brains (Calvo-Ochoa and Arias 2015), results in 
decreased glucose uptake and metabolism which has been confirmed as an early event in 
AD progression through the use of fluorodeoxyglucose (FDG)-PET scans (Mosconi et al. 
2010).  The decreased glucose metabolism results in decreased pyruvate production which, 
combined with amyloid-beta-mediated mitochondrial complex IV inhibition (Wong-Riley et 
al. 1997) and tau-mediated mitochondrial complex I inhibition (Rhein et al. 2009), results 
in decreased mitochondrial energy metabolism and ATP levels.  Most cells in the body 
show metabolic flexibility and can increase mitochondrial fatty acid beta-oxidation when 
glycolytic output decreases to maintain cellular ATP levels.  Neurons contain very low 
levels of fatty acid beta-oxidation enzymes (Panov et al. 2014), so they instead rely upon 
ketone body catabolism, amino acid catabolism, or catabolism of lactate released from 
astrocytes (Mächler et al. 2016) to maintain cellular ATP levels.  Ketone body levels are 
normally very low in the well-fed and unexercised human body (Sleiman et al. 2016). 
Therefore, amino acid catabolism together with lactate metabolism and limited glucose 
metabolism likely play essential roles in maintaining cellular ATP levels in AD neurons. 
Data supporting this hypothesis come from clinical studies that show a 44% decrease in 
glucose utilization in autopsied early-onset familial Alzheimer’s disease brain. The AD 
brains showed no deficits in oxygen utilization as free amino acids (and perhaps lactate) 
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were oxidized for energy generation in replacement of glucose, leading to decreased amino 
acid levels (Hoyer et al. 1988).  Once brain amino acid levels were depleted, brain ammonia 
levels decreased as well.  These data indicate that amino acid supplementation or high 
protein diets may help to energize the AD brain. 
The most abundant amino acids present in the human brain as a potential energy 
source are glutamate and glutamine, present at roughly 7-8 mM, while the next most 
abundant amino acids are aspartate and taurine which are present at roughly 1.2 mM, and 
then serine, GABA, and glycine that are present at roughly 0.5 mM (Cooper and Jeitner 
2016).  The brain contains a glutamate-glutamine cycle where glutamate is released by 
neurons into synaptic clefts; the glutamate is then taken up by astrocytes where some is 
broken down for energy but most is converted to glutamine which is exported from the 
astrocytes and taken up once again by neurons and converted back into glutamate.  To 
facilitate this cycle, the brain has been shown to possess high levels of two neuronal 
glutaminase genes, GLS and GLS2 (phosphate-activated mitochondrial glutaminase), to 
function in the breakdown of glutamine to glutamate that releases ammonia, but small 
amounts of glutaminase (mostly GLS) have also been localized to astrocytes (Cardona et al. 
2015).  GLS2 activity is strongly upregulated by ADP (Masola and Ngubane 2010) and has 
been shown to decline with aging (Walton and Dodd 2007), particularly in AD brain 
(Akiyama et al. 1989). 
Further release of ammonia in the brain can occur if glutamate is catabolized to 
alpha-ketoglutarate by glutamate dehydrogenase.  In addition to the normal mammalian 
glutamate dehydrogenase gene, GLUD1, primates have a second glutamate dehydrogenase 
gene, GLUD2, that is expressed in astrocytes and may be needed in those cells to preserve 
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alpha-ketoglutarate levels in the presence of high glutamine synthetase activity (Spanaki 
and Plaitakis 2012).  Glutamine synthetase activity has been shown to decline in AD brain 
(Smith et al. 1991).  Mitochondrial GLUD1 is negatively regulated by the GTP formed from 
citric acid cycle function, while GLUD2 is relatively unaffected by guanine nucleotides but is 
positively regulated by ADP and branched chain amino acids (Zaganas et al. 2014).  The 
negative regulation of GLUD1 when energy levels are high allows for preservation of 
glutamate levels needed for neurotransmission as well as prevents the toxic buildup of 
ammonia.   Glutamate can also be metabolized to alpha-ketoglutarate to fuel citric acid 
cycle metabolism without the release of free ammonia through the function of the alanine, 
aspartate, and branched chain aminotransferases (McKenna et al. 2016) if the 
corresponding ketoacids are present in adequate amounts.   
Normally both neurons and astrocytes oxidize glucose by glycolysis and the 
resulting pyruvate by oxidative phosphorylation to maximize ATP yield (Patel et al. 2014).  
However, there is much evidence that indicates astrocytes are more metabolically flexible 
than neurons due to their slightly lower energy demands (Stobart and Anderson 2013).  
Therefore, astrocytes can survive predominately by glycolysis with little oxidative 
metabolism. In metabolically stressful times, such as in AD, astrocytes may convert the 
pyruvate produced from glycolysis into lactate to maintain the cellular redox state and then 
export the lactate which can then be taken up by neurons, converted back to pyruvate, and 
used for oxidative energy metabolism, a process called the astrocyte-neuron lactate shuttle 
(Pellerin and Magistretti 2012).  Astrocytes may also be able to increase the amount of 
glutamine released to neurons to be utilized as an energy source under these conditions 
when neuronal glycolysis is impaired.  Astrocytes possess some fatty-acid beta-oxidation 
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capabilities (Panov et al. 2014) which likely becomes important during these times when 
neuronal energy metabolism is impaired. 
A study using AD mice found that a high protein/low carbohydrate diet resulted in a 
5% reduction in the brain weight in AD mice, including decreased neuronal density and 
volume in the CA3 region of the hippocampus that is important for memory (Pedrini et al. 
2009).  A high protein/low carbohydrate diet has also been associated with increased 
excitotoxicity in the aged brain (Pal and Poddar 2008).  These data suggest that high levels 
of amino acids or products of their catabolism may contribute to neurodegeneration.  
Consistent with this assessment, catabolism of branched chain keto acids by branched 
chain ketoacid dehydrogenase (BCKDH) in mitochondria results in substantial production 
of damaging superoxide radical (Quinlan et al. 2014).  In addition, mice on a low 
protein/high carbohydrate diet lived longer than those on a high protein/low carbohydrate 
diet and had lower insulin levels and lower mTOR activation (Solon-Biet et al. 2014). 
However, the health benefits of a low protein/high carbohydrate diet may only extend 
through middle age as aged mice and humans on a high protein diet showed protection 
from disease (Levine et al. 2014).  Therefore, amino acid supplementation therapies may 
best be explored as therapies for late-onset AD.  Interestingly, plasma levels of all three 
branched chain amino acids showed a positive correlation with dietary protein intake in 
mice, while the plasma levels of most other amino acids showed a negative correlation with 
dietary protein intake. Therefore, some of the beneficial health effects conferred by the low 
protein diet in young and middle aged mice may be mediated by decreased plasma 
branched chain amino acid levels.  
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The Urea Cycle and AD 
Amino Acid Metabolism, Ammonia, and the Urea Cycle 
 Proteins are digested in the stomach and intestine by a variety of peptidases into 
free amino acids and dipeptides; the dipeptides are further catabolized into amino acids by 
first pass hepatic metabolism.  These amino acids are then transported by the blood to 
other tissues where the amino acids are used for protein synthesis or broken down in 
processes that produce ammonia when levels exceed their requirements.  The α-amino 
group of the amino acid is often transferred to α-ketoglutarate to form glutamate and an α-
keto acid.  Glutamate can undergo oxidative deamination to form ammonia and α-
ketoglutarate, or the amino group can be transferred to oxaloacetate to form aspartate and 
α-ketoglutarate. Aspartate is required for urea cycle function.  In the brain and muscle 
(tissues normally lacking appreciable urea cycle function) aspartate can enter the purine 
nucleotide cycle to release fumarate and ammonia.  Other reactions produce ammonia as 
well; histidine, serine, threonine, and tyrosine-derived catecholamine catabolism each 
release ammonia through separate reactions.  Ammonia is toxic and needs to be eliminated 
quickly or converted to a less toxic form. Once ammonia and glutamate combine to form 
glutamine through the action of the glutamine synthetase enzyme, the glutamine is 
exported from the tissue and transported through the blood to the liver where the free 
ammonia is released through the action of the glutaminase enzyme.  The urea cycle can 
then function to convert the ammonia to urea, which is excreted from the body. 
 The first and second steps of the urea cycle occur in the mitochondria, while the 
other three steps occur in the cytoplasm.  First, ammonia combines with CO2, H2O, and 
HCO3- to form carbamoyl phosphate.  N-acetylglutamate is required as a cofactor for this 
159 
 
reaction to proceed.  Carbamoyl phosphate reacts with ornithine to produce citrulline, 
which is transported out of mitochondria and then reacts with aspartate to form 
argininosuccinate.  Arginosuccinate is converted by argininosuccinase into fumarate and 
arginine.  In the final step, arginase converts arginine into ornithine and urea.  Figure 5.1 
summarizes amino acid catabolism leading up to and including the urea cycle. 
 
 
 
 
Figure 5.1: Overview of the urea cycle.  Ammonia produced as a result of metabolic 
processes involving amino acids and other biomolecules is converted into nontoxic urea in 
the urea cycle for excretion.  The intermediates are in boxes and the enzymes and other 
necessary substrates are next to the arrows in lowercase.  These intermediate metabolite 
and enzyme levels are altered in the brain in Alzheimer’s disease. 
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Changes in Components of the Urea Cycle in AD 
 Levels of enzymes and metabolic intermediates of the urea cycle are altered in 
patients with AD.  It is widely accepted that the urea cycle occurs almost exclusively in the 
liver and intestines (Takiguchi and Masataka 1995).  It has been shown that normal human 
brain has low or no ornithine transcarbamoylase (OTC) activity, thus preventing urea cycle 
activity (Bensemain et al. 2009).  Carbamoyl phosphate synthetase activity is also low in 
brain tissue.  However, studies using autopsied brains from AD patients have challenged 
this exclusive localization of the urea cycle.   Hansmannel and colleagues identified mRNA 
expression for all enzymes of the urea cycle in the brains of both normal adults and 
patients with AD (Hansmannel et al. 2010).  However, the mRNA levels of OTC were 
extremely low in the non-AD subjects, and the normal cytoplasmic urea cycle enzyme 
arginase I was extremely low in both populations.   Arginase is one of the more studied 
urea cycle enzymes that appears to be dysregulated in AD.  Arginase converts arginine to 
urea and ornithine (see Figure 5.1).  Two groups, Lui et al. (P. Liu et al. 2014) and 
Hansmannel et al. (Hansmannel et al. 2010), found the same trend of increased 
mitochondrial arginase II (Arg2) levels in autopsied AD patient brain.  Hansmannel et al. 
used RT-PCR to find a 55% increase in Arg2 mRNA levels in AD patients compared to 
controls (Hansmannel et al. 2010), whereas Lui et al. used Western blot to show an 
increase in the total amount of Arg2 protein in two different brain regions with no change 
in a third (P. Liu et al. 2014). 
There are several important consequences of increased Arg2 expression in AD 
brain. First, increased arginase activity increases urea and ornithine levels, the latter being 
a precursor of polyamine synthesis.  Polyamines can play an important neuroprotective 
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role in the brain.  Second, increased arginase activity decreases arginine levels, which can 
lead to decreased mTOR activity.  Arginine is also a substrate for nitric oxide synthase 
which produces the vasorelaxing free radical nitric oxide that can increase 
neuroinflammation.  Therefore, transgenic overexpression of arginase I showed 
neuroprotection in a tau-overexpressing model of AD (Hunt et al. 2015).  However, an 
arginase inhibitor showed neuroprotective effects in an amyloid-beta-producing  mouse 
model of AD (Kan et al. 2015).  Therefore, it is possible that arginase expression has 
different effects on amyloid and tau pathology.  Arg2 is the main isoform in AD brain and is 
highly expressed in endothelial cells.  Therefore, it is also possible that arginase I activity is 
neuroprotective while arginase II activity is neurotoxic due to expression in different cell 
types or different subcellular localizations.  
Bensemain et al. used RT-PCR to detect the transcription of the ornithine 
transcarbamylase (OTC) gene and other enzymes of the urea cycle in AD brains as well 
(Bensemain et al. 2009).  OTC activity was exclusively localized to brain endothelial cells, 
and its activity in cerebrospinal fluid was nearly 9 times higher in AD patients than in the 
control group (Bensemain et al. 2009).  It is interesting that OTC activity was concentrated 
in the endothelia in the vasculature of the brain in AD (Bensemain et al. 2009); these areas 
are severely affected by amyloid plaques (Koizumi et al. 2016).  Taken together, these 
results indicate that the urea cycle may occur in the endothelial cells of AD patients, but 
this may rely upon the transport of arginine from the cytoplasm to the mitochondria to be 
metabolized by arginase II.  The mitochondrial ornithine carriers ORC1, ORC2, and 
SLC25A29 are also able to transport arginine (Monné et al. 2015).  ORC1 and ORC2 are 
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expressed at very low levels in brain (Begum et al. 2002), but this may be enough to allow 
low level urea cycle activity in the endothelial cells from AD patients. 
Perhaps the most notable urea cycle metabolite change in the AD brain is in the level 
of urea.  The direction of the change in level of urea depends on the clinical or pathological 
sample or the mouse model tested.  Serum from human AD patients showed a 44% 
decrease in urea levels when assayed using GC/MS (Gonzalez-Dominguez et al. 2015). The 
same group found decreased urea in the serum of APP/PS1 AD model mice (González-
Domínguez et al. 2015).  A decrease in urea in the hippocampus of the senescence-
accelerated SAMP8 mice was also measured (H. Wang et al. 2014).  SAMP8 mice show 
neurodegeneration similar to that observed in AD.  The decreased urea levels are 
consistent with decreased arginase levels found in APP/PS1 mouse brain (Tapia-Rojas et 
al. 2015).  Data collected from studies of human brain tell a completely different story. A 
study by Gueli and Taibi using GC/MS on temporal lobe extracts demonstrated that urea 
was increased in brain tissue of AD patients over 2-fold (Gueli and Taibi 2013).  Xu and 
colleagues measured urea in six different regions of the brain to find that urea was 
increased in AD patients’ brains by an average of more than 5-fold (Xu et al. 2016). This 
increase in urea levels is consistent with the increased Arg2 levels in human AD brain.  
Interestingly, in the striatum of post-mortem Huntington’s disease brain, urea was found to 
be the most decreased (3.2-fold) metabolite (Graham et al. 2016), but another study found 
opposite results that urea was increased in all brain regions examined in post-mortem 
Huntington’s patients (Patassini et al. 2015). 
Ornithine levels were decreased in AD brain and serum (P. Liu et al. 2014; Gonzalez-
Dominguez et al. 2015; Xu et al. 2016).  Although ornithine is the product of an enzyme that 
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is upregulated (Arg2), the decrease is consistent with other findings because ornithine is 
the substrate of OTC, another upregulated enzyme in AD brain (Bensemain et al. 2009), 
and ornithine is a precursor for the production of polyamines that increase in abundance in 
AD brain (Guerra et al. 2016).  Citrulline, however, appears to remain unchanged in AD 
brains (P. Liu et al. 2014; Pan et al. 2015).  Citrulline is a strong antioxidant and citrulline 
supplementation prevented age-related changes in lipid metabolism in mouse 
hippocampus (Marquet-de Rougé et al. 2013).  Aspartate reacts with citrulline to form 
argininosuccinate.  Aspartate levels  are decreased in AD patient serum (Gonzalez-
Dominguez et al. 2015), and both aspartate and arginine levels are decreased in the brain 
of AD patients (Gueli and Taibi 2013; Xu et al. 2016).  Decreased levels of urea cycle 
intermediates could indicate their efficient metabolism.  Considering that different groups 
have shown increased urea levels in biopsied AD brains as well as increased expression of 
one or more urea cycle genes, current evidence suggests that urea cycle activity may be 
induced in endothelial cells from AD patient brain.  It is possible that a urea cycle 
metabolite such as arginine that is produced in neurons and glia is imported into AD 
endothelial cells where Arg2 levels are high and OTC is exclusively present to finish the 
urea cycle there.  The citrulline produced from endothelial cell OTC activity could also be 
exported to neurons or glia to finish the urea cycle.  However, it is also possible that the 
higher urea levels found in AD brain are strictly due to increased Arg2 levels independent 
of complete urea cycle function. 
Increased urea levels in AD brain raises questions as to what could be leading to the 
increased expression of OTC and arginase II.  The main function of the urea cycle is to safely 
dispose of nitrogenous waste from amino acid catabolism and other sources.  Therefore, it 
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has been hypothesized that abnormal nitrogen metabolism may play a role in the 
pathogenesis of AD (Seiler 1993).  One of the early hypotheses for the pathogenesis of AD, 
proposed by Seiler in 1993, was the ammonia hypothesis; this posits that increased levels 
of ammonia accumulate in and are toxic to the AD brain (Seiler 1993).  However, the 
amyloid cascade hypothesis was proposed the year before (Hardy and Higgins 1992), and 
the ammonia hypothesis was not thoroughly investigated (Seiler 2002).  The ammonia 
hypothesis of AD was generated due to the following observations: increased ammonia 
levels measured in the plasma from AD patients (Fisman et al. 1985; Hoyer et al. 1990), 
decreased glutamine synthetase enzyme levels in AD astrocytes to scavenge ammonia 
(Smith et al. 1991; Le Prince et al. 1995), increased adenosine deaminase activity in AD 
brain (Sims et al. 1998), and increased monoamine oxidase activity in AD brain (Nakamura 
et al. 1990; Jossan et al. 1991); the latter two enzymes produce ammonia.  Ammonia has 
also been implicated as a cause of oxidative damage in the brain as it was found to increase 
reactive oxygen species levels in SH-SY5Y cells (Bobermin et al. 2015) and astrocytes 
(Murthy et al. 2001) and lead to RNA oxidation in rats (Görg et al. 2008).  Furthermore, 
mitochondrial activity in rat and mouse models appears to be impaired by ammonia.  
Ammonium acetate injection into rats led to decreased state III respiration (Kosenko et al. 
1997), cytochrome c oxidase activity (Rama-Rao et al. 1997), and decreases in various 
other respiratory complexes in isolated synaptic mitochondria (Qureshi et al. 1998).  
Impaired mitochondrial function is often associated with increased oxidative damage. This 
may in part explain the increase in reactive oxygen species in the presence of ammonia. 
Increased ammonia production would either necessitate urea cycle function to metabolize 
the toxic ammonia to urea or necessitate increased reaction of ammonia with glutamate 
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catalyzed by astrocytic glutamine synthetase followed by export of glutamine from the 
brain.  Evidence from studies of the urea cycle and amino acid metabolism in AD subjects 
and mouse models justifies further investigation into the production and detoxification of 
ammonia in the AD brain.   
 
Considerations for Dietary Metabolite Supplementation as a Treatment for AD 
 Increasing or decreasing the levels of specific amino acids and other metabolites in 
the diet has shown some promise in improving markers of aging and longevity (Fernstrom 
2005), so it is possible that nutrient supplementation or restriction may improve neural 
functioning in AD patients as age is the major risk factor for AD.  However, there are several 
hurdles to overcome before an efficacious treatment can be formulated.  For example, 
studies on intestinal transport, bioavailability, hepatic metabolism and excretion, and 
blood-brain barrier transport are needed in order to choose the optimal formulations.  
Much of this information is present for a few commonly studied amino acids, but much of it 
is absent for the vast majority of amino acids.  From what is known, it appears that hepatic 
metabolism, especially of amino acids, presents the greatest challenge to overcome for the 
supplementation of many of the amino acids for their use in the treatment of 
neurodegeneration, but intestinal transport may also become limiting in the elderly 
(Levine et al. 2014).  Several of the amino acids also have limited blood-brain permeability.  
We will present one promising strategy taking these many challenges into consideration. 
   As mentioned above, intestinal uptake of amino acids declines past age 65.  It has 
been shown that the bioavailability of individual amino acids and dipeptides is slightly 
better than that of amino acids consumed as polypeptides since the individual monomers 
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can be absorbed quickly without the need for further enzymatic hydrolysis in the gut. 
Therefore, dietary supplementation with individual amino acids or combinations of 
individual amino acids would likely benefit the elderly in addition to a high protein diet 
that promotes health in the elderly (Levine et al. 2014).  The use of individual amino acids 
also has the added benefit of being able to stimulate specific signaling pathways.  Due to the 
limited intestinal uptake of amino acids in the elderly, they may particularly benefit from 
supplementation with hydrophobic, more membrane permeable forms of amino acids such 
as amino acid ethyl esters or N-acetyl amino acids. These amino acid derivatives show a 
greater probability of diffusion across membrane bilayers such as intestinal epithelia and 
the capillary endothelia of the blood-brain barrier where the activity of specific membrane 
transporters may be limiting.  These more hydrophobic amino acid derivatives are cleaved 
by esterases and other hydrolytic enzymes intracellularly or extracellularly to release the 
free amino acid.  This hydrolysis may occur to a large extent during first pass hepatic 
metabolism. 
 Dietary aspartate, glutamate, and glutamine are oxidized as primary sources of fuel 
for intestinal cells (Reeds et al. 2000).  In addition, these amino acids, especially glutamate 
and aspartate, are transported very poorly through the blood-brain barrier (Hawkins et al. 
2006) even though they are present at high concentrations in the brain.  Other amino acids 
that are transported poorly through the blood-brain barrier include glycine, alanine, 
proline, and GABA.  Medium and large side chain, non-polar amino acids are transported 
readily by the blood-brain barrier into the brain including aromatic amino acids, BCAAs, 
methionine, histidine, and threonine (Smith 2000). These amino acids all compete for 
transport through the L1 transport pathway.  Glutamine and asparagine are also likely 
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transported by this pathway.  Another amino acid transporter called the y+ system 
transports basic amino acids such as arginine, lysine, and ornithine as well as many neutral 
amino acids such as serine through the blood brain barrier (Hawkins et al. 2006).  One 
potential therapeutic strategy for AD patients is to supplement their diets with high levels 
of BCAAs, aromatic amino acids, and threonine.  Through competition for the L1 amino acid 
transport system, this therapy could limit the transport of methionine into the brain, 
perhaps yielding the known metabolic and neuroprotective benefits of methionine 
restriction (Sanchez-Roman and Barja 2013; Tapia-Rojas et al. 2015).  However, 
methionine is also transported into the brain to a limited extent through the y+ system; this 
may hinder the effectiveness of this strategy.  A second potential therapy is to omit leucine 
and/or isoleucine from the previously mentioned supplementation strategy.  These two 
amino acids are not transported by the y+ system (Hawkins et al. 2006).  Depletion of 
leucine or isoleucine in the brain would lead to amino acid imbalance, activation of GCN2 
kinase, and possibly the inhibition of mTOR kinase to slow protein translation rates that 
may be beneficial for reducing the levels of neurofibrillary tangles formed from 
hyperphosphorylated aggregates of tau protein.  These amino acid supplementation 
therapies could be combined with supplementation with other metabolic fuels such as D-
beta-hydroxybutyrate (a ketone body), citric acid cycle intermediates, pyruvate, and/or 
lactate, which would decrease the reliance of AD neurons on the use of amino acids as a 
fuel.  Consumption of high levels of these alternative metabolic fuels may function to 
restore neuronal amino acid levels.   
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Summary and Conclusions 
 Dietary amino acids provide a large amount of carbon and nitrogen to the body that 
can be metabolized by a myriad of biochemical pathways.  Amino acids have roles in 
neuronal signaling, energy production, and nitrogenous waste production and elimination.  
These processes are important for normal physiology, so it is not surprising that disease 
states result from major metabolic dysfunction, but whether relatively minor perturbations 
of this metabolism contribute to neurodegeneration requires further study.  Brains and 
serum from AD patients have consistently shown alterations in amino acid levels and 
metabolism that could provide a basis for some of the symptoms of the disease.  These 
individual changes may each play a different role in the disease, highlighting the complexity 
that underlies AD pathology.  An increase in urea in the brains of AD patients together with 
the altered expression of urea cycle enzymes suggests that urea cycle activity is induced in 
AD brain endothelial cells.  Viewing AD as a metabolic disease provides valuable insight 
into possible new targets for drug discovery in the AD research field.  A summary of some 
of the altered amino acid metabolism that occurs in AD is shown in Figure 5.2. 
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Figure 5.2: Pathogenic processes and proposed physiological responses in Alzheimer’s 
disease. A) An overview of the pathogenic processes of Alzheimer’s disease.  B)  An 
overview of how the body may respond to AD to minimize damage by changing the 
expression of enzymes involved in amino acid catabolism. 
 
The measurement of metabolite levels provides a snapshot of a very dynamic 
process.  While this information is extremely useful, it is not sufficient by itself to 
understand the pathological changes associated with AD.  Further studies measuring 
enzyme activities could provide complementary information about the dynamics of amino 
acid metabolism in AD.  In addition, studies overexpressing OTC and Arg2 to activate the 
urea cycle in the brain endothelial cells of an AD mouse model would help clarify the effects 
of endothelial urea cycle activity on brain physiology and cognitive function.  Studying AD 
from a metabolic perspective could lead to dietary supplementation therapies that could 
delay disease progression or alleviate some of the suffering caused by the disease. 
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Abstract 
 Ammonia is a toxic byproduct of protein catabolism and is involved in changes in 
glutamate metabolism.  Therefore, ammonia metabolism genes may link a range of diseases 
involving glutamate signaling such as Alzheimer’s disease (AD), major depressive disorder 
(MDD), and type 2 diabetes (T2D).  We analyzed data from a National Institute on Aging 
study with a family-based design to determine if 45 single nucleotide polymorphisms 
(SNPs) in glutaminase (GLS), carbamoyl phosphate synthetase 1 (CPS1), or glutamate-
ammonia ligase (GLUL) genes were associated with AD, MDD, or T2D using PLINK 
software.  HAPLOVIEW software was used to calculate linkage disequilibrium measures for 
the SNPs.  Next, we analyzed the associated variations for potential effects on 
transcriptional control sites to identify possible functional effects of the SNPs.  Of the SNPs 
that passed the quality control tests, four SNPs in the GLS gene were significantly 
associated with AD, two SNPs in the GLS gene were associated with T2D, and one SNP in 
the GLUL gene and three SNPs in the CPS1 gene were associated with MDD before 
Bonferroni correction.  The in silico bioinformatic analysis suggested probable functional 
roles for six associated SNPs.  Glutamate signaling pathways have been implicated in all 
these diseases, and other studies have detected similar brain pathologies such as cortical 
thinning in AD, MDD, and T2D.  Taken together, these data potentially link GLS with AD, 
GLS with T2D, and CPS1 and GLUL with MDD and stimulate the generation of testable 
hypotheses that may help explain the molecular basis of pathologies shared by these 
disorders. 
 
 
184 
 
Keywords 
Ammonia, Glutamate, Alzheimer’s Disease, Major Depressive Disorder, Type 2 Diabetes 
 
Background 
 Excess dietary protein is catabolized to release ammonia.  Because of the relative 
toxicity of ammonia (Auron and Brophy 2012), it is removed from the body by the urea 
cycle and excreted as the relatively non-toxic compound urea.  The urea cycle is thought to 
occur almost exclusively in the liver (Dimski 1994).  However, certain types of ammonia 
metabolism such as glutamate cycling can occur in other tissues.  Among the enzymes 
involved in ammonia metabolism are glutaminase (GLS, EC 3.5.1.2), carbamoyl phosphate 
synthetase 1 (CPS1, EC 6.3.4.16), and glutamate-ammonia ligase (GLUL, EC 6.3.1.2), also 
known as glutamine synthetase.  CPS1 is the first committed step of the urea cycle.  
Individuals who lack a functional CPS1 gene have severe hyperammonemia resulting in 
cognitive impairment (Klaus et al. 2009).  The majority of cells in the body (such as those in 
the brain) that lack a functional urea cycle rely on GLUL to locally remove ammonia by 
ligating it to glutamate to form glutamine (Cooper and Jeitner 2016).  Glutaminase 
catalyzes the reverse process, releasing ammonia from glutamine to form glutamate.  The 
human genome contains two glutaminase genes.  Data from the Human Protein Atlas 
(www.proteinatlas.org) suggest GLS is expressed primarily in the brain and kidney 
(http://www.proteinatlas.org/ENSG00000115419-GLS/tissue) (Uhlén et al. 2015).  
Because glutamate is an important neurotransmitter and signaling molecule, both GLUL 
and GLS are necessary for proper neural functioning (Cooper and Jeitner 2016).   
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 Because (1) glutamine and glutamate are abundant and ubiquitous amino acids 
involved in ammonia metabolism, (2) ammonia is a byproduct of protein catabolism, and 
(3) glutamate is an important signaling molecule, we hypothesized that the CPS1, GLUL, 
and GLS ammonia metabolism genes could influence various disease processes across a 
range of tissues.  Evidence for a link between ammonia metabolism genes and type 2 
diabetes (T2D) includes studies that have found changes in GLS activity in a rat model of 
diabetes (Ardawi 1987).  In addition, a SNP in the GLUL gene has been associated with all-
cause mortality in individuals with T2D (Prudente et al. 2015), and a separate study has 
found a transcriptomic link between T2D and GLUL (Mirza et al. 2014).  Ammonia and 
glutamate metabolism changes have also been linked to mood disorders such as major 
depression.  For example, glutamate signaling pathways have been shown to be altered in 
major depressive disorder (MDD) (Bernard et al. 2011).  Furthermore, GLUL expression 
has been shown to be changed in individuals with MDD (Choudary et al. 2005; Miguel-
Hidalgo et al. 2010; Bernard et al. 2011).  However, one study reports no change in GLUL 
activity in astrocytes from the brains of individuals with MDD (Chandley et al. 2013).  
Further evidence supporting this connection is that researchers were able to induce 
behaviors consistent with depression in mice by inhibiting enzymes involved in ammonia 
and glutamate metabolism (Lee et al. 2013).   
The potential link between ammonia metabolism and Alzheimer’s disease (AD) is 
particularly well-supported.  The amyloid cascade hypothesis is the dominant hypothesis 
for the pathogenesis of AD (Hardy and Higgins 1992).  However, increasing evidence 
suggests increased amyloid-beta levels are only one facet of this complex disease (Herrup 
2015).  The ammonia hypothesis for the etiology of AD was first proposed in 1993 (Seiler 
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1993), but it has not yet been thoroughly investigated.  The ammonia hypothesis suggests 
ammonia toxicity plays a causal role in AD.  This is supported by several observations 
reviewed by Seiler (Seiler 2002). Briefly, individuals with AD have been found to have 
increased blood ammonia (Fisman et al. 1985) and cerebrospinal fluid ammonia levels.  
The negative effects of ammonia on cognitive functioning are well documented (Raabe 
1987), and studies have suggested that there are high ammonia concentrations in AD brain 
(Hoyer et al. 1990).  AD patients have also been shown to have increased plasma glutamate 
compared to controls (Miulli et al. 1993).  Further studies suggest changes in the activity of 
ammonia metabolism genes may be involved in AD.  Researchers have found changes in 
GLUL expression in AD patients (Robinson 2000) as well as in mouse models of AD 
(Kulijewicz-Nawrot et al. 2013).  Changes in GLS expression in AD brains have been found 
as well (Akiyama et al. 1989; McGeer et al. 1989; Burbaeva et al. 2014).  The 
aforementioned studies suggest an association between GLUL, GLS, and CPS1 genes and 
disorders such as AD, T2D, and MDD.  While all three of the genes of interest have not been 
explicitly implicated in all three diseases, there is sufficient evidence for the involvement of 
ammonia metabolism genes in the pathologies of these diseases to warrant further 
investigation. 
All three of these diseases have genetic heritability; AD is estimated to have a 
heritability of 0.74 (Gatz et al. 1997), MDD of 0.37 (Sullivan et al. 2000), and T2D of 0.47-
0.77 (Willemsen et al. 2015).  There is also ample epidemiological evidence of associations 
among MDD, T2D, and AD.  T2D has been found in several studies to be linked to the 
incidence of AD (Ott et al. 1999; Luchsinger et al. 2005; Gudala et al. 2013; Li et al. 2015).  
Two separate analyses of a GWAS found SNPs that were associated with both T2D and AD 
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(Hao et al. 2015; Gao et al. 2016), suggesting the possibility of a shared genetic etiology.  
However, none of the hits from these studies were the genes we tested.  There is also 
epidemiological evidence of an association between AD and MDD.  Individuals with a 
history of depression were shown to have an increased risk for AD (Geerlings et al. 2008).  
Finally, T2D has been shown by several studies to nearly double the risk of developing 
MDD (Anderson et al. 2001; Ali et al. 2006).  However, not every study supports a genetic 
association amongst these diseases.  A study of 32 genetic variants identified in GWAS 
studies of individuals with T2D found no association with AD (Chung et al. 2015).  Another 
study also found no association between SNPs associated with T2D and risk of AD (Proitsi 
et al. 2014).  A third study found no common genetic variants between individuals with AD 
and MDD (Gibson et al. 2017).  Studies that continue to investigate the genetic component 
of these diseases could help untangle knowledge of genetic associations and elucidate 
targets for novel treatment strategies.   
 To investigate the potential association between these select ammonia metabolism 
genes and AD, MDD, and T2D, we used data from a family-based study of Alzheimer’s 
disease patients.  The variations significantly associated with one or more of these diseases 
were interpreted considering previously published experimental results and 
bioinformatics analysis of possible effects of variants on gene expression.  This study 
generates several hypotheses useful for guiding future work into mechanisms of 
pathogenesis of AD, MDD, and T2D and investigations into how these mechanisms may 
interact and overlap. 
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Methods 
NIA-LOAD Family Study Subjects 
Data for this study came from the National Institute on Aging—Late Onset 
Alzheimer’s Disease Family Study: Genome-Wide Association Study for Susceptibility 
Loci—Study Accession: phs000168.v1.p.  There were 3,007 individuals selected consisting 
of 1266 AD, 247 T2D, and 1688 MDD individuals, and 1279 non-AD individuals from 1386 
pedigrees (589 nuclear families). Details on these subjects have been previously published 
(Lee et al. 2008).  Population stratification does not apply to a family-based study design.  
The number of individuals in this data set with each type of disease and combinations of 
co-occurrences are shown in Table 6.1. 
 
Table 6.1  Number of individuals with co-occurrence of AD, MDD, and T2D in the data seta 
AD Only MDD Only T2D Only 
AD and 
MDD Only 
AD and 
T2D Only 
MDD and 
T2D Only 
AD, MDD, 
and T2D 
166 877 16 372 32 93 46 
aIndividuals with an unknown disease state for either AD, MDD, or T2D were not included in 
this count 
 
 
Analytic Procedures 
 A total of 45 SNPs in GLUL (4 SNPs), GLS (8 SNPs), and CPS1 (33 SNPs) were 
available in the data set for association testing.  A family-based association analysis for risk 
of AD, T2D and MDD was performed using the PLINK DFAM procedure. Empirical p-values 
for single marker analyses were calculated by 100,000 permutation tests using the Max (T) 
permutation procedure implemented in PLINK v1.07 software 
(http://zzz.bwh.harvard.edu/plink/index.shtml) (Purcell et al. 2007).  Haplotype analysis 
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was conducted in 2-SNP sliding windows using PLINK software to obtain p-values, chi-
square values, and haplotype frequencies for affected and unaffected individuals.  
HAPOVIEW v4.2 software (https://www.broadinstitute.org/haploview/haploview) 
(Barrett et al. 2005) was used to determine minor allele frequencies (MAFs) and to test for 
Hardy-Weinberg equilibrium (HWE) using all founders in the family-based dataset.  The 
quality control cutoff values for HWE and MAF are <0.001 and <0.05, respectively.  The 
linkage disequilibrium (LD) structure was constructed and r2 and D' values were 
determined using HAPLOVIEW. To correct for multiple testing, the Bonferroni correction 
(α=0.05/45=0.00111) was used. 
 
Bioinformatics Analysis 
 Because the significantly associated SNPs were all intronic, the 11 SNPs associated 
with AD, MDD, or T2D were input into the Human Splice Finder v3.0 program 
(http://www.umd.be/HSF3/) (Desmet et al. 2009) to determine if any of the SNPs may 
affect silencing and enhancing regions of the genes.  The sequence immediately 
surrounding the SNP was obtained from the NCBI dbSNP database 
(https://www.ncbi.nlm.nih.gov/snp).  PERFECTOS-APE was used to predict transcription 
factor (TF) binding sites affected by the SNPs, and the hits were compared with the results 
of database searches for transcription factors that have been experimentally determined to 
be associated with the genes studied.  We searched the transcription factor databases 
Human Transcriptional Regulation Interaction Database 
(http://www.lbbc.ibb.unesp.br/htri/) (Bovolenta et al. 2012) and RegNetwork 
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(http://www.regnetworkweb.org/)  (Liu et al. 2015) for transcription factors that have 
been experimentally determined to interact with the genes of interest. 
 
Results 
Single Marker Analysis 
 PLINK single marker analysis revealed several SNPs associated with AD, MDD, and 
T2D with an empirical p-value < 0.05. 
 
Alzheimer’s Disease. There were four SNPs significantly associated with AD before 
the Bonferroni correction (rs6758866, p = 0.00350; rs2355570, p = 0.03675; rs1921907; 
p = 0.00334; and rs883844, p = 0.00163).  All four of these SNPs are located in the GLS 
gene on chromosome 2, and all have a HWE p > 0.001 and a MAF of p > 0.05, therefore, 
they passed the quality control test.  These results are shown in Table 6.2. 
 
 
Table 6.2  SNPs associated with risk of AD 
SNP Position Allelea Gene EMP1b MAFc HWEd 
rs6758866 191464646 A GLS 0.00350 0.440 0.1046 
rs2355570 191489414 C GLS 0.03675 0.258 0.3147 
rs1921907 191493020 A GLS 0.00334 0.437 0.1691 
rs883844 191534014 T GLS 0.00163 0.381 0.3054 
aMinor allele 
bEmpirical p-value generated by 100,000 permutation tests using Max (T) permutation  
           procedure in PLINK 
cMinor allele frequency in founders 
dHardy-Weinberg equilibrium p-value 
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Major Depressive Disorder. Five SNPs were significantly associated with MDD 
before the Bonferroni correction.  Four of these SNPs (rs6749597, p = 0.02776; 
rs9789405, p = 0.01283; rs2287602, p = 0.01692; and rs2302909, p = 0.02103) are 
located in the CPS1 gene on chromosome 2, while one SNP (rs12735664, p = 0.03640) is 
located in the GLUL gene.  While each of these has a MAF > 0.05, rs2302909 failed to pass 
the test for Hardy-Weinberg equilibrium (p = 2.0E-4).  These results are shown in Table 
6.3. 
 
Table 6.3  SNPs associated with risk of MDD 
SNP Position Allelea Gene EMP1b MAFc HWEd 
rs12735664 180622702 C GLUL 0.03640 0.103 0.9515 
rs6749597 211128370 T CPS1 0.02776 0.138 0.4310 
rs9789405 211131628 T CPS1 0.01283 0.146 0.7266 
rs2287602 211135486 C CPS1 0.01692 0.150 0.0344 
rs2302909 211211801 A CPS1 0.02103 0.103 2.0E-4 
aMinor allele  
bEmpirical p-value generated by 100,000 permutation tests using Max (T) permutation  
          procedure in PLINK 
cMinor allele frequency in founders 
dHardy-Weinberg equilibrium p-value 
 
 
Type 2 Diabetes. As shown in Table 6.4, three SNPs were significantly associated 
with T2D before the Bonferroni correction, two in the GLS gene (rs1921915, p = 0.01794; 
and rs1517354, p = 0.00072) and one in the CPS1 gene (rs2302909, p = 0.00647).  All of 
these SNPs have a MAF of > 0.05, but rs2302909 failed to pass the test for Hardy-Weinberg 
equilibrium (HWE p = 2.0E-4).   
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Table 6.4  SNPs associated with risk of T2D 
SNP Position Allelea Gene EMP1b MAFc HWEd 
rs1921915 191460572 G GLS 0.01794 0.062 0.1093 
rs1517354 191524111 C GLS 0.00072 0.084 0.0066 
rs2302909 211211801 A CPS1 0.00647 0.103 2.0E-4 
aMinor allele 
bEmpirical p-value generated by 100,000 permutation tests using Max (T) permutation  
          procedure in PLINK 
cMinor allele frequency in founders 
dHardy-Weinberg equilibrium p-value 
 
 
Two-SNP Haplotype Analysis 
PLINK two-SNP haplotype analysis revealed several haplotypes associated with AD (one 
haplotype), MDD (11 haplotypes), and T2D (15 haplotypes).  The haplotypes with p < 0.05 
are listed in Table 6.5 (AD), Table 6.6 (MDD), and Table 6.7 (T2D). 
 
 
Table 6.5  Haplotype analysis of risk of AD based on PLINK in family-based study design 
Haplotype  Gene Affected 
Frequency (%) 
Unaffected 
Frequency (%) 
Chi-
square 
p value 
rs883844 rs10932334 GLS/CPS1     
C T  14.34 30.55 3.894 0.0485 
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Table 6.6  Haplotype analysis of risk of MDD based on PLINK in family-based study design 
Haplotype  Gene Affected 
Frequency (%) 
Unaffected 
Frequency (%) 
Chi-
square 
p value 
rs3856348 rs6725303 CPS1     
T C  27.91 18.57 7.005 0.0081 
rs6725770 rs759688 CPS1     
A T  23.51 30.22 3.881 0.0488 
rs918233 rs1509821 CPS1     
A G  56.22 47.8 4.545 0.0330 
rs17773128 rs6749597 CPS1     
C T  14.64 8.242 5.459 0.0195 
rs6749597 rs2887913 CPS1     
T C  14.64 8.242 5.459 0.0195 
rs2887913 rs9789405 CPS1     
C T  15.52 8.242 6.748 0.0094 
rs9789405 rs2287603 CPS1     
T T  15.42 8.171 6.723 0.0095 
C T  62.9 71.56 5.157 0.0232 
rs2287603 rs2287602 CPS1     
T C  16.01 8.929 5.719 0.0168 
T T  61.72 69.64 3.925 0.0476 
rs2287602 rs10515951 CPS1     
C G  15.95 8.929 5.644 0.0175 
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Table 6.7  Haplotype analysis of risk of T2D based on PLINK in family-based study design 
Haplotype  Gene Affected 
Frequency (%) 
Unaffected 
Frequency (%) 
Chi-
square 
p value 
rs1921915 rs6758866 GLS     
T G  47.95 56.67 4.034 0.0446 
rs2355570 rs1921907 GLS     
T A  26.03 17.15 6.942 0.0084 
rs1921907 rs17748089 GLS     
A G  51.37 42.8 3.894 0.0485 
rs17748089 rs1517354 GLS     
G C  14.38 7.64 7.744 0.0054 
rs1517354 rs883844 GLS     
C C  5.37 1.02 17.06 3.63E-5 
rs1509821 rs981024 CPS1     
G C  41.78 50.64 4.105 0.0428 
rs10515951 rs6714124 CPS1     
T C  2.74 7.06 3.957 0.0467 
rs2371001 rs3821135 CPS1     
A C  2.14 6.87 4.822 0.0281 
G A  52.84 43.3 4.756 0.0292 
rs3821135 rs7607205 CPS1     
C T  6.85 13.0 4.568 0.0326 
rs7607205 rs12468557 CPS1     
G C  9.03 3.97 7.675 0.0056 
rs12468557 rs2302909 CPS1     
C A  19.01 8.87 14.89 1.14E-4 
C C  46.05 55.59 4.751 0.0293 
rs2302909 rs7599931 CPS1     
A G  5.43 2.27 5.155 0.0232 
A T  14.43 6.96 10.21 0.0014 
 
 
 
LD Structure  
The linkage disequilibrium (LD) structures for these genes are shown in Figure 6.1.  
The GLS and CPS1 genes are located on chromosome 2 (2q32.2 and 2q34, respectively), 
while the GLUL gene is located on chromosome 1 (1q25.3).  SNP pairs with an r2 value > 
0.5 and a D' value greater than 0.8 are listed in Table 6.8. 
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Figure 6.1: Linkage disequilibrium structure of founders from the data set using HAPLOVIEW software.
196 
 
 
Table 6.8  Top linkage disequilibrium measures 
SNP 1 SNP 2 D' r2 
rs10932334 rs3856348 1 0.979 
rs6725303 rs6725770 1 0.951 
rs6749597 rs9789405 1 0.941 
rs6749597 rs2287602 1 0.937 
rs6714124 rs7573258 1 0.718 
rs2371000 rs2371001 1 0.71 
rs6725770 rs918233 1 0.622 
rs6758866 rs1921907 0.997 0.984 
rs2012564 rs2887913 0.997 0.932 
rs981024 rs2012564 0.997 0.929 
rs7573258 rs2371001 0.996 0.703 
rs2355570 rs883844 0.995 0.561 
rs9789405 rs2287602 0.994 0.977 
rs13010236 rs12997383 0.991 0.62 
rs1921907 rs883844 0.99 0.777 
rs1921915 rs1517354 0.988 0.707 
rs6758866 rs883844 0.987 0.764 
rs7573258 rs2371000 0.986 0.97 
rs6714124 rs2371000 0.982 0.695 
rs6714124 rs2371001 0.981 0.947 
rs981024 rs2887913 0.98 0.958 
rs6725303 rs918233 0.978 0.626 
rs7607205 rs12468557 0.955 0.788 
rs2371001 rs7607205 0.948 0.567 
rs3856348 rs2887913 0.948 0.554 
rs10932334 rs2887913 0.945 0.563 
rs3856348 rs981024 0.939 0.543 
rs10932334 rs981024 0.936 0.551 
rs6714124 rs7607205 0.935 0.542 
rs3856348 rs2012564 0.931 0.571 
rs759688 rs10515951 0.922 0.631 
rs10932334 rs2012564 0.906 0.551 
rs2887913 rs6714124 0.885 0.501 
SNP pairs with D'>0.8 and r2>0.5 
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Bioinformatics Analysis 
 All the SNPs tested are intronic.  Of the 11 SNPs with a significant association with 
AD, MDD, or T2D, bioinformatics analysis suggests a function for seven.  Of these, only 6 
SNPs are in HWE; the other SNP, rs2302909, will not be considered further.  Three SNPs 
(rs6758866, rs2355570, and rs1517354) were predicted to create enhancer sites, and one 
SNP decreased the likelihood of the sequence binding to transcription factors that have 
been experimentally determined to interact with the gene sequences of interest 
(rs1921907).  Another two SNPs (rs9789405 and rs2287602) both created an enhancer 
site and decreased the likelihood of binding with a transcription factor.  The details of these 
results are presented in Table 6.9. 
 
Table 6.9 Bioinformatics analysis predicted functional effects of SNPs   
                    associated with AD, MDD, or T2D 
SNP Gene Disease 
Association 
Transcription Factor 
Binding Affected 
Enhancer Site 
Formation 
rs6758866 GLS AD 0 + 
rs2355570 GLS AD 0 + 
rs1921907 GLS AD ETS1 0 
rs883844 GLS AD 0 0 
rs1921915 GLS T2D 0 0 
rs1517354 GLS T2D 0 + 
rs12735664 GLUL MDD 0 0 
rs6749597 CPS1 MDD 0 0 
rs9789405 CPS1 MDD E2F4 + 
rs2287602 CPS1 MDD FOXP3 + 
rs2302909 CPS1 MDD/T2D 0 + 
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Discussion 
Alzheimer’s Disease 
Because of the potential effect of ammonia levels on the onset and progression of AD 
described above (Seiler 1993), we hypothesized that SNPs in the ammonia metabolism 
genes GLUL, CPS1, and GLS may be associated with AD.  However, single marker analyses 
only found SNP markers statistically associated with AD in the GLS gene (Table 6.3) in this 
current study.  Bioinformatics analysis using the Human Splice Finder software and the 
PERFECTOS-APE program suggest three of these intronic SNPs may have a direct 
functional role in GLS regulation (Table 6.9).  The minor alleles of SNPs rs6758866 and 
rs2355570 are predicted to create enhancer sites. Each of these variations may increase 
the expression of GLS.  The minor allele of SNP rs1921907 is predicted by the PERFECTOS-
APE software to decrease the likelihood of binding to the transcription factor ETS1.  ETS1 
has been shown to be expressed in brain 
(http://www.proteinatlas.org/ENSG00000134954-ETS1/tissue) (Uhlén et al. 2015) and to 
interact with the GLS gene (Hollenhorst et al. 2009).  Because ETS1 can be either a 
repressor or an activator of transcription (Dittmer 2003), it is not possible to predict the 
direction of regulation.  The statistical association of the SNP rs883844 with AD is likely the 
result of an indirect association.  The SNP may possibly act as a marker for a nearby 
unsequenced variation involved in the disease process, or its association may be due to its 
proximity to the other three SNPs in the GLS gene identified in this study as being 
associated with AD.  Data in Table 6.8 reveal rs883844 is in LD with rs2355570 (D' = 
0.995, r2 = 0.561), rs1921907 (D' = 0.990, r2 = 0.777), and rs6758866 (D' = 0.987, r2 = 
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0.764).  This may explain the significant association with AD in the absence of a predicted 
function.   
As mentioned earlier, GLS is the isoform of glutaminase mostly found in the brain 
and kidneys (Uhlén et al. 2015).  In contrast, GLS2 is mostly localized to the liver 
(http://www.proteinatlas.org/ENSG00000135423-GLS2/tissue) (Uhlén et al. 2015).  GLS 
breaks down glutamine to ammonia and glutamate.  Glutamate, an excitatory 
neurotransmitter, is important for synaptic transmission and memory formation (Esposito 
et al. 2013), but increased levels can lead to excitotoxic neuronal cell death in the brain.  If 
the observed variants in the GLS gene or nearby unsequenced SNPs in LD affect 
glutaminase levels and enzyme activity, they would affect the regeneration of the glutamate 
used to remove neurotoxic ammonia.  Changing these glutamate levels could impact 
cognitive function in AD (Myhrer 1998).  Several studies agree that GLS levels in AD brain 
are decreased (Akiyama et al. 1989; McGeer et al. 1989; Burbaeva et al. 2014).  Two of the 
three SNPs associated with AD and predicted to have a function may create an enhancer 
site, but enhanced expression of GLS in AD is inconsistent with the published literature.  It 
is possible that the predicted enhancer sites created are in linkage disequilibrium with 
nearby unsequenced SNPs that are more important for transcriptional regulation, or ETS1 
usually acts as a relatively strong activator in this system.  Experimental studies of 
autopsied AD patient brains have found an increase in glutamate levels (Xu et al. 2016).  
However, another study found decreased glutamate in the temporal cortex of AD brain 
(Gueli and Taibi 2013).  Both increases and decreases in brain glutamate are associated 
with cognitive decline (Myhrer 1998).  It is possible that changes in glutamate levels in AD 
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brain are region-specific and occur because of disrupted glutamate and ammonia 
homeostasis. 
 
Major Depressive Disorder 
Several SNPs in the CPS1 gene were linked to MDD in this study (Table 6.3).  CPS1 is 
critically important in ammonia metabolism as evidenced by the devastating effects of 
hyperammonemia in CPS1-deficient individuals (Suzuki et al. 1986; Finckh et al. 1998).  
Therefore, the variations identified in this study could potentially have major effects on 
blood ammonia levels if the variations are linked to changes in CPS1 activity.  As previously 
mentioned, CPS1 is mainly found in the liver 
(http://www.proteinatlas.org/ENSG00000021826-CPS1/tissue) (Uhlén et al. 2015), and it 
catalyzes the incorporation of ammonia into carbamoyl phosphate in the urea cycle.  The 
clinical observations described above suggest changes in CPS1 activity may have an impact 
on blood ammonia levels, and changes in blood ammonia levels may also impact glutamate 
levels in the brain, affecting cognition (Suárez et al. 2002).  Several studies suggest changes 
in glutamate levels in several areas of the brain could be linked to mood disorders through 
disruption of the levels of glutamate and glutamine (Sanacora et al. 2012).   
Bioinformatics analyses suggest two SNPs in HWE analyzed in this study may have a 
functional role in MDD (Table 6.9).  The minor allele of the SNP rs9789405 is predicted by 
the Human Splice Finder program to create an enhancer site.  The same SNP variant is 
predicted by PERFECTOS-APE to decrease the likelihood of binding by the transcription 
factor E2F4.  E2F4 is mainly a transcriptional repressor (Crosby and Almasan 2004) and 
has been experimentally demonstrated to interact with the CPS1 gene (Litovchick et al. 
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2007).  The minor allele of the SNP rs2287602 is predicted by Human Splice Finder to 
create an enhancer site and by PERFECTOS-APE to decrease the likelihood of association 
with the transcription factor FOXP3.  This transcription factor mainly plays a role in 
regulatory T-cell function (Vent-Schmidt et al. 2014), but it has recently been found to play 
a role in promoting mitochondrial oxidative metabolism (Angelin et al. 2017) and can even 
localize to mitochondria in hepatocytes (Rojas et al. 2016).  FOXP3 is known to either 
increase or decrease gene expression depending upon the other transcription factors with 
which it associates (Szylberg et al. 2016).  The Human Protein Atlas reports mRNA for both 
E2F4 (http://www.proteinatlas.org/ENSG00000205250-E2F4/tissue) and FOXP3 
(http://www.proteinatlas.org/ENSG00000049768-FOXP3/tissue) in human liver (Uhlén 
et al. 2015).  Based on the predicted functions of these variants, we predict there may be 
altered expression of CPS1 in the liver of some MDD subjects.  Altered CPS1 expression may 
change the levels of ammonia in the blood, therefore changing the glutamate levels in the 
brains of individuals with MDD.  A SNP in CPS1 significantly associated with MDD that was 
not assigned a function by our bioinformatics analysis, rs6749597, is in linkage 
disequilibrium with the predicted functional SNPs (rs6749597:rs9789405, D' = 1, r2 = 
0.941; rs6749597:rs2287602, D' = 1, r2 = 0.937).  All variations in CPS1 that passed the 
quality control tests are in the same haplotype block (Figure 6.1). 
 
Type 2 Diabetes 
SNPs in the GLS and CPS1 genes were associated with T2D (Table 6.4).  The SNP in 
the CPS1 gene (rs2302909) is not in HWE, so it will not be further considered. The liver is 
the major hub of ammonia metabolism and gluconeogenesis, so it is not surprising that 
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ammonia metabolism genes are linked to type 2 diabetes.  Excess glutamate in the liver can 
be deaminated, fed into the citric acid cycle, and then used for gluconeogenesis, 
contributing to the high blood glucose levels observed in T2D.  Although T2D is 
traditionally associated with insulin resistance in liver and peripheral tissues, one of the 
hallmarks of the later stages of T2D is the inability of β-cells in the pancreas to secrete 
enough insulin to activate insulin signaling pathways in insulin-resistant tissues (Cantley 
and Ashcroft 2015).  The incretin pathway is involved in insulin secretion in the pancreas 
(Yokoi et al. 2016).  Several experimental drugs for the treatment of T2D have been 
designed to increase the effectiveness of the incretin pathway (Drucker et al. 2010).  
Glutamate has been found to increase insulin excretion by amplifying the incretin pathway 
in beta cells (Gheni et al. 2014).  Therefore, changes in glutamate levels in the pancreas 
may affect the response to glucose signaling in T2D.  As discussed above, CPS1, GLUL, and 
GLS may all affect the levels of glutamate available for signaling.  GLS is expressed in 
pancreatic tissue (http://www.proteinatlas.org/ENSG00000115419-GLS/tissue) (Uhlén et 
al. 2015), so changes in expression of these genes could affect pancreatic function.  These 
changes may play a role in the disease processes of T2D. 
One SNP in HWE in the GLS gene is predicted to have a functional role that may be 
associated with T2D (Table 6.9).  The SNP rs1517354 was predicted by Human Splice 
Finder to create an enhancer site (Table 6.9), possibly leading to an increase in GLS gene 
expression in T2D.  This variation may lead to an increase in the rate at which glutamine is 
catabolized to glutamate and ammonia.  When released from neurons, increased glutamate 
levels in the synaptic cleft can lead to excitotoxicity (Zhou and Danbolt 2014).  A recent 
study suggests some of the pathology of T2D may be due to increased activity of pancreatic 
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receptors for glutamate (Huang et al. 2017).  Glutamate excitotoxicity in the brain is mainly 
mediated by the NMDA receptor (NMDAR) (Lau and Tymianski 2010).  A functional role 
for NMDARs has also been found in pancreatic beta cells (Inagaki et al. 1995; Marquard et 
al. 2015).  The NMDAR agonist, glutamate, was found to be increased in the plasma of 
diabetic patients and in a rat model of diabetes (Huang et al. 2017).  In vitro studies have 
shown that blocking NMDAR activation reduces glucose-mediated damage to pancreatic 
beta cells and improves beta cell function (Huang et al. 2017).  These results suggest that 
changes in the expression of genes involved in glutamate metabolism may play a role in 
type 2 diabetes by affecting the function of pancreatic beta cells. 
 
Changes in Expression of Ammonia Metabolism Genes: An Explanation for Some Common 
Pathologies in AD, MDD, and T2D? 
Cortical thinning is a feature of AD (Du et al. 2007), MDD (Tu et al. 2012), and T2D 
(Yoon et al. 2017 Apr 27).  The temporal cortex appears to be specifically affected.  Cortical 
thinning may be caused by cell death due to glutamate excitotoxicity.  As previously 
discussed, the epidemiology of these diseases seems to be linked.  For example, a study 
found that individuals with AD are at increased risk for T2D (Janson et al. 2004).  A more 
recent study concluded that comorbidity of MDD and T2D increased the risk of dementia 
(Katon et al. 2012).   
Memantine, an NMDAR antagonist, is a drug used to reduce glutamate excitotoxicity 
for the treatment of AD.  Memantine was also found to have protective effects on pancreatic 
beta cells and to reduce blood glucose levels in a mouse model of diabetes (Huang et al. 
2017), and it improved some measures of cognitive functioning in a mouse model of type 2 
204 
 
diabetes (Iwanami et al. 2014).  Double-blind studies suggest memantine may also be an 
effective treatment for MDD (Amidfar et al. 2017).  The efficacy of this drug for the 
treatment of several different diseases suggests clinically significant commonalities in the 
disease mechanisms.  Because glutamate signaling is so tightly tied to ammonia 
metabolism, changes in the expression of ammonia metabolism genes may be at least 
partially responsible for the observed cortical thinning and disease phenotypes in all three 
of these disorders. 
 
Testable Hypotheses Generated and Study Limitations 
 This study generates several testable hypotheses: 1) Individuals with the minor 
allele variants of rs6758866, rs2355570, and rs1517354 have altered GLS gene expression 
and glutaminase enzyme activity.  2) Individuals with abnormal GLS gene expression are at 
greater risk for AD or T2D.  3) Individuals with the minor allele variants rs9789405 and 
rs2287602 have altered expression of the CPS1 gene and altered CPS1 enzyme activity.  4)  
Individuals with altered CPS1 gene expression are at higher risk for major depressive 
disorder.  5) Individuals with abnormal blood ammonia levels are at higher risk for major 
depressive disorder, and reducing blood ammonia may alleviate some of the symptoms of 
MDD. 6) Changes in glutamate levels in the brain due to changes in the expression of GLS, 
GLUL, or CPS1 are common to AD, MDD, and T2D, and these changes contribute to the 
common tissue pathology observed in these diseases.  7)  Drugs that regulate glutamate 
signaling may alleviate some symptoms of AD, MDD, and T2D. 
While this study’s results generate many hypotheses consistent with the published 
literature, the study also has several limitations.  We report a genetic association from just 
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one data set; to decrease the risk of a type 1 error, other data sets with similar and different 
study designs should also be examined for comparable associations.  Only rs1517354, the 
C-C haplotype from rs1517354 and rs883844, and the C-A haplotype from rs12468557 and 
rs2302909 with T2D (Tables 6.4 and 6.7) showed significant associations after a 
Bonferroni correction (p < 0.00111).  Thus, our current findings might be subject to type I 
error, and the results need to be supported by additional large samples in a future study. 
Second, it was not possible to predict the direction of change in gene expression of the 
SNPs rs2287602 and rs1921907 because they were predicted to interact with 
transcription factors that can be either activators or repressors.  Third, GWAS have largely 
not indicated ammonia metabolism gene associations with AD, T2D, or MDD.  This may be 
because the associations are weak or because of incomplete genomic coverage in GWAS 
datasets.  Lastly, the bioinformatics results of this study need to be supported by 
experimentation to verify these predictions.  Even with these limitations, the findings of 
this study are potentially clinically relevant and warrant further investigation due to their 
high explanatory power and their consistency with experimental results. 
 
Conclusions 
 This study used data from a family-based study design to find a novel 
epidemiological association of select ammonia metabolism genes with Alzheimer’s disease, 
major depressive disorder, and type 2 diabetes.  Bioinformatics analyses suggest a 
functional role for many of the identified SNPs.  These functional roles generally fit with 
previously published experimental results.  The associations found in this study should be 
confirmed by other genetic epidemiological studies to increase confidence in our 
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conclusions.  One data set which may replicate the current results is from the Columbia 
University Study of Caribbean Hispanics with Familial and Sporadic Late Onset Alzheimer's 
Disease, dbGaP Study Accession: phs000496.v1.p1.  The next step would be to 
experimentally verify the effects of these SNPs on gene expression and protein levels.  This 
study is a step toward understanding the genetic and metabolic underpinnings of complex 
diseases with heritable components. 
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CHAPTER 7 
CONCLUSIONS 
 
Hypotheses Supported 
 The studies reported in this dissertation investigated similarities in factors involved 
in the pathogenesis of several neurological diseases. Two main hypotheses are supported 
by this research: 
(A) Amyloidogenic proteins have similarities in their residue interaction network  
structures that will provide insight into the formation of amyloid plaques. 
(B) Altered ammonia metabolism and changes in the amount of dietary protein 
under certain conditions affect neurological function and play causative roles 
in several neurological diseases.   
 
Specific Aim 1: Conclusions and Future Directions 
To determine if amyloidogenic proteins have commonalities in their residue 
interaction networks and to determine how these network structures may affect amyloid-
beta plaque formation when combined with 3D structural data. This aim addresses 
hypothesis (A). 
Results from the use of lysozyme as a model for amyloidogenesis demonstrated that 
combining 3D structural data and RIN data can be a powerful approach in the study of 
amyloid formation. Novel residues were identified that are likely to be involved in its 
primary nucleation (residues 21, 62, 104, 122, and 112-117). Next, similar techniques were 
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applied to compare a group of amyloidogenic proteins to random network controls or real 
protein controls. Network characteristics specific to amyloidogenic proteins were 
identified. These characteristics may provide insight into the primary nucleation of a 
variety of amyloidogenic proteins. Abeta42 was analyzed in more detail, and two residues 
(residues 24 and 31) were identified which may be involved in preventing primary 
nucleation. 
 The results reported in this manuscript are in silico and are therefore preliminary. 
Experimental studies are needed to verify the findings. The group of amyloid proteins 
studied was small, so data from the analysis of more structures obtained using a variety of 
solvent conditions would increase confidence in the findings. Mutating the amino acid 
residues that we identified to be of interest for both lysozyme and Abeta42 could provide 
support for the conclusions drawn. 
 
Specific Aim 2: Conclusions and Future Directions 
To create a mathematical model to determine if the amount of dietary protein and 
degree of liver function interact to affect blood ammonia levels and to determine if the 
predicted changes could affect neuron health. This aim addresses hypothesis (B) and 
investigates the potential role of ammonia metabolism in neural function using an 
organismal and tissue level approach. 
There is a large body of evidence that suggests Abeta contributes to oxidative 
damage in AD. One of the most susceptible proteins to oxidative damage in the brain is 
GLUL, an enzyme that functions in the removal of ammonia from the brain and other 
peripheral tissues. Because of the primary role of glutamate metabolism in neural function 
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and the toxicity of ammonia to the central nervous system, I next investigated the effects of 
changing the activities of enzymes involved in liver ammonia metabolism on blood and 
brain ammonia levels. The relationship between dietary protein intake and blood ammonia 
is surprisingly understudied in humans. The in silico model of whole-organism ammonia 
metabolism supports a complex interplay between the amount of dietary protein, the blood 
ammonia concentration, and the activities of ammonia metabolism enzymes. Protein 
restriction for the treatment of hepatic encephalopathy may be appropriate for some 
patients to limit blood and brain ammonia levels. In addition, heterozygosity for CPS1, a 
prevalent condition, may cause chronic, low-level hyperammonemia. Because of the high 
relative toxicity of ammonia on neural cells, the hyperammonemia may lead to cognitive 
impairment and other neurological dysfunction. 
 Considering the potential link between protein level in the diet and blood ammonia 
level, clinical studies elucidating the relationship between the two should be performed. 
Many of the animal studies examining the relationship used exaggerated protein diets, so 
studies using diets that are comparable in protein level to those consumed by humans are 
needed. The decreased viability of differentiated neuroblastoma cells exposed to 
pathological ammonium chloride levels warrants further investigation into the role of 
ammonia in the pathogenesis of neurological diseases. 
 
Specific Aim 3: Conclusions and Future Directions 
To determine if there is an association between single nucleotide polymorphisms 
(SNPs) in the GLS, CPS1, and GLUL genes and AD, MDD, and T2D, and to predict the effects 
of any associated SNPs in the disease processes. This aim addresses hypothesis (B) where I 
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suggest that altered ammonia metabolism stimulates neuropathology on a molecular and 
cellular level. 
 Data from investigating Specific Aim 2 resulted in further evidence supporting a role 
for pathological changes in the activities of enzymes involved in ammonia metabolism 
causing changes in blood ammonia levels and demonstrated that these altered ammonia 
levels may be toxic to neurons. Considering these results and the existing literature on the 
involvement of changes in glutamate and ammonia metabolism in AD, I investigated the 
possibility that mutations in ammonia metabolism genes were linked to AD, MDD, or T2D. 
SNPs in the GLS gene were found to be linked to AD and T2D, and SNPs in the GLUL and 
CPS1 genes were found to be linked to MDD. Bioinformatic analysis revealed that some of 
these SNPs are predicted to affect the binding of certain transcription factors to the 
promoters of the genes, possibly affecting the levels of expression of the ammonia 
metabolism genes in these diseases. Since these diseases are each associated with cortical 
thinning, since treatment with the NMDA receptor antagonist memantine is beneficial, and 
since they often display comorbidity, dysfunctional ammonia metabolism may partially 
explain some of the common pathologies of these diseases.  
 To further test the hypotheses generated from the data obtained from investigating 
Specific Aim 3, the data from a separate set of subjects could be analyzed to test for similar 
associations. The predicted changes in the affinity of transcription factors for DNA 
sequences containing the predicted functional SNPs would lead to further insight as well. 
Because of the reported associations with ammonia metabolism genes, the beneficial 
effects of memantine and other drugs that interfere with glutamate signaling should be 
further evaluated for the treatment of AD, MDD, and T2D. Altered ammonia and glutamate 
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metabolism appears to be an important factor in the development of several neurological 
diseases. 
 
Summary of Conclusions 
The studies performed further elucidate several common features of neurological 
diseases. First, I used RINs to detect similar features of amyloidogenic proteins that have 
not previously been reported. Because Abeta and ammonia both cause oxidative damage in 
the AD brain, and GLUL, an ammonia metabolism enzyme, is especially susceptible to 
oxidative damage, I explored the possible role of altered ammonia metabolism and altered 
dietary protein intake in the regulation of systemic ammonia levels using a computational 
model of hepatic encephalopathy and CPS1 deficiency. As hypothesized, I found blood 
ammonia levels likely depend heavily on the interaction of protein diet with the activities 
of GLUL, GLS, and CPS1. Because high ammonia levels are toxic to neurons and ammonia 
metabolism genes are involved in critical glutamate signaling, I investigated the possibility 
that SNPs in ammonia and glutamate metabolism genes are linked to AD, MDD, and T2D. 
Each of these diseases had an association with GLUL, GLS, or CPS1, and some of the intronic 
SNPs are predicted to regulate gene expression. These associations may partially explain 
the common neural pathology observed in these diseases. This dissertation demonstrates 
that taking a broad view of neurological diseases and their causes can provide novel 
insights into their pathogeneses. 
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Personal Perspective 
My undergraduate research included elucidating the interaction of Abeta with 
resveratrol and the interaction of insulin with phenol red. This work with amyloidogenic 
proteins in monomeric form sparked an interest in AD and related amyloidoses that I 
carried with me into my Ph.D. studies. During my graduate coursework, I realized that 
complex network analysis could provide a unique perspective on protein structural studies 
because it is a relatively new approach. I was able to find no studies that had applied 
complex network analysis to amyloidogenic proteins. Since there is little 3D structural and 
sequence similarity among amyloidogenic proteins in their soluble form, I hypothesized 
that there may be similarities in network connections. The results of my studies have 
encouraged me to continue using the approach in future research. 
There is a need for more protein structural studies using network analysis. To 
advance the field, protein structures with well-known functions should be re-examined 
from a network perspective to find correlations with network metrics (Chapter 2). In 
addition to correlations, drug design approaches that consider residue interaction 
networks could be effective. For example, the results reported in Chapter 3 suggests that 
drugs that stabilizes the network structure of Abeta42 in a more nonpolar environment 
could prevent unfolding and subsequent oligomer and fibril formation. This could occur 
through stabilizing the predicted interaction between Val24 and Ile31. However, if 
stabilizing the network is the goal, perhaps other residues in the vicinity could also be a 
target. A network perspective could provide a wider range of drug targets not previously 
considered. The allosteric inhibition and activation of enzymes provides an example of this 
principle. The binding of an inhibitor or activator to residues away from the active site can 
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change both the 3D and network structures of a protein and therefore change the activity 
of the enzyme. Similarly, network analysis may help researchers discover previously 
unidentified drug targets that exert profound effects on enzyme activity even though they 
are not near the active site. 
The series of studies on ammonia and glutamate metabolism in this dissertation was 
inspired by my grandfather, Wayne Birchfield. His stroke and subsequent medical care 
helped me understand the strong connection that exists between ammonia and glutamate 
metabolism and brain function. During a literature search on the cognitive effects of 
hyperammonemia, I found research supporting a role for ammonia in other neurological 
diseases, particularly AD. I came to appreciate the roles that ammonia and glutamate 
metabolism appear to play in a variety of neurological diseases (Chapters 4, 5, and 6).  
When initiating my research, I discovered that the focus of AD research is currently 
on the Abeta peptide. While Abeta exerts negative effects on the brain in AD, the lack of 
understanding of the nature of its role in both AD and normal physiology is striking. Even 
the structure of Abeta and which forms in the brain are most prevalent are contested after 
25 years of intense study (Wildburger et al. 2017), a testament to the complexity of AD 
pathogenesis. 
 The paucity of current treatment options should encourage researchers to examine 
other factors of AD pathology besides Abeta oligomerization and fibrillization (Herrup 
2015). I reviewed the literature on changes in amino acid metabolism in AD (Chapter 5) 
and found much evidence supporting pathological changes. Furthermore, identifying these 
changes provides opportunities for therapeutic intervention. Researchers need to untangle 
which changes contribute to disease and which changes are protective adaptations to 
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disease processes. Treatments for AD patients may one day include dietary supplements to 
help alleviate some symptoms that may occur due to changes in metabolism in AD. While 
AD will not be cured by dietary interventions alone, they may alleviate some symptoms or 
delay progression of the disease. 
After finishing my Ph.D. studies at East Tennessee State University, I will begin as an 
Assistant Professor of Biology at Mars Hill University. There I will continue research into 
neurological diseases and other interests. I would like to continue exploring the role of 
ammonia in neurological functions using C. elegans as a model organism. Does ammonia 
affect the ability of C. elegans to learn? (Yes, there are assays for C. elegans memory 
(Nuttley et al. 2002; Ardiel and Rankin 2010; Li et al. 2013)!) If so, what factors are 
involved? Because magnetic fields are effective as a treatment for some neurological 
diseases (Chou et al. 2015; Rutherford et al. 2015), I would also like to use C. elegans and S. 
cerevisiae as models for the effects of static magnetic fields on mitochondrial function 
(which declines in neural aging). I plan to further investigate residue interaction networks 
in CPS1, antimicrobial proteins, and protein toxins. I will also continue ongoing projects 
investigating tryptophan metabolism in AD, glutathione metabolism in AD, and pneumonia 
infection in AD patients. My Ph.D. research has helped me understand the power of the 
scientific method and an interdisciplinary approach. I will emphasize these points in my 
future endeavors in both research and higher education. 
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